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The following thesis chapters chronicle evolving efforts throughout 2016 – 2021 to support research 
toward improving the pediatric clinical pharmacology of monoclonal antibodies (mAbs). Translating 
the benefits of successful mAbs from adults to children (and even infants) has proved challenging 
since the first attempts in the early 2000s. Children tend to achieve low pharmacokinetic exposures 
and poor efficacy when the adult dose is scaled to children by body weight alone (mg/kg), with 
infliximab as the main example of this case. Physiologically-based pharmacokinetic (PBPK) models 
were selected as the tool of choice to explore this discrepancy based on their established success with 
pediatric extrapolation for small molecule drugs. PBPK models enable mechanistic representations of 
drug disposition in virtual individuals and can be used to identify the drivers of altered 
pharmacokinetics in anatomically or physiologically distinct special populations, such as children.  
The early chapters review the state of the field and the mechanistic underpinnings of mAb 
pharmacokinetics, and an example of an adult PBPK model for trastuzumab is provided. An open-
source model for large molecule drugs was launched in 2018 inside the Open Systems Pharmacology 
software package, and shortly thereafter we trialed the use of this model to predict infliximab 
pharmacokinetics in children 4 – 17 years of age. Scaling pharmacokinetics to children by size alone 
failed to correctly predict the pharmacokinetics in this population, suggesting that other factors were 
at play. Therefore, a comprehensive review was conducted to generate physiological hypotheses to 
explain the observation with particular attention to infants (< 2 years of age), where the 
pharmacokinetic differences are most drastic. The following hypotheses were proposed: 
1. The fraction of extracellular fluid volume in the body decreases with age and provides large 
weight-normalized volumes of distribution in infants.   
2. Extravasation of antibodies into tissues occurs quickly in infants as they have a large 
capillary surface area per unit volume available for plasma protein exchange and a large proportion of 
“leaky” tissues, where capillary permeability is highest.   
3. A fast rate of lymph flow in infants drives a fast rate of absorption after extravascular 
administration. 
4. Infants have higher concentrations of circulating hematopoietic cells, which may contribute 
to extensive cellular uptake and fast elimination. 
 
v 
5. Intracellular metabolism and elimination may be increased due to low expression of FcRn – 
the neonatal salvage receptor – and the relatively high concentration of endogenous IgG competing 
for FcRn binding after birth. 
In 2019, the first four hypotheses were integrated into a PBPK model for mAbs in premature 
infants that was successful for characterizing pharmacokinetics in infants even 1 day old at 28 weeks 
gestational age. However, this parameterization was based on the mechanistic understanding of mAb 
disposition at that time, and it was destined for change.  
The results of the latest experiments in mice with site-specific FcRn deletion and macrophage 
knockdown prompted a reinvestigation of the contribution of hematopoietic cells – in particular 
monocytes and macrophages – to mAb pharmacokinetics. In this work, the role of the macrophage is 
redefined to a highly efficient protector of IgG, rather than an eliminating cell. A model-based 
analysis of the data revealed that it is very unlikely that a high concentration of circulating monocytes 
can contribute to explaining the fast weight-based clearance of mAbs in very young children.  
In the end, four of the five hypotheses remain, and the investigations continue. Pediatric 
extrapolation for mAbs is a modestly more achievable task because of the efforts herein, hopefully 
improving outcomes for this vulnerable population in the future. Other contributions of the thesis 
include highlighting the influence of cancer and inflammatory disease states on mAb 
pharmacokinetics, proposing an empirical exponent for scaling volume of distribution to children and 
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Pediatric Dose Selection for Therapeutic Proteins 
1.1 Abstract 
Selecting optimal dosing regimens in support of the clinical use of monoclonal antibodies and other 
therapeutic proteins in pediatric indications needs to appreciate the unique pharmacokinetic properties 
of this class of biologicals as well as the underlying physiologic and pathophysiologic processes and 
their modulation by childhood growth and development. During drug development, first-in-pediatric 
dose selection is a capstone event in the pediatric investigation plan that relies heavily on 
extrapolation of pharmacokinetic and pharmacodynamic data from adult to pediatric populations. It is 
facilitated by combinations of pharmacometric approaches, including allometry, physiologically-
based pharmacokinetic modeling and population pharmacokinetic analyses, although data on 
reliability and qualification of some of these tools in the context of therapeutic proteins are still 
limited but emerging. Presented data suggest nonlinear relationships between body weight and both 
clearance and volume of distribution for therapeutic proteins in pediatric populations, with allometric 
exponents of 0.75 and 0.8, respectively. For newborns and infants (<1 year), even higher nonlinearity 
seems to occur. Translation of the quantitative characterization of the pediatric pharmacokinetics of 
therapeutic proteins into dosing regimens for the drug label requires compromising between precision 
dosing and clinical practicability, with tiered dosing algorithms based on size or age strata being the 
currently most frequently applied methodology. 
1.2 Introduction 
Harnessing the advances in biotechnology and genetic engineering to develop proteins for therapeutic 
applications is one of the greatest feats of modern medicine. The first successes for therapeutic 
proteins (TPs) were in protein replacement therapy, oncology, endocrinology, and immunology, with 
the latter largely spurred on by the popularity of monoclonal antibodies (mAbs). Twenty-five years 
later, TPs are offered as treatments in almost every clinical domain, from cardiology to neurology. In 
contrast to traditional small molecule drugs, TPs often possess favorable safety profiles, high 
specificity, and long circulating half-lives, making them preferred therapeutic interventions in many 
indications.1,2 
Children deserve equal access to these interventions. Both the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) have enacted regulations to advance drug 
 
2 
development for pediatric indications. FDA regulations were mandated by the Best Pharmaceuticals 
for Children Act (BPCA) in 2002 and the Pediatric Research Equity Act (PREA) in 2003. The EMA 
followed close behind with pediatric regulations in 2007. For all new drug applications, including 
biologic license applications, clinical studies must now be conducted in children to inform labelling 
unless a waiver, partial waiver or deferral is granted.3,4 
Based on this legislative framework, a pediatric investigation plan (PIP) is formulated during early 
clinical development for most drug development projects that lays out the design for the first trial or 
sequence of trials in pediatric patients, and the rationale for the first-in-pediatric dose. Fewer children 
are required for the trial when efficacy can be extrapolated from adults, as guided by the FDA 
Pediatric Study Decision Tree.4 To extrapolate, the foundational assumptions are that the disease 
progression and the exposure-response relationship are sufficiently similar between the two 
populations.5 In this case, studies seek to evaluate pediatric dosing regimens to produce exposure 
levels that match the adult exposure levels. Among TPs, and even among TPs with similar structure 
and mechanism of action, different exposure metrics have been used to guide dosing in children. Most 
commonly, the trough concentration at steady state (Cmin,ss) or the area-under-the-curve over the 
dosing interval (AUC0-τ,ss) is used as the exposure target.6-8  
Selecting the first-in-pediatric dose is frequently done when little or no pediatric data are available. 
Pharmacokinetic (PK) data from adults is usually leveraged heavily to create mathematical models of 
drug disposition in the body, either empirical or mechanistic in nature. When the mechanisms of drug 
disposition and/or their age-dependency are not well understood, the principle of allometry is often 
used to scale PK from adults to different age groups of children based on the power relationship 
between basal metabolic rate and body weight across multiple species.9-11 On the other hand, a 
physiologically based pharmacokinetic (PBPK) modeling approach can be used when the 
mechanisms of disposition have been deeply explored, and when there is a solid understanding of 
how young age, developmental stage and disease processes may modulate them in pediatric 
patients.12 In this framework, virtual adults are created with quantitative knowledge of anatomy and 
physiology, and drug disposition is modeled with rate-based equations representing the underlying 
mechanisms responsible.13,14 The adults are then replaced with virtual children for simulating PK 
while holding all other parameters constant. PBPK modeling may be particularly advantageous 
relative to allometry for predicting PK in children less than 2 years of age since the impact of 
immature physiology can be more readily considered if their mechanistic basis is well understood and 
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characterized.15 While these approaches have been qualified and applied for many small molecule 
drugs, the same is not yet true for TPs. 
After first experiences with the first-in-pediatric dose studies have been obtained, the applied PK 
models can be further optimized by refining uncertain model parameters with the newly available 
data to better understand drug disposition in children. A population pharmacokinetic (PopPK) 
analysis using non-linear mixed effects modeling can be performed to identify demographic or 
disease covariates that affect and are predictive of exposure in patient subgroups. If a suitable 
biomarker for pharmacodynamic (PD) effects is measurable, a combined PK/PD model can be 
created to test alternative dosing regimens for therapeutic response. Full exposure-response analyses 
are often impractical to conduct in children since multiple dose levels are required to derive the 
relationship, but the data collected on pediatric outcomes can be used to confirm or deny the 
assumption that the exposure-response relationship is similar between adults and children.16 With the 
results of these advanced analyses, the final dose recommended in the drug label can be different 
from the first-in-pediatric dose rationalized in the PIP.4 
From beginning to end, pediatric dose selection for TPs is complicated by several factors. Inter-
individual variability in PK is substantial (but within the same magnitude of many small molecule 
drugs), and often remains unexplained.17,18 So far, body size is the only consistent covariate found to 
explain some of this variability between individuals.  
TPs binding to abundant in vivo targets may display non-linear PK as a result of target-mediated 
drug disposition (TMDD).19 Drugs subject to TMDD are often dosed to saturate the in vivo target, or 
at least achieve a high receptor occupancy.20 When extrapolating the pharmacokinetic behavior of 
TPs to pediatric patients, knowledge about potential differences in abundance, turnover kinetics, and 
binding affinity to these targets in pediatric populations are usually lacking. Consequently, the 
pragmatic assumption is often made that the in vivo target levels are equivalent between adults and 
children if they are not measurable. Clearance, however, can be dramatically increased if the 
concentrations of target or its turnover kinetics are higher in the pediatric disease state. For example, 
IL-6 levels and other inflammatory cytokines are significantly elevated in systemic juvenile 
idiopathic arthritis (sJIA) as compared to the standard form of juvenile idiopathic arthritis and adult 
rheumatoid arthritis.21 As a consequence, the anti-IL6 mAb tocilizumab requires a two-fold higher 




Finally, patients can experience sudden loss of response to TPs after therapy that was initially 
successful. Development of anti-drug antibodies is a common cause.23 There is currently very limited, 
if any evidence of different immunogenic potential between adults and children.24,25 However, there 
may be differences in the incidence of immunogenicity over time if children are significantly under-
dosed relative to adults, as subtherapeutic TP concentrations have been associated with an increased 
propensity of anti-drug antibody formation.26 
The story of the pediatric use of infliximab highlights these concepts. Infliximab was among the 
first TPs approved for adults and later approved for children. It is an intravenously administered IgG1 
mAb directed against tumor necrosis factor alpha and is used to treat autoimmune conditions. The 
approved weight-based induction and maintenance dose algorithm for children is the same as for 
adults (e.g., 5 mg/kg for inflammatory bowel disease). The first and largest evaluation of infliximab 
PK in pediatric patients over 6 years of age was conducted by Fasanmade et al. and noted comparable 
clearance (in mL/kg/day), but higher peripheral volume of distribution (in L/kg) in children.27 
Applying the same principles as for small molecules, the consensus was that no dose adjustment was 
necessary. In the landmark REACH trial, over 60% of pediatric patients with Crohn’s disease 
achieved clinical response or remission after one year of therapy.28 However, half of the patients 
required an increased dose or a shortened dosing interval to maintain a clinical response.29 While the 
dose adjustments in the REACH trial were based on clinical evaluation and response, a target trough 
concentration of 3 – 5 µg/mL was soon identified for therapeutic drug monitoring in practice.30-32 Re-
visiting the original analyses by Fasanmade et al. revealed that 60% of children would achieve 
subtherapeutic trough concentrations with the labelled dose.33 The European Society for Paediatric 
Gastroenterology Hepatology and Nutrition subsequently revised their recommendations and 
advocates for upfront intensification of the induction regimen for children less than 10 years of age.31 
Results of a systematic review further suggest that dose increases are necessary for all pediatric 
inflammatory bowel disease patients with low serum albumin or with no concurrent 
immunomodulator therapy.32 In retrospect, it can be concluded that the adult weight-based dosing was 
not appropriate for the pediatric label.32 
Considering these complexities of the pediatric use of TPs, this manuscript summarizes what is 
known about the disposition of TPs in children and offers a commentary about the utility of different 
methods for pediatric PK extrapolation and dose selection. There are two pivotal events in the process 
of pediatric dose selection that are presented – determining the first-in-pediatric dose for the PIP and 
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preparing the final pediatric dosing regimen for the drug label. To address foundational concepts, the 
discussion is primarily focused on the case where a TP is administered intravenously and exhibits 
linear pharmacokinetics. For a more detailed discussion on the current knowledge regarding age-
associated differences in the mechanisms underlying disposition of TPs, the reader is referred to other 
recent reviews by our groups.25,34 
1.3 Observations on Pediatric Exposure 
Deriving dosing regimens for TPs in children requires a consensus for the typical PK in children as 
compared to adults. Until recently, the statement that children have a larger weight-normalized 
volume of distribution and faster weight-normalized clearance than adults has been based on the 
pediatric experience with mAbs, with some conflicting reports.35,36 More recently, additional PopPK 
models have been published for mAb and non-mAb-based TPs that provided the opportunity to 
further clarify the body weight effect on PK parameters for TPs. 
A literature search was performed to collect PopPK models for TPs and explore trends in exposure 
from very young children to adults. Models were included if they described the PK of an intravenous 
TP from adults down to children less than 1 year of age with dose-independent clearance. By focusing 
on intravenous TPs with linear PK, we limited possible confounding factors on distribution and 
elimination parameters, such as the effect of TMDD or incomplete absorption from an extravascular 
administration site. In the reviewed pediatric PopPK models, trends in exposure are described by 
quantitative relationships between body size measures (weight, lean body weight, fat-free mass, body 
surface area) and PK parameters (clearance, volume of distribution). For small molecules, the 
principle of allometry suggests that there is a nonlinear power relationship between body weight and 
clearance with an exponent of 0.75, and a linear relationship between body weight and volume of 
distribution (an exponent of 1.0). In other words, conventional allometry suggests that the weight-
normalized clearance should be higher in young children (in mL/h/kg), but that weight-normalized 
volume of distribution should be consistent with adults (in L/kg). We investigated whether this 
relationship also holds true for TPs. 
6 
Table 1. Select population pharmacokinetic models for intravenous therapeutic proteins across adults and young children 
Study Drug INN 
(Trade name) 
Class Age Range 
(years) 
Covariate Relationships for PK Parametersa 
(CL, Q2, Q3 in mL/h; V1, V2, V3 in L) 
Abrantes et 
al., 201737 




(Factor VIII)  
0 – 73 
*correction 
for age ≤1 





× [1 − 0.0068 × (𝐴𝑔𝑒 − 20)]  

























1.1 – 66 





× [1 − 0.0045 × (𝐴𝑔𝑒 − 22)]  






𝑄2 = 147  






Chelle et al., 
201939 
Plasma derived 






1 – 72 





× [1 − 0.0121 × (𝐴𝑔𝑒 − 25)]𝐴𝑔𝑒>25  






𝑄2 = 78  














0.6 – 80 














1 – 61 












𝑄2 = 190  
𝑉2 = 0.637  
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0.5 – 21 





× 1.11  





× 1.14  





































0.2 – 90 





× [1 − 0.0089 × (𝐴𝑔𝑒 − 34)]𝐴𝑔𝑒<34  





× [1 − 0.0115 × (𝐴𝑔𝑒 − 34)]𝐴𝑔𝑒<34  































0.6 – 29 












𝑄2 = 7.625  








0 – 69 

































1 – 60 

















𝑄2 = 134  
𝑉2 = 0.265  
BW = body weight, LBW = lean body weight, FFM = fat-free mass, BSA = body surface area, VWF = von Willebrand factor 
a Covariates not related to body size or age are excluded 
9 
Eleven PopPK models were available in the literature for a variety of TPs with molecular weights 
ranging from 50 to 267 kDa (Table 1). Most of the PK models used a two-compartment structure 
(n=8), though one-compartment (n=2) and three-compartment (n=1) models were also used. Four of 
the models used at least one fixed allometric exponent (0.75 or 1) to describe the relationship between 
body weight and PK parameters according to conventional allometry.37,42-44 Consistent with the 
allometry hypothesis, the median exponent for the effect of body weight on clearance was 0.80 (range 
0.76 – 0.80) among the models where body weight effects were estimated from the available data.38,45-
47 Two of the models with data-informed body weight effects on clearance also found mild effects of 
age-related covariates, but excluding these studies does not change the median result.38,47 For volume 
of distribution parameters, the median exponent derived for the covariate effect of body weight was 
0.81 (range 0.70 – 1.02), in contrast to the conventional linear relationship (with an exponent of 1.0) 
from small molecule PK.37,38,42,45-47 
This result supports the notion that – in contrast to conventional allometry – both clearance and 
volume of distribution for TPs are expected to be higher in children than in adults on a per kg body 
weight basis. The consequence is that terminal elimination half-life can be the similar between adults 
and children, but overall concentrations are lower for an intravenously administered TP with weight-
normalized dosing. These observations are in agreement with similar results reported specifically for 
mAbs.48 A consistent pattern of exposure was observed for all TPs in this study, regardless of size or 
affinity for the neonatal Fc receptor (FcRn). Consequently, children will require higher weight-based 
doses of TPs to match the exposures in adults.  
To determine the degree of underdosing that may occur when children are given the same weight-
based doses as adults, we performed simulations with a generic two compartment PK model with 
parameters of a typical mAb:49 


























where V1 and V2 are the volumes of distribution of the two compartments, CL is the elimination 
clearance, Q2 is the intercompartmental clearance, and BW is the body weight in kg.  
The model was simulated with body weights for one mean individual at each year of age from 1 to 
18 years together with a 25-year-old adult (n = 19). Typical body weights were taken from the ICRP 
database.50 The area-under-the-curve (AUC) and 28-day trough concentration for each individual 
were then compared against the simulated adult values (Figure 1). With the same weight-based dose, 
the generic model predicts that typical children who are 1, 5, 10 and 15 years old would achieve 
plasma AUC measurements that are only 64%, 74%, 83% and 95% of the AUC of a 25-year-old 
adult, respectively. The deficits in trough concentrations are even slightly larger, with typical children 
who are 1, 5, 10 and 15 years old achieving trough concentrations of 59%, 70%, 81% and 94% of the 
trough concentration of a 25-year-old adult, respectively.  
 
Figure 1. Projected AUC and trough concentrations for a typical mAb in typical individuals aged 1 to 
25 years relative to adults if a constant weight-based dose were given across all ages. 
These findings are supported by real-world data from the Web-Accessible Population 
Pharmacokinetic Service - Hemophilia program (www.WAPPS-Hemo.org).51 This program provides 
a PK-based dose tailoring for clotting factor replacement therapy in hemophilia-A patients that 
produce minimal or no endogenous clotting factor VIII (molecular weight: ~240 kDa). WAPPS-
Hemo uses Bayesian techniques to calculate individual PK parameters for clotting factor VIII 
concentrates in hemophilia patients using underlying PopPK models, with only small numbers of 
factor VIII activity measurements. Figure 2 presents the dose-normalized AUC for factor VIII derived 
by WAPPS-Hemo based on dosing and demographic information for 2,453 infusions of factor VIII 
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concentrate in 1,897 patients between 1 and 35 years of age, including a trendline fitted by locally 
estimated scatterplot smoothing (Loess). With the same weight-based dose, typical children who are 
1, 5, 10 and 15 years old achieve plasma AUC measurements that are only 58%, 70%, 82% and 91% 
relative to the AUC in a 25-year-old adult (100%), respectively. An allometric function for clearance 
with an exponent of 0.75 was tested against the data and was able to characterize the trend well.  
 
Figure 2. Dose-normalized AUC for factor VIII concentrates in pediatric and adult patients with 
hemophilia, derived from real-world data of the WAPPS-Hemo program. The circles denote 
individual patient data, the red solid line was created with locally estimated scatterplot smoothing 








Limited available data suggest that the observed nonlinearity between TP clearance and volume of 
distribution versus body weight may be even more pronounced in neonates and infants. Figure 3 
presents PK data for intravenous TPs in preterm and term neonates relative to adults. In both cases, 
volume distribution and clearance are higher in infants than adults on a per kg basis, and the infant 
plasma concentrations are markedly lower. Pagibaximab is a chimeric monoclonal antibody (MW 150 
kDa) against lipoteichoic acid (LTA) for the prevention of staphylococcal sepsis. The presented 
concentration-time profiles were digitized from publications of studies in healthy adults and very-
low-birth-weight preterm infants less than 7 days old.52,53 Since the assay measured total anti-LTA, 
the baseline measurement was subtracted from each subsequent concentration to approximate the 
exogenous pagibaximab concentration. For epoetin alfa (MW 30.4 kDa), the data originated from 
studies in healthy adults and neonates with hypoxic-ischemic encephalopathy receiving an 
intravenous infusion on the first day of life.54,55 The neonates had induced hypothermia as part of the 
treatment protocol for encephalopathy, and half of the subjects had renal dysfunction – two conditions 
that theoretically slow the clearance of epoetin. Nevertheless, the same trend of lower exposures and 
faster clearance (in mL/h/kg) was also observed for these infants.  
 
Figure 3. Pharmacokinetic profiles for preterm and term neonates for intravenous therapeutic proteins 
as contrasted with adults: Left panel: Pagibaximab52,53; Right panel: Epoetin Alfa54,55 
To summarize, neonates, infants and children receiving weight-based doses of TPs are expected to 
achieve lower AUC and trough concentrations than their adult counterparts. This trend seems 
consistent across multiple types and sizes of TPs including mAbs, growth factors and clotting factors. 
At 2 years of age, children are projected to require weight-based doses that are ~60% higher than 
adults for equivalent exposure. Real-world data from the WAPPS-Hemo program support the 
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projected pediatric exposures and showed that an allometric exponent of 0.75 is appropriate for 
characterizing the unspecific clearance of TPs in children down to 1 year of age. Furthermore, our 
review of PopPK models describing the pediatric PK of intravenous TPs with linear kinetics did not 
find sufficient evidence to support a linear relationship between volume of distribution parameters 
and body weight (i.e. an allometric exponent of 1). Instead, a median exponent of 0.8 was noted to 
describe the effect of body weight on volume of distribution among existing models. 
1.4 First-in-Pediatric Dose Selection 
The first-in-pediatric dose is selected as part of the PIP with usually little or no pediatric data 
available to inform the decision. Thus, drug developers have to rely heavily on mathematical methods 
to scale PK and PD from adults to children. Allometry is preferred for scaling PK when the drug 
exhibits linear kinetics without time-dependent clearance or TMDD. PBPK modeling can be used 
when disposition processes for the TP and their age-associated differences are reasonably well 
understood and a mechanistic framework for characterizing drug disposition would be beneficial. The 
rationale for the first-in-pediatric dose selection is rarely published, but the underlying reasoning was 
explained for abatacept and tocilizumab.25 In the primary literature, one combination of allometry and 
PK/PD strategy is described for domagrozumab, but its success is unknown since the development 
program was terminated in 2018.6 Similarly there is one PBPK strategy published for asunercept.56 
The exposure target for the first-in-pediatric study depends on the exposure-response relationship 
derived in adults and the confidence with which investigators can anticipate PD effects in children. 
Steady state AUC, steady state trough concentrations or post-induction trough concentrations are the 
parameters commonly linked to response. If a full or partial extrapolation exercise indicates that the 
exposure-response relationship can be assumed similar between adults and children, the plasma 
exposure target will be the same as for adults. If the exposure-response relationship is different, a new 
exposure target must be derived. Measurable biomarkers of disease in children (e.g., circulating 
antigen concentrations) can be incorporated into a PK/PD or PBPK/PD framework for extrapolation 
of an exposure target.6,57-59 
Since children require higher weight-based doses of TPs than adults in cases where the exposure-
response relationship is similar as discussed in the preceding section, it is arguably ethically 
questionable to initiate a trial with the adult dose and perform a subsequent dose escalation. Ethical 
recruitment of children for clinical studies mandates that the pharmacotherapy is for a therapeutic 
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purpose. For a dose escalation study, more children would be required for the trial, and some of them 
would be knowingly exposed to doses that are likely subtherapeutic. Thus, this strategy should only 
be entertained if very little is known about the PD and exposure-response of the drug in children and 
the risks of unintended over-exposure are high (e.g., in the case of cytotoxic protein-drug conjugates). 
The commonly used approaches for first-in-pediatric dose selection include conventional allometric 
approaches, modified allometric approaches, hybrid approaches and PBPK modeling. As already 
mentioned, conventional allometric approaches scale PK parameters in proportion to body weight 
with empirical power relationships, with allometric exponents of 1 for volume and 0.75 for clearance 
terms. This approach has, in many instances, acceptable accuracy for predicting the PK of small 
molecules in children down to 2 years of age.15 However, the allometric approach has not been fully 
qualified for use with TPs, with ongoing debate about the proper exponents, and limitations with 
respect to very young age groups. Published examples are largely limited to older children where the 
effects of maturation and ontogeny on PK are expected to be mild. One case study, for example, 
describes how allometry was used to guide the first-in-pediatric dose for domagrozumab in children 
6-10 years of age.6  Similarly, several objective evaluations of conventional allometry for children 
older than 4 years suggest that predictions for TP concentrations fell within a 1.5 to 2-fold error in the 
majority of the model extrapolations.48,60 However, there was considerable variability in accuracy 
when multiple adult PopPK models were scaled for one drug (infliximab), with the poorest model 
making predictions within 2-fold error for only 47% of the observed concentrations.60 This result 
stresses the importance of a strong understanding of TP disposition in adults prior to scaling to 
children and provides some idea of the worst case prediction scenario.  
Deviating from conventional allometry, our review finds that exponents between 0.7 and 1.0 are 
most frequently applied for describing the effect of body weight on volume of distribution for TPs in 
children (median = 0.81). Similarly, but specific to mAbs, a recent review also noted allometric 
exponents between 0.7 and 0.9 in 20 PopPK models for children, although the authors cautioned that 
their results may have been confounded by poor sampling schemes.48 The allometric exponent of 0.8 
for volume of distribution has physiological relevance, as it reflects that young children have higher 
extracellular water fractions than adults.61,62 Convincingly, Figure 4 shows a good fit between the 
allometric function with an exponent of 0.8 and the observed data for extracellular water fraction in 
children (as estimated by iohexol distribution volume).61 This allometric approach only misses to 
capture the very high extracellular water fractions for infants under 1 year of age or 10 kg in body 
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weight (values up to 60% in newborns). Considering the totality of evidence, we anticipate that the 
allometric exponents of 0.75 for clearance and 0.8 for volume of distribution will be best when 
empirically scaling the PK of a TP for children from >1 – 18 years of age.  
 
Figure 4. Observed data for extracellular water fraction (ECWF) in children as approximated by the 
iohexol distribution volume.61 The circles denote individual data for boys, the diamonds denote 






). The reference value for the ECWF of a 70 kg adult is 19% of body 
weight. The black dashed line marks the threshold of 10 kg body weight, below which the use of the 
allometric function to describe ontogeny in ECWF does not seem warranted. 
In theory, a modified allometric approach could be used when age-dependent effects on PK 
parameters are known. For instance, age-dependent effects on PK can be captured by a maturation 
function with post-menstrual or post-natal age as an input to clearance. However, maturation 
functions with any predictive value would need to be derived from dense PK data in very young 
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children for multiple TPs. As these functions are generally not rooted in well understood age-
associated molecular or physiological processes, their current use is often merely a fudge factor in 
pediatric PopPK modeling that compensates for the error associated with assumptions in the model 
development process (e.g., using fixed allometric exponents for newborns and infants, or assuming 
consistent extravascular bioavailability across age for subcutaneously administered TPs).35,36 
A hybrid approach of allometry and PBPK modeling is offered for TPs in the commercially 
available software SimCyp (Certara, Princeton, NJ).63 In this package, virtual individuals are 
represented by physiological organ volumes and blood flows. Distribution of TPs is modeled by a 
combination of convection, diffusion, and transcytosis within the two-pore framework, with lymph 
recirculation from the interstitial fluid. Non-specific catabolism of TPs is modeled as a plasma 
clearance and optimized using the adult data. Pan et al. made excellent predictions for pediatric PK by 
replacing the virtual adults with virtual children (with modifications for lymph flow) and scaling the 
non-specific catabolism by conventional allometry.63 Evaluated protein products for the hybrid 
approach include recombinant erythropoietin and anakinra, which support the use of the model to 
predict plasma PK for non-mAb based proteins down to neonates. For mAbs and Fc fusion proteins, 
the software package pragmatically attributes the effect of ontogeny on elimination to a lower FcRn 
concentration in children that was optimized to the circulating IgG levels at each age, although there 
are currently no convincing mechanistic data available to suggest reduced abundance or function of 
FcRn in young pediatric patients. The lower circulating IgG subclass concentrations can also be 
explained by other plausible mechanisms, for example the well-described increased generalized 
protein metabolism in young pediatric patients, and/or a potentially reduced IgG synthesis rate,25 and 
further understanding of the ontogeny of the underlying physiological processes will be needed to 
fully support this approach for the typical uses of full PBPK models (e.g. approximating target organ 
exposure, modeling disease effects on PK, etc.) in pediatric patients younger than 2 years of age.  
PBPK modeling is considerably more complex than allometry and can be used to scale PK from 
adults to children when the mechanisms of drug disposition are well-understood. The processes 
governing the absorption, distribution, and elimination of TPs are very different from the processes 
driving the PK of small molecules, and have been reviewed previously.2 Despite this complexity, the 
PK of a wide range of TPs (10 kDa to 300 kDa) can be described within one common paradigm. As 
mentioned, the distribution of a TP is confined to the extracellular water volume. Extravasation from 
the plasma to the interstitial fluid occurs by a combination of convection and diffusion through 
 
17 
vascular pores and is limited by the hydrodynamic radius. Lymph flow returns the drug from the 
interstitial fluid to the venous blood. Elimination occurs when TPs are taken up into cells by 
phagocytosis, pinocytosis, or in specific cases, receptor-mediated endocytosis. Certain TPs related to 
immunoglobulins or albumin escape intracellular degradation by interacting with the salvage receptor 
FcRn. Renal metabolism can be prominent for TPs less than 70 kDa.64 
The workflow to build a pediatric PBPK model is well-established.12,13 Virtual adults are first 
created with quantitative knowledge of anatomy and physiology, and drug disposition is modeled 
with rate-based equations representing the actual mechanisms responsible. Uncertain or unknown 
parameters are optimized to the observed data in adults, and the final model is externally verified by 
predicting PK in heterogeneous scenarios. The virtual adults are then replaced with virtual children 
that are parameterized to account for immaturity in physiological processes relevant to drug 
disposition. PBPK modeling may be advantageous over allometry for predicting PK in children less 
than 2 years of age since the impact of immature physiology can be mechanistically considered. 
The physiological drivers of faster absorption, distribution, and clearance of endogenous and 
exogenous (i.e, therapeutic) proteins in children have been reviewed and applied to a PBPK model for 
mAbs in premature infants.34,65 Fast absorption is driven by a lymph flow that is up to three times 
faster in infants than in adults. High extracellular water volumes increase the extent of distribution on 
a per kg body weight basis. Relatively large central organs with leaky vasculature and dense capillary 
networks enable fast extravasation into interstitial fluid. High concentrations of circulating leukocytes 
increase cellular uptake and subsequent degradation. FcRn function has sometimes been postulated to 
be lower in children, but this argument is not supported by clear in vitro or in vivo evidence. The 
strongest argument against the hypothesis is that the pattern of pediatric exposure is identical for 
proteins that bind to FcRn, and those that do not (Table 1).63 Two PBPK models for TPs are available 
[PK-Sim (Open Systems Pharmacology)66; SimCyp63], but have not been mechanistically translated 
to pediatrics for these purposes.  
The inherent strength of a PBPK model is that drug concentrations or receptor occupancy at the 
target site (e.g., the brain, a tumor, or an inflamed bowel) can be feasibly extrapolated from animals 
through adults to pediatric patients with sufficient in vivo evidence.67 The burden of an active disease 
state and its impact on PK can be mechanistically represented, as it has for example been done for the 
impact of inflammation on the PK of TPs in animals and humans.60,68,69 In addition, PBPK modeling 
allows us to concurrently explore more multiple competing mechanisms relevant for TP disposition 
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and their changes in children, such as the interaction of endogenous IgG and exogenous Fc-containing 
TPs with FcRn and the interdependencies of the resulting effects. As this application is in its infancy, 
there have been no PBPK models used to inform a pediatric drug label for a TP to date.70 The 
growing PK data available for TPs and the foundational similarities in disposition throughout the drug 
class will likely enable more broad pediatric PBPK applications for first-in-pediatric dose selection in 
the near future, especially if more mechanistic understanding on the ontogeny of underlying drug 
disposition processes is emerging. 
For a substantial number of TPs, extrapolation of PK to pediatric patients is further complicated by 
TMDD.71 TMDD is the phenomenon where the binding of the TP to its target, either soluble or 
membrane-bound, triggers an additional elimination pathway for the TP. Since this TMDD 
elimination pathway is usually saturable at therapeutic concentrations, clearance decreases with 
increasing doses until the target is overwhelmingly saturated, resulting in dose-dependent, nonlinear 
PK behavior. As nonlinear clearance parameters are rarely correlated with body weight, scaling non-
linear clearance depends on what is known about differences in target abundance, turnover, binding 
kinetics and TP-target complex degradation between the adult and pediatric populations.71 A 
Michaelis-Menten approximation is often used to model nonlinear clearance, particularly when there 
is limited information available on the target kinetics. Among adults and young children with the 
same disease state, constant values for the Michaelis-Menten constant (KM) and the maximum 
elimination rate (VMAX) for all ages have achieved acceptable PopPK model fits for thymoglobulin, 
alemtuzumab and nab-paclitaxel.72-74 While there is usually consensus to use the same KM parameter 
in both populations, weight based scaling has at least been suggested for VMAX when scaled for first-
in-human studies.75 If sufficiently characterized at least in adults, the full TMDD model allows for 
more flexibility in pediatric scaling as physiologic and mechanistic information about age-specific or 
population-specific differences in target concentration or production can be integrated.6,58 This was 
recently exemplified in a PBPK model for epoetin alfa with a quasi-equilibrium approximation of the 
TMDD model where the nonlinear PK in adults and children was characterized with a constant 
parameter set.63 In one combined TMDD and PK/PD model for canakinumab, the turnover of the 
target (IL-1β) was noted to be modestly increased in young children vs. older children.57 
Similar to TMDD, extrapolating the processes related to subcutaneous or intramuscular 
administration from adult to pediatric patients remains challenging. Currently first-in-pediatric dosing 
of mAbs administered via the extravascular route is done through allometric extrapolation from adult 
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extravascular dosing.70 Development programs typically seek approval for an intravenous route of 
administration first and later add the subcutaneous route approval based on exposure matching and 
non-inferiority trials. Examples include secukinumab, pertuzumab, abatacept, tocilizumab, and 
daratumumab. For pediatrics, doses are then extrapolated from adult subcutaneous doses, as for 
example done for abatacept, tocilizumab, and etanercept. Due to the limited understanding of the 
determinants of rate and extent of absorption after subcutaneous administration of TPs, the ability for 
mechanism-based extrapolation to pediatric patients remains limited.76 Based on the increased 
extracellular water content and a higher perfusion rate (both blood and lymph) relative to adults, one 
might expect a faster rate of absorption in young pediatric patients relative to adults.34 For the extent 
of absorption, the situation seems to be less clear, having potentially counteracting increased protein 
turnover and decreased lymphatic residence time and degradation.34 These mechanistic differences 
seem to translate into quantifiable differences in the PK of TPs: For example, the absorption rate was 
three times faster in infants and young children compared to adults on IM administration of 
palivizumab, but the extent of absorption remained unchanged.35 Some of these aspects have been 
incorporated into semi-mechanistic and PBPK models used to predict absorption pharmacokinetics in 
pediatric patients by borrowing animal and human physiological data from the literature, but 
published success of these approaches remains scarce.77-79 
Considering the available tools and anticipated challenges, we have formulated general 
recommendations for first-in-pediatric dose selection for TPs (Figure 5). Presented data suggest 
nonlinear relationships between body weight and both clearance and volume of distribution for TPs in 
pediatric populations, with allometric exponents of 0.75 and 0.8, respectively. The ease of use for 
allometry and relative confidence as compared to PBPK modeling make allometry or hybrid 
allometry the preferred approaches to scaling PK down to children 1 year of age, or ≥10 kg body 
weight. For newborns and infants (i.e. <1 year of age or <10 kg body weight), even higher 
nonlinearity seems to occur. PBPK models are under development to support extrapolation to these 
vulnerable populations. Previous clinical trial experience with older children increases the confidence 
with which an extrapolation can be made. When administering by an extravascular route or when the 
drug is subject to significant TMDD, the same allometric principles can be used to scale foundational 
PK parameters with the modifications outlined in the previous paragraphs, but more uncertainty in the 
dose predictions can be expected. An uncertainty analysis should be conducted to assess the risk of 




Figure 5. Rationalized approach to first-in-pediatric dose selection for therapeutic proteins. PK = 
pharmacokinetics, FDA = US Food and Drug Administration, CL = clearance, Q2 = 
intercompartmental clearance, V1 = volume of distribution in the central compartment, V2 = volume 
of distribution in the peripheral compartment, TMDD = target-mediated drug disposition, VMAX = 
maximal rate of nonlinear elimination, KM = Michaelis-Menten constant, PBPK model = 
physiologically based pharmacokinetic model 
The way forward for improving first-in-pediatric dose selection will be paved by more detailed 
access to pediatric PK data for TPs from which we can learn, more detailed physiological data on 
ontogeny of processes relevant for TP disposition, and in general more pediatric drug development 
experience for TPs. Inevitably, the ontogeny of the extravascular absorption rate and processes, for 
example, will be able to be quantified with enough PK data for a variety of molecules. More detailed 
physiological data can be directed toward refining ontogeny profiles in infant PBPK models for 
parameters such as leukocyte content, capillary density, lymph flow rate and FcRn concentration. 
Finally, there is a need to standardize an approach to variability and virtual pediatric populations. 
While adult parameters from a PopPK model can be scaled to children by allometry, it is not known 




1.5 Pediatric Dose Selection for Labelling 
When pediatric data has been collected in the first-in-pediatric trial and subsequent studies, the 
disposition of a TP drug in pediatric patients can often be characterized with high granularity using 
the aforementioned PopPK or PBPK tools.16 However, translating the mathematical relationships 
established in these models back into clinically useful dosing recommendations is far from trivial. 
After all, healthcare providers cannot be expected to use complex mathematical relationships to 
derive a dose, especially if they involve patient-specific covariates that may be difficult to measure 
(e.g., body surface area).  
The first-in-pediatric dose selection as outlined in the previous section and the underlying 
understanding of the influence of body size, age and disease on PK, PD and the exposure-response 
relationship for the TP of interest can either be confirmed or further refined during the pediatric 
clinical development program. Independent of the exact course of this pathway, however, in the end 
usually carefully characterized PK and/or PKPD relationships and their modulation by physiologic, 
pathophysiologic and ontogenic processes need to be converted into pediatric dosing 
recommendations that are part of the drug product labeling. As such, pediatric dose selection for 
labeling can be viewed as a compromise between precision medicine and practicability: The relatively 
precisely defined mathematical relationship between demographic, physiologic and pathophysiologic 
covariates and dose requirements in individual patients has to be balanced with the clinical 
requirements of limited complexity to avoid overburdening healthcare providers and prevent 
medication dosing errors. The acceptable degree of simplification is dependent on the individual TP 
in a specific indication, particularly the steepness of the exposure-response relationship, the 
narrowness of the therapeutic index of the TP, and the degree of between-patient variability in PK and 
PD.  
While TPs, and most specifically mAbs, have been reported to exhibit 20-59% between-subject 
variabilities in PK parameters (similar to those of small molecule drugs), many TPs have high 
tolerability and very limited off target toxicity, leading to relatively wide therapeutic indices for many 
indications.16,18,49 In these instances, wider ranges of exposure may be equally safe and efficacious as 
compared to more narrowly defined exposure metrics. Consequently, pediatric dosing 
recommendations for TPs are frequently defined by relatively broad patient strata that can easily be 
implemented in healthcare settings but provide sufficient granularity for age-appropriate dosing.4,80 
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Tiered dosing is the most frequently used approach to implement this concept in pediatric 
pharmacotherapy, and has been explored in detail for use with TPs.3 With this dosing approach, one 
of several body weight- or age-defined patient strata receive either a flat or a body size-adjusted dose. 
For example, adalimumab pediatric dosing in juvenile idiopathic arthritis is based on body weight 
where patients above 2 years of age receive a subcutaneous dose of either 10, 20 or 40 mg every other 
week, dependent on whether their body weight falls within the strata of 10 to <15 kg, 15 to <30 kg, or 
≥30 kg.81 Similarly, patients above 2 years of age also receive different doses of tocilizumab if their 
body weight is lower or higher than 30 kg. But in contrast to adalimumab, tocilizumab dosing is 
further weight normalized (12 mg/kg and 8 mg/kg IV every 4 weeks for <30 kg and ≥30 kg, 
respectively) to allow for more granular dose adjustments.82 If available, dose selection may be 
further guided by clinically accessible biomarkers if these have a major impact on the PK and PD of 
the TP. Omalizumab is a prime example for this application, where the pediatric dosing 
recommendations are based on age and weight strata that are further modified by pretreatment serum 
IgE levels, the molecular target of omalizumab in the treatment of allergic asthma.83 
The translation of a pediatric PK model into clinical dosing recommendations for regulatory 
approval is exemplified by the approval of adalimumab for adolescents 12 years and older with 
hidradenitis suppurativa.84 While the underlying population pharmacokinetic modeling framework 
described the clearance of adalimumab with a nonlinear weight-based relationship, the resulting 
approved dosing recommendation is a tiered dosing with flat dosing in two body weight strata, 30 to 
<60 kg and ≥60 kg. The translation was facilitated through extensive model-based exposure 
simulations in the target population supported by extrapolation exercises for efficacy and safety of 
adalimumab from adults to adolescents, particularly the assumptions of similar disease progression 
and response to adalimumab in hidradenitis suppurativa, and a similar exposure-efficacy relationship 
in adults and adolescents.84 
While dose individualization based on therapeutic drug monitoring is performed for clotting factors 
with their relatively short half-lives as shown earlier in this manuscript, we do feel that such dosing 
approaches are neither practical nor warranted for most TPs with long elimination half-lives, except 
in situations where between-patient exposure is highly variable, difficult to predict and may lead to 




In summary, pediatric dose selection for TPs is an evolutionary process from allometric and model-
based approaches over first-in-pediatric dosing to clinical dosing recommendation that is grounded in 
a strong scientific framework of understanding the PK and PD of these compounds and their 
dependency on ontogeny and differences in body size, composition, and functioning between children 
and adults. Thus, TPs require approaches distinctively different compared to small molecule drugs 
based on their disposition properties and the molecular and physiological processes determining them. 
While some understanding of these processes is emerging, substantial gaps and uncertainties are 
remaining that hamper a more widespread and reliable application of especially model-based 
approaches to support pediatric dose selection. We are hopeful that filling these gaps with an 
improved understanding of the ontogeny of clinically relevant drug disposition processes for TPs, 
pediatric dose selection for this class of medications will become a more reliable and precise process 
in the near future. 
1.7 Study Highlights 
This manuscript describes the current state of knowledge on the pediatric pharmacokinetics of 
monoclonal antibodies and therapeutic proteins. The scope of the problem when extrapolating doses 
from adults to children is presented. Relevant methods for extrapolation are reviewed, and best-





Pharmacokinetic Considerations for Antibody-Drug Conjugates 
against Cancer 
2.1 Abstract 
Antibody-drug conjugates (ADCs) are ushering in the next era of targeted therapy against cancer. An 
ADC for cancer therapy consists of a potent cytotoxic payload that is attached to a tumour-targeted 
antibody by a chemical linker, usually with an average drug-to-antibody ratio (DAR) of 3.5 – 4. The 
theory is to deliver potent cytotoxic payloads directly to tumour cells while sparing healthy cells.  
However, practical application has proven to be more difficult. At present (September 18, 2017) there 
are only two ADCs approved for clinical use. Nevertheless, in the last decade there has been an 
explosion of options for ADC engineering to optimize target selection, Fc receptor interactions, 
linker, payload and more. Evaluation of these strategies requires an understanding of the mechanistic 
underpinnings of ADC pharmacokinetics. Development of ADCs for use in cancer further requires an 
understanding of tumour properties and kinetics within the tumour environment, and how the 
presence of cancer as a disease will impact distribution and elimination. Key pharmacokinetic 
considerations for the successful design and clinical application of ADCs in oncology are explored in 
this review, with a focus on the mechanistic determinants of distribution and elimination.   
2.2 Introduction 
Antibody-drug conjugates (ADCs) are ushering in the next era of targeted therapy against cancer. An 
ADC for cancer therapy consists of a potent cytotoxic payload that is attached to a tumour-targeted 
antibody by a chemical linker, usually with an average drug-to-antibody ratio (DAR) of 3.5 – 4. The 
theory is to deliver potent cytotoxic payloads directly to tumour cells while sparing healthy cells. 
ADCs can be used to improve the therapeutic window of systemic chemotherapeutics and to open the 
door for chemotherapeutics that may have previously failed because of poor permeability or a lack of 
selectivity for tumour cell killing. When the ADC binds its target protein on the surface of tumour 
cells, it can be internalized by receptor-mediated endocytosis. It is subsequently degraded in the cell 
and the payload is released into the intracellular space. Current payloads under investigation primarily 
interfere with microtubule formation or crosslink DNA. Ideally, only cells that express the target 
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protein for the antibody will be exposed to the cytotoxic effects and systemic toxicity will be avoided. 
However, non-specific uptake occurs to a small degree in all tissues.   
While the initial theory is simple, practical application has proven to be more difficult and only two 
ADCs are currently available for therapeutic use: trastuzumab emtansine86 and brentuximab vedotin87 
(September 18, 2017). Nevertheless, as of 2016, approximately 50 ADCs are in the clinical pipeline.88 
Other forms of ADCs, such as radioimmunoconjugates and enzyme-immunoconjugates have been 
studied in preclinical contexts for many years and radioimmunotherapy is effective for hematologic 
malignancies.89 These are once more emerging with promise for solid malignancies, though these are 
beyond the scope of this review. 
For drug developers, academic researchers and clinicians alike, ADCs present unique 
pharmacokinetic opportunities and challenges. They are large molecules (~150kDa) with a 
distribution of the intact ADC that is mostly confined to the plasma, interstitial fluid and lymph.90 
They often possess long plasma residence times because of their dynamic interactions with the 
neonatal Fc receptor (FcRn) and are administered intravenously every 1-4 weeks.91-93 In most but not 
all cases, they exhibit nonlinear pharmacokinetics and dose-dependent clearance due to saturable 
target binding and elimination.94,95 No consistent pattern has yet been identified between the ADCs 
that exhibit dose-dependent clearance and those that do not.94 In theory, the degree of nonlinearity 
will be proportional to the whole body target load. Figure 6 displays the mechanistic processes that 
are thought to affect the distribution and elimination of ADCs in humans. Physiologically-based 
pharmacokinetic (PBPK) models are emerging to describe the biodistribution of ADCs as a function 
of these key processes.96 
A typical pharmacokinetic assessment of an ADC involves an analysis of multiple drug species in 
circulation, including the conjugated antibody, the total antibody (both conjugated and unconjugated) 
and the free payload, as well as any anti-drug antibodies (ADAs) that may have been generated.97 
While it is a standard of practice in industry,97,98 the scientific value of this type of pharmacokinetic 
assessment is limited on its own. As with all drugs, plasma concentrations are only loosely correlated 
with efficacy at the tumour site.99 The high inter-individual variability in plasma protein 
pharmacokinetics confounds predictions for dose-response relationships.92,93 Plasma stability and the 
extent of deconjugation in circulation can be estimated with direct measurements of the conjugated 
fraction.97 The free payload concentrations can be used to evaluate payload-dependent toxicity, 
though this toxicity is not easily distinguishable from the toxicity that occurs when the conjugated 
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antibody is taken up into normal tissues.100 With respect to ADA analysis, it is important that ADCs 
possess low immunogenic potential – though with the increasing use of humanized or fully human 
IgG backbones and the low antigenicity of typical payloads, clinically-significant immunogenicity of 
ADCs is becoming a problem of the past.101 
In the last decade there has been an explosion of options for ADC engineering to optimize target 
selection, Fc receptor interactions, linker, payload and more.102 Evaluation of these strategies requires 
an understanding of the mechanistic underpinnings of ADC pharmacokinetics. Development of ADCs 
for use in cancer further requires an understanding of tumour properties and kinetics at the tumour 
site, and how the presence of cancer as a disease will impact distribution and elimination. Key 
pharmacokinetic considerations for the successful design and clinical application of ADCs in 
oncology will now be explored, with a focus on the mechanistic determinants of distribution and 





Figure 6. The main physiologic processes governing the disposition of ADCs. ADCs administered 
intravenously cross the blood vessel wall and enter tissues by convection through pores or (to a lesser 
extent) by transcytosis through the vascular endothelium. Movement through the interstitial matrix is 
slow and erratic. ADCs in the interstitial fluid bind their target receptor expressed on the cell surface 
and are internalized by receptor-mediated endocytosis. Internalized ADCs undergo lysosomal 
processing in cells and then release their cytotoxic payload. In endothelial, epithelial and 
hematopoietic cells, ADCs can be protected from lysosomal degradation through binding to the 
neonatal Fc receptor (FcRn). ADCs that fail to bind their target are mostly recycled through the 
lymph and back to the venous circulation. Macrophages, monocytes and other immunoregulatory 
cells that express the Fc-gamma family of receptors (FcγR) may phagocytose ADCs locally and in the 




Table 2. Pharmacokinetic considerations for antibody-drug conjugates against cancer 
1. Target-Mediated Drug Disposition 
• High target expression in tumours and 
relatively low expression in normal tissues 
is required 
• Saturable target-mediated elimination 
contributes to nonlinear pharmacokinetics 
• The nature of binding to target at the tumour 
rim may hinder penetration into tumours 
(binding site barrier effect) 
 
2. Circulation and Tissue Distribution 
• Tissue distribution is dependent on 
perfusion, vascular permeability and target 
expression 
• Recycling through the lymphatic system 
allows ADCs to avoid persisting in non-
target-bearing tissues 
3. Fc Receptor Interactions 
• FcRn may facilitate transcytosis of intact 
ADC across endothelial and epithelial layers 
• Affinity for FcRn influences plasma half-
life 
• FcγR-mediated phagocytosis may contribute 
to elimination and toxicity 
 
4. Payload Kinetics 
• The intracellularly-released payload must 
maintain nanomolar cytotoxic potency 
• Hydrophobic payloads diffuse to nearby 
cells, causing a bystander effect 
• Nonpolar payloads may be vulnerable to 
efflux by P-gp  
 
5. Linker Kinetics 
• Site-specific conjugation maximizes 
homogeneity and avoids aggregation due to 
close packing of hydrophobic payloads 
• ADCs with high DARs are cleared quickly 
and accumulate in the liver 
 
6. Tumour Properties 
• High interstitial fluid pressure hinders ADC 
penetration at the tumour rim 
• Normalizing tumour vasculature is a 
double-edged sword 
• Retention in tumours is mediated by poor 
lymphatic drainage and the dense 
extracellular matrix 
• Shifted extracellular pH may alter stability 




2.3 Target-Mediated Drug Disposition 
ADCs are designed to bind to the extracellular domain of a membrane-bound target protein that can 
facilitate internalization into tumour cells by receptor-mediated endocytosis.103 Because of the high 
affinity of the initial binding interaction, ADCs are said to undergo target-mediated drug disposition 
(TMDD), meaning that the properties of the target influence the pharmacokinetics of the drug.19,95 
TMDD can be observed on a small scale, affecting drug penetration into tumour tissue104 and on a 
large scale, governing drug exposure across the whole body.105 Target expression, internalization, 
turnover, accessibility and binding affinity all impact the pharmacokinetics of ADCs and must be 
considered for optimal target selection. 
2.3.1 Target-Mediated Distribution 
After administration, ADCs distribute to occupy target sites that are present in both normal and 
diseased tissue. Therapeutic doses often achieve maximum target occupancy around the body. If the 
dose is not enough to saturate all target sites, ADCs will distribute to target sites in tissues that are 
highly perfused and permeable106,107 or have high target expression.108  
For optimal specificity, the tumour target load (presence) should be as high as possible compared to 
the whole body target load. In reality, the tumour target load makes up less than 1% of the whole 
body load,109 even with significant target overexpression and upregulation in tumours. New exploits 
target proteins that are uniquely mutated in tumour tissues so that uptake into normal tissues can be 
minimized.110,111 In mice, high target expression in normal tissues can impede the distribution of an 
ADC into tumour tissue by forming a target sink.108   
It has been suggested that this challenge can be obviated by pre-dosing patients with naked 
antibody before administration of the ADC to partially saturate the target sink so that ADC specificity 
for the tumour can be improved and also so that payload toxicity to normal tissues can be 
minimized.112 When using this strategy, a proportion of target sites in the tumour tissue must be left 
unsaturated after the dose of the naked antibody or payload toxicity to tumours will also be 
compromised. However, feasibility would depend precisely on relative tissue perfusion and the nature 
of drug distribution after dosing. There is significant inter-individual variability in target expression 
and each patient would require a different dose of the naked antibody to achieve selective target 
saturation in normal tissues, making this strategy rather impractical. Furthermore, it is likely that the 
naked antibody itself will have activity, either by secondary effects through the immune system or by 
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target modulation (activation or internalization). We therefore do not anticipate this strategy will 
easily translate into clinical application. 
The efficacy of ADCs is dependent on the degree of receptor occupancy or target saturation.113 The 
notion of target accessibility is important, and this idea surfaced after the predicted doses required to 
saturate targets were much higher than observed clinically.114 The density of cell-cell packing and the 
prevalence of tight junctions may limit the accessibility of targets on cell membranes. Target 
accessibility can also be impeded if targets form dimers or oligomers that block or hinder the 
antibody binding domain.68   
2.3.2 Target-Mediated Elimination 
Target-mediated elimination refers to the binding of an ADC to its target, internalization by receptor-
mediated endocytosis and degradation within the cell. Saturable target-mediated elimination 
contributes to the nonlinear pharmacokinetic profile of ADCs. When target sites are saturated, 
elimination follows a zero order rate and when they are unsaturated, elimination follows a first order 
rate.   
Along with target expression, the internalization rate of the drug-target complex also influences 
target-mediated elimination of ADCs. In contrast to small molecules, high target-mediated 
elimination – or in other words, a high rate of internalization into cells – could be desirable for ADCs 
because efficacy depends on internalization into tumour cells.115,116 Antibodies of different sizes or 
antibodies directed against different epitopes of the same target may have drastically different 
internalization rates.117 In some cases, binding of an antibody induces internalization of the target,118 
while in other cases it does not.119 ADCs that induce internalization of the target, rather than passively 
internalize are predicted to have strong efficacy at first, but may struggle with sustained efficacy and 
tumour specificity if the target is quickly depleted on tumour cells. In that case, few target receptors 
would remain for ADC binding.   
The extra-cellular domain (ECD) of membrane-bound targets can often be found in circulation in 
patients whose tumours overexpress the target.120 A mathematical model suggests that the rate of 
shedding is influenced by target expression and the internalization rate.121 Antibodies form immune 
complexes with circulating ECD proteins and are eliminated by immunoregulatory processes with a 
half-life of two days.122,123 Pool et al. determine that antibodies bound to the ECD of EGFR 
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accumulate in the liver.124 Therefore, ADCs against targets that have high shed ECD levels in plasma 
may incur more toxicity to the liver.   
A population pharmacokinetic study of trastuzumab in breast cancer patients concludes that the 
serum ECD concentration is a significant covariate increasing clearance and volume of distribution.125  
However, both a mechanistic model68 and a study in mice126 demonstrate that the effects on plasma 
concentrations are marginal when antibodies are administered at therapeutic doses. It is likely that the 
significance of ECD concentrations as a covariate is related to its role as an indicator of more 
advanced disease in humans, rather than its role as a target sink.   
2.3.3 Binding Site Barrier Effect 
The effects of TMDD are prominent on a smaller scale in solid tumours.104 The binding site barrier 
effect encompasses the cumulative effects of target expression, turnover and binding affinity that may 
hinder ADC penetration throughout solid tumours. If target expression in tumour tissue is 
exceptionally elevated and binding affinity is high, then large ADC concentrations are required in the 
tumour environment to saturate the available receptors at the tumour rim so that free ADC molecules 
can proceed to penetrate into the deeper layers.127,128 ADCs face a similar kinetic challenge when 
target turnover is high and there is a quick replenishment of internalized targets.127 The only 
modifiable component of the binding site barrier effect is target binding affinity. In the tumour 
environment, antibodies with high affinity are more likely to be sequestered by the first available 
targets, rather than to distribute to more distal targets.129 However, a sufficient binding affinity is 
required for internalization and efficacy. It is a balance – there exists an optimal antibody affinity for 
each tumour size and target expression level to maximize distribution of ADCs within tumours while 
maintaining sufficient internalization and efficacy. This problem has been analytically addressed with 
modeling in the context of ADCs.128 
The effects on conjugation on binding affinity must be investigated on a drug-by-drug basis. While 
in many cases the affinity is unaffected,130 some results suggest otherwise. For example, Bondza et al. 
found that conjugation decreased binding affinity for cetuximab but did not affect binding affinity for 
an anti-CD44v6 antibody.131 More research is required to determine the effects of conjugation site 
and payload properties on target binding affinity. 
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2.3.4 Circulating Lymphocyte Antigens 
Of the two ADCs currently on the market, one is directed against HER2, a solid carcinoma target,86 
while the other is directed against CD30, a lymphocyte antigen in Hodgkin’s lymphoma.87 ADCs 
against lymphocyte antigens may require a unique pharmacokinetic approach because the target cells 
may be spread throughout different tissues, the lymphatic system or the peripheral circulation. 
Approximately 30% of ADCs in development are directed against hematologic and lymphoid 
cancers.88 To date, there have been no clear pharmacokinetic differences in phase 1 trials between 
ADCs against solid carcinoma targets and those against hematologic or lymphoid cancers.94 However 
this assessment is limited by the low sample sizes in phase 1 trials, the diversity of patients, the 
diversity of disease and the wide inter-individual variability in ADC pharmacokinetics. From a 
mechanistic standpoint, circulating lymphocytes may be highly accessible for ADCs because their 
distribution is similar to ADC distribution (see below).132 In addition to payload-induced toxicity, 
binding of ADCs to circulating lymphocytes can cause elimination by immunoregulatory processes 
and activation of complement.133 Mechanistic pharmacokinetic modeling of the two ADC subclasses 
may illuminate more subtle differences that can be observed through the lens of the pharmacokinetic 
profile in plasma.132 
2.4 Circulation and Tissue Distribution 
ADCs are large molecules with a molecular weight of approximately 150kDa. Because they are 
structurally similar to endogenous IgG, they have a distribution similar to IgG and they are affected 
by many of the same physiologic processes in vivo. Distribution is generally confined to the plasma, 
interstitial fluid and lymph.90 Convective fluid flow facilitates the transport of ADCs through and 
between these physiologic mediums.134   
After IV administration, the first method by which ADCs can pass through the capillary wall and 
into the interstitial fluid of tissues is by filtration, or the convective flow of plasma through vascular 
pores (junctions, fenestrae, sinusoids, etc.).134 While there is fluid flow in both directions across the 
capillary wall, net flow of plasma proteins and ADCs in normal tissues is out of the blood vessels and 
into the interstitial fluid. The Starling equation describes the net movement of fluid across capillary 
walls as a function of opposing hydrostatic and osmotic pressures.134 Once in the interstitial fluid, 
ADCs are free to interact with membrane-bound targets. ADCs that do not contact a target in the 
interstitial space are recycled to the venous circulation through the lymphatic system. Throughout 
 
33 
circulation, ADCs may be vulnerable to non-specific proteases, though this clearance mechanism is 
considered negligible for most IgG products.135 
An analysis of the upper limit of pore size for capillaries and the blood perfusion in each tissue can 
be used to understand the tissue-specific distribution pattern of ADCs (Table 3).136,137 The level of 
target expression also contributes to distribution by sequestering ADCs in tissues with prominent and 
accessible target loads.108 Biodistribution studies in mice show that the liver, spleen, kidneys, lungs 
and heart are the dominant organs for tissue distribution shortly after administration; highly perfused 
tissues reach their Cmax quickly, while poorly perfused tissues reach their Cmax as long as 24 hours 
after IV administration.106-108,112,138,139 
Table 3. Tissue-specific distribution profile of antibody-drug conjugates 
Tissues Capillary Characteristics Perfusion Distribution 
Brain Non-fenestrated capillaries 
with tight junctions 
Minimal Minimal 
Muscle, skin, large 
intestine, adipose 
Non-fenestrated capillaries 





Fenestrated capillaries  Moderate Low 
Bone marrow Sinusoidal capillaries Moderate Moderate 
 
Heart, lung Non-fenestrated capillaries 
with loose junctions 
High Moderate 
Kidney Fenestrated capillaries  
 
High High 





Resistance to flow through pores is due to the size, charge and hydrophilicity of an ADC. Because 
conjugation impacts these parameters, the degree of conjugation has been shown to alter 
biodistribution. At low drug-antibody ratios (DARs), there is no significant difference in tissue 
distribution between conjugated and unconjugated antibodies.106,107,139 However, at DARs greater than 
four, conjugation induces a fast plasma clearance with a trend toward accumulation in the liver.107,138 
An explanatory hypothesis is that the hydrophobicity associated with increasing DARs may make 
ADCs more vulnerable to non-specific uptake into hepatocytes and Kupffer cells by pinocytosis 
and/or phagocytosis.   
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The filtration rate of antibodies and ADCs through vascular pores can be measured with visible 
tagging and in vivo imaging. Using such measurements, Parving and colleagues have demonstrated 
that the flow of plasma proteins through capillaries can change proportionally to blood pressure140 and 
can be affected by such perturbations as liver cirrhosis,141 diabetes,142,143 congestive heart failure,144 
and inflammatory conditions.145 Furthermore, the presence of cancer may impact the TER and the 
tissue uptake of ADCs. There are conflicting measurements of the TER in patients with cancer, 
though it can be up to two-fold higher in cachectic patients with cancer than in healthy subjects 
(Table 4).146-148 Population pharmacokinetic analyses with both antibodies and ADCs in cancer have 
identified disease staging and tumour burden as significant covariates causing increased plasma 
clearance.49,149 As mentioned earlier, the whole body target load is only marginally increased by a 
larger tumour burden109 and would be unlikely to be responsible for such remarkable changes in the 
pharmacokinetic profile. The increased plasma clearance is likely indicative of high tissue uptake and 
facilitated by the systemic vascular hyperpermeability150 that is attributable to the inflammatory 
burden of advanced cancer. ADCs may then have the highest tissue uptake and potential off-target 
toxicity in patients with advanced cancer and comorbid conditions that increase vascular permeability 
to plasma proteins (see Table 4).  
Table 4. The transcapillary escape rate (TER) in patients with comorbid conditions 




Healthy140 3.0 (0.7) 5.2 (1.0) 
Hypertensiona 140 4.7 (1.0) 7.8 (0.9) 
Liver Cirrhosis141 8.4 (0.8) 7.4 (1.9) 
Short-Term Type 1 Diabetesb 142  5.5 (1.0) 
Long-Term Type 1 Diabetesc 143 4.4 (1.0) 7.4 (1.1) 
Chronic Right Heart Failure144  8.3 (1.6) 
Inflammatory Skin Disease145  8.6 (1.1) 
Cancer146-148  5.5 – 12.1d 
a mean arterial blood pressure: 193/119 mmHg 
b mean duration: 2.6 years 
c mean duration: 20 years with microangiopathy 
d range of reported medians in three studies 
 
Focused ultrasound (FUS) therapy can be used to induce enhanced permeability of tumour tissue to 
therapeutic antibodies by hyperthermia. When the temperature of tumour tissue in mice is increased 
to 42°C by FUS therapy for 3 – 5 minutes, the uptake of trastuzumab and other plasma proteins into 
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tumour tissue is increased up to two-fold.151 Multiple short rounds of hyperthermia have additive 
effects on antibody uptake.151   
The brain is the most inaccessible tissue for ADCs due to the complete restriction of convective 
flow through the blood-brain barrier. Researchers have explored osmotic, biochemical, radiological 
and focused ultrasound therapy methods for disrupting the blood-brain barrier and enabling 
convective flow of therapeutic antibodies into brain tissue, which are reviewed in detail by Chacko et 
al.152 The most promising hypothesis for the route of entry of mAbs into the brain is via the 
circulation of the cerebrospinal fluid (CSF).153   
The movement of ADCs and other macromolecules within the interstitial space is not consistent or 
predictable. The interstitium is a fibrous matrix of collagens, proteoglycans, laminins and other 
structural proteins woven around the blood and lymphatic capillaries.134 The surrounding interstitial 
fluid is derived from plasma and contains ions, small solutes, plasma proteins and leukocytes.134 
Transport of ADCs through the interstitium is slow and erratic.134 The movement of proteins and 
solutes is driven by hydrostatic pressure, osmotic pressure, chemical or electrical gradients and 
interactions with matrix components. Large pore microdialysis is being used to measure interstitial 
concentrations of antibodies154 and may prove useful for evaluating the interstitial distribution of 
ADCs.   
From the interstitium, ADCs can be taken up into lymphatic capillaries through cleft-like 
junctions.134 They will be transported through the lymphatic system at a rate that is estimated to be 
0.2% of the plasma flow rate.135 After collection into the thoracic duct or the right lymphatic duct, 
ADCs will re-enter venous circulation at an interface with the left or right subclavian vein, 
respectively.134 Recycling through the lymphatic system allows ADCs to avoid localizing in non-
target-bearing tissues.   
The mononuclear phagocyte system (MPS) is present throughout circulation and plays a role in the 
regulation of antibodies and the immune system.155 It largely consists of monocytes in circulation and 
macrophages that are distributed in tissues.155 Many of these mononuclear phagocytic cells express 
Fc-gamma receptors (FcγR), which can bind the Fc region of IgG molecules and clear them from 
circulation by phagocytosis.156 The primary tissues involved in the MPS are the liver, spleen, lymph 
nodes, thymus and bone marrow.155  
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Subcutaneous administration has not yet been utilized for an ADC, but is common for 
unconjugated antibodies.157 After subcutaneous administration, ADCs must reach the systemic 
circulation either through the lymphatic system, or by diffusion against the net fluid flux from 
interstitial space and into plasma at the local capillary beds.158 The subcutaneous bioavailability of 
unconjugated antibodies ranges from 53-82%,157 likely due to specific phagocytosis into cells of the 
MPS in lymphoid organs before reaching the venous circulation. This cellular uptake of ADCs could 
cause undue toxicity in lymphoid organs, limiting the subcutaneous administration route. 
Subcutaneous bioavailability of antibodies is correlated with FcRn affinity159 (because cells of the 
MPS express FcRn) and can be as low as 28% in FcRn-deficient animals.160  
2.5 Fc Receptor Interactions 
Fc receptors are so named because they bind to the Fc region of antibodies and help to regulate their 
distribution and elimination in the body. The Fc receptors that interact with IgG-based drugs are the 
neonatal Fc receptor (FcRn) and the family of Fc-gamma receptors (FcγR). Each receptor subtype 
affects ADC pharmacokinetics in different ways. 
FcRn is present in vascular endothelium, intestinal epithelium, the blood-brain barrier, placental 
syncytiotrophoblasts, kidney podocytes and macrophages.161 Its primary purpose is to salvage IgG 
from intracellular degradation. It may also facilitate the endocytic transport of antibodies and ADCs 
across epithelial and endothelial boundaries, such as the intestinal wall in the neonate or the capillary 
wall. Figure 7 describes the main features of this transit. ADCs may be taken up by fluid-phase 
pinocytosis or receptor-mediated endocytosis from both apical and basolateral surfaces.91,162 The 
method of uptake depends on the surrounding pH because FcRn binds ADCs in a pH-dependent 
manner, with high affinity below pH 6.5 and low affinity at pH 7.4.161 During transit, FcRn binds to 
ADCs in a 2:1 conformation and acts as a shuttle protein to protect them from lysosomal 
degradation.161 The pH-dependence of binding affinity causes ADCs to bind FcRn with highest 
affinity when the threat of degradation in lysosomes is highest. ADCs will compete with endogenous 
IgG for binding to FcRn, and the available concentrations are saturable.109,135,163 Any ADCs that fail 
to bind FcRn in the endosome are degraded.91,163 There is theoretical and experimental evidence to 
suggest that approximately two thirds of FcRn-bound ADCs in endothelial cells are shuttled to the 
apical surface and returned to the plasma, while one third is expelled into the interstitial fluid at the 





Figure 7. Summary of proposed mechanisms for transcytosis and FcRn binding. ADCs may pass 
through vascular endothelium by FcRn-mediated transcytosis. ADCs are taken up by fluid-phase 
endocytosis into vascular endothelial cells (and others). During endocytic trafficking and sorting, they 
may bind to the neonatal Fc receptor (FcRn) with pH-dependent affinity and in a 2:1 conformation, 
which protects them from lysosomal degradation. Mechanistic models suggest that approximately 
two-thirds of antibodies bound to FcRn are recycled to the plasma space, while one-third is shuttled to 
the interstitial fluid. 
Antibody plasma half-life is correlated with its affinity for FcRn binding.91,109,135 For ADCs in 
particular, increased FcRn affinity results in higher efficacy, a longer half-life and improved 
tolerability, as demonstrated by Hamblett et al. with four different ADCs in a mouse experimental 
model.164 The Fc region is the site of conjugation for a number of ADCs102 as well as the contact point 
for FcRn binding;164 therefore the effect on conjugation on FcRn affinity must be assessed. A 
thermodynamic analysis concludes that FcRn affinity of ADCs may be decreased for ADCs with a 
high degree of conjugation to small hydrophilic payloads with PEG-based hydrophilic linkers.165 A 
more recent in vitro assay explores the affinity of brentuximab for FcRn at varying ratios of 
conjugation with vedotin, a large hydrophobic payload.166 Conjugation with 2-4 molecules of vedotin 
decreased FcRn affinity relative to the unconjugated antibody, while conjugation with 8 molecules of 
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vedotin actually increased FcRn affinity relative to the unconjugated antibody.166 Further 
investigations are required to understand how the location and degree of conjugation and the nature of 
both the linker and payload affect FcRn affinity and plasma half-life.   
FcγR receptors are present on monocytes, granulocytes (neutrophils, eosinophils, basophils and 
mast cells), lymphocytes (T cells, B cells and NK cells), antigen-presenting cells (macrophages, 
dendritic cells, Kupffer cells) and platelets.167 The three major subtypes (I, II and III) are 
differentiated by their binding affinity for the Fc region, structure, function and tissue distribution.167 
Together they facilitate the antibody-dependent functions of the immune system, such as antibody-
dependent cell-mediated cytotoxicity (ADCC) and the elimination of soluble immune complexes.167 
Binding of IgG to FcγRI occurs with nanomolar affinity and induces internalization of the IgG-
receptor complex,156 while binding of IgG to FcγRII and FcγRIII is 10-1000 times less efficient and 
internalization only occurs when receptors are crosslinked by interactions with multivalent circulating 
IgG complexes.167 The majority of these interactions occur within the MPS (liver, spleen, lymph 
nodes, thymus and bone marrow).167   
Pharmacokinetic studies with antibodies against both soluble and membrane-bound targets in FcγR 
knockout mice have determined that FcγR interactions have a negligible impact on plasma 
pharmacokinetics.168,169 However, cytotoxicity to FcγR-bearing cells appears to be the main driver of 
dose-limiting toxicities for many ADCs,100,170 supporting the hypothesis that this uptake may be 
clinically significant. For trastuzumab emtansine, the dose-limiting toxicity of thrombocytopenia is 
hypothesized to occur due to FcγRIIa-mediated uptake into megakaryocytes.100,171,172 It has been 
suggested that FcγR interactions are most important when the antibody or ADC binds to a circulating 
target – either soluble or present on circulating lymphocytes – which can be opsonized with many 
IgG molecules and phagocytosed by FcγR-bearing cells more efficiently.160 FcγR interactions may 
also be relevant for efficacy in the tumour microenvironment. Tumour-associated macrophages that 
express FcγR may phagocytose ADCs and release the payload to nearby tumour cells through the 
bystander effect (see Payload Kinetics).173   
Fc affinity engineering is an effective method for achieving a desired pharmacokinetic profile for 
antibodies and ADCs. For example, Ko et al. engineered an antibody with increased FcRn affinity so 
that it achieved an extended plasma half-life and improved localization in intestinal epithelium in 
primates.174 In this work, FcRn affinity was engineered without concurrent changes to FcγR affinity 
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so that the ADCC function was not compromised.174 However, Grevys et al. note that concurrent 
changes to FcγR affinity should be expected.175 
2.6 Payload Kinetics 
The first payloads for ADCs were selected from among existing chemotherapeutic small molecules. 
Doxorubicin was one of these candidates.176,177 However, the success of doxorubicin as a payload was 
limited by its poor potency at the tumour site and lack of overall efficacy compared to doxorubicin 
monotherapy.176,177 Chemotherapeutic small molecules for direct use are evaluated with parameters in 
mind that do not cross over well to make them good candidates as payloads for ADCs.178 Selection of 
optimal payloads requires an understanding of the intracellular processing of ADCs (Figure 8). 
Ideal payloads must have tumour cell killing potencies (half maximal inhibitory concentration, 
IC50) in the sub-nanomolar range because only a small number of molecules are internalized into each 
cell. Cytotoxic small molecules that show excessive toxicity when administered as monotherapy 
become possible candidates as payloads.179-181 Directed delivery by antibodies will spare systemic 
toxicity and increase the therapeutic window.   
Molecules that initially failed due to poor membrane permeability also become eligible as payloads 
for cancer because antibodies can facilitate internalization into tumour cells. For example, Ogitani et 
al. demonstrate tumour cell killing with a topoisomerase I inhibitor that has poor membrane 
permeability by linking it to a variety of antibodies against different targets to facilitate 
internalization.182 Poor membrane permeability may be beneficial. If the linker holding the payload 
degrades or the payload spontaneously dissociates in systemic circulation, toxicity to normal tissues 
can occur if the free payload can easily pass into cells. 
The two payloads currently approved for use are DM1, a maytansinoid derivative and MMAE, an 
auristatin derivative. Both compounds bind to tubulin and inhibit microtubule formation, inducing 
mitotic arrest.183-185 A mechanism of action targeting intracellular components is desirable because 
that is where the payload is usually released.186 Anti-microtubule activity makes these payloads 
somewhat selective to proliferating cells. A number of payloads are in development that target DNA, 




Figure 8. Summary of ADC cellular uptake and the bystander effect. Uptake of ADCs into cells 
occurs by receptor-mediated endocytosis after target binding or by pinocytosis. If FcRn is not present, 
ADCs are degraded in lysosomes and the cytotoxic payload is released into the intracellular space. A 
portion of the released payload may diffuse out of the cell or be transported out by efflux pumps to 
induce cytotoxicity in neighbouring cells (the bystander effect). The exit of permeable payloads cells 
may contribute to concentrations in systemic circulation or in the bile. 
The catabolite or linker-payload fragment that is formed after linker degradation inside cells must 
retain its cytotoxic activity. DM1 is released from trastuzumab emtansine as lysine-SMCC-
DM1.188,189 This catabolite is charged and has poor membrane permeability, but retains its activity 
against tubulin.190 MMAE is released cleanly from brentuximab vedotin with full activity.186 In 
contrast to lysine-SMCC-DM1, MMAE is moderately permeable across membranes and causes 
toxicity in nearby cells186 – a phenomenon that has been named the bystander effect.191 
The bystander effect may be useful against tumours where target expression is heterogeneous or 
where high receptor occupancy in the tumour is difficult to achieve.192 Kovtun et al. show that linkers 
can be manipulated to select for catabolites with varying permeability and bystander killing 
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potential.193 With respect to heterogeneity, Golfier et al. report an 82% reduction in the size of tumour 
xenografts in which only 20% of cells express the target – a result that has been attributed to the 
lipophilicity and bystander effects of the reduced disulfide-DM4 catabolite.192,194 Li et al. show a 
similar result against heterogeneous tumours using the permeable payload, MMAE.195 They solidify 
the bystander effect by recording poor cell killing when using a less permeable payload as a control 
(MMAF).195 A recent pharmacokinetic/pharmacodynamic model quantifies the effect based on in 
vitro tumour cell culture measurements.196 The bystander effect in a heterogeneous tumour becomes 
less prominent over time as cells that express the target are killed.196 
While leveraging the bystander effect may offer enhanced efficacy against heterogeneous tumours, 
there are concerns about safety. It may increase toxicity to healthy cells.170 After experiments in 
mouse models, Ogitani et al. suggest that bystander killing is only observed in close neighbouring 
cells and that the risk for systemic toxicity is low.197 However, more research is required to confirm 
this safety in humans. Generally, the amount of drug released for bystander effects is thought to be 
below the threshold for systemic effects. A comparison of the toxicity profiles of ADCs stratified by 
the potency of their bystander effects could shed light on this issue.   
Cellular efflux transporters, such as P-glycoprotein (P-gp) affect the cellular disposition of many 
payloads.198 Both of the payloads currently on the market are substrates for P-gp.199,200 Nonpolar 
payloads are particularly vulnerable to efflux transporters. Kovtun et al. are able to minimize P-gp-
mediated resistance for maytansinoid derivatives by using hydrophilic linkers which increase the 
polarity of the linker-payload catabolite that is released in the cell.198 Toppmeyer et al. show that it is 
also possible to reduce P-gp-mediated drug resistance by administration of a competing co-substrate, 
such as verapamil.200 
2.7 Linker Kinetics 
Cytotoxic payloads are attached to the Fc region of antibodies by chemical linkers. A myriad of 
options for linker design and chemistry have emerged in recent years. Established linkers include 
hydrazones that are sensitive to pH, peptide linkers that are cleavable by cathepsin-B, disulfide 
bridges that are reducible by glutathione and other non-cleavable covalent attachments, such as 
thioether and maleimidocaproic acid linkers.102 The field of available linkers has widened to include a 




The linker must be stable in the plasma, interstitial fluid and lymph to minimize off-target toxicity 
and to ensure maximal delivery to the intracellular space of tumours. These fluids have varying 
physicochemical properties and enzyme content throughout the body and within tumour tissue, 
making global stability difficult to achieve. Linker cleavage in circulation is responsible for the faster 
clearance that is observed for the conjugated antibody vs. the total antibody.201,202 
The linker must efficiently release the payload in the intracellular space. Payload release should be 
predictable and consistent. Linkers can be grouped into cleavable and non-cleavable linkers. A 
cleavable linker depends on the intracellular pH, chemical conditions and the presence of proteases or 
other peptides to break the linker by hydrolysis or proteolysis. In contrast, a non-cleavable linker can 
only release the payload when the ADC has undergone intracellular processing within lysosomes.  
Increasing numbers of ADCs in development are being constructed with non-cleavable linkers.102 
Whether cleavable or not, the metabolites that are formed must retain the cytotoxic activity of the 
original payload.203 Non-cleavable linkers tend to release payload metabolites that include a residual 
amino acid, which may compromise activity and alter membrane permeability. Drug developers and 
clinicians may prefer that the active metabolites maintain poor permeability across cell membranes so 
that they remain in the cell to exert their cytotoxic effect.190 
The drug-antibody ratio (DAR) is used to measure the degree of conjugation. Most ADCs in 
development have DARs between two and four. DARs up to 20 have been reported using branched 
polymer linkers with multiple payload molecules attached to each backbone by ester bonds.204 The 
heterogeneity of an ADC is a measure of the distribution of DARs in the product and the variety in 
conjugation sites. Homogeneity achieved by site-specific conjugation enhances both safety in rats and 
efficacy in murine tumour xenograft models.205 
Higher DARs are associated with stronger in vitro and in vivo potency against tumour cells.206,207 
However, the improvement in potency is offset by an increase in plasma clearance, with a trend 
toward accumulation in the liver.107,206 The hydrophobicity of ADCs can be affected by close packing 
of four or more hydrophobic payloads.206,208 Hydrophobic interactions and subsequent aggregation are 
thought to be largely responsible for the increase in plasma clearance that is observed.166,206,208,209  
Strop et al. avoid the limitations of hydrophobicity by strategically selecting conjugation sites that 
avoid close packing of payloads.207 They are able to increase the therapeutic index of ADCs by 
improving the DAR and the potency.207 Both the conjugation site and stoichiometry must be 
optimized to make homogenous ADCs with optimal therapeutic indices.   
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Site-specific conjugation has not yet been employed in an ADC product that is on the market 
(2017). Site-specific conjugation involves engineering the exact location on the Fc region where the 
linker and payload are attached, so as to create more homogenous drug molecules. Recent reviews 
describe the progress with these methods.210-213 By using site-specific conjugation, Pillow et al. are 
able to improve the therapeutic activity and the plasma stability of trastuzumab emtansine in mice.214 
In similar fashion, Thompson et al. demonstrate that ADCs that employ site-specific conjugation have 
superior stability and efficacy compared to conventionally conjugated ADCs with the same DAR.215 
Based on various works, enhanced linker stability in plasma is likely responsible for the benefits of 
site-specific conjugation.207,216-220 Payload release likely remains the same whether site-specific 
conjugation is used or not.221 
Proper linker method selection must take into account many factors, including the biochemical 
predisposition of the payload and the antibody. The activity of the payload and the binding affinities 
of the antibody must be preserved. As mentioned before, there is conflicting evidence about whether 
the degree of conjugation impacts target or FcRn affinity.130,131,165,166,222 Maruani et al. suggest that the 
internalization rate of ADC-target complexes is not impaired by conjugation of the ADC.223 
2.8 Tumour Properties 
The nature and structural properties of tumours present challenges and opportunities for antibody-
drug conjugates targeted against cancer. This section elaborates on the unique tissue properties and 
fluid effects within the microenvironment of solid tumours that may impact exposure to ADCs. 
Thurber and Wittrup propose a theoretical model for antibody uptake into solid tumours that 
encompasses many of these considerations and enhances practical understanding.224 
Conventional assumptions about plasma protein distribution and extravasation into tissues do not 
apply to solid tumours. Capillaries are the gatekeepers governing the entry of ADCs into tissues. The 
efficacy of antibody-based therapies depends on vascular access; biologic therapies are generally not 
effective against early stage tumours because significant capillary access to solid tumours is not 
achieved until stage 3. In contrast to normal vasculature, tumour capillaries have erratic and irregular 
architecture.225,226 Blood supply is chaotic and inconsistent, with blood pools in some areas and 
hypoxic or acidic patches in others.225,226 As a result, the distribution of antibodies in a tumour is 
highly heterogeneous.227,228   
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A variety of forces are at play along the walls of tumour capillaries. They often lack a basement 
membrane and are notoriously “leaky” due to large irregular fenestrae, wide intercellular junctions 
and poor support from pericytes.226 In addition, vascular function may be compromised by tumour 
cells taking over the role of endothelial cells in certain locations of the vessel wall.229 However, this 
leakiness does not necessarily lead to improved penetration of antibodies into tumours.230 Jain 
explains that increased leakiness gives rise to high interstitial fluid pressure (IFP), which causes net 
convective flow to be directed out of tumours.228,231,232 ADCs are large proteins which must rely on 
convective transport for penetration into solid tumours. Other barriers to convective transport include 
poor drainage of lymph from the tumour, interstitial fibrosis and irregularities in the extracellular 
matrix.225,233 Reductions in IFP measurements have been shown to be correlated with therapeutic 
response to chemotherapy and radiation.234-236 Further research is required to confirm the hypothesis 
that ADC exposure is a function of measured IFP in humans. 
Attempts have been made to lower tumour IFP so that antibody penetration can be improved. High 
IFP can be alleviated by normalizing tumour vasculature.237-239 Bevacizumab, an anti-VEGF antibody, 
blocks angiogenesis, restricts tumour vasculature and reduces IFP.240-242 However, vascular 
normalization is a double-edged sword; even though bevacizumab can lower IFP, antibody 
penetration into tumours is not necessarily improved because vascular access is simultaneously 
compromised.243-245 Other research using imatinib to reduce microvessel density and improve 
antibody penetration may be more promising in certain strains of tumours.246,247 IFP can also be 
lowered by increasing plasma colloid osmotic pressure with systemic infusions of 20% human serum 
albumin as demonstrated by Hofmann et al. in mouse models.248 A recent review by Baronzio, Parmar 
and Baronzio elaborates on other available methods to regulate IFP, such as inducing hyperthermia or 
using ultrasound therapy.249 
Matsumura and Maeda describe an “enhanced permeability and retention (EPR) effect” in solid 
tumours for macromolecules larger than 48 kDa.250,251 The hypotheses are that tumours have 
enhanced permeability to plasma proteins due to leaky tumour blood vessels and that plasma proteins 
are retained at the tumour site due to poor lymphatic drainage.250,251 However, much of their 
information about enhanced permeability and its mechanism comes from infection models rather than 
solid tumours, which do not have high IFP as a barrier to convective flow.252 Recent research into the 
EPR effect supports the IFP hypothesis regarding reduced convective flow in the tumour bulk and 
enhanced delivery and permeability only to the rim region of the tumour. Maeda and colleagues show 
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that the EPR effect is consistent for small tumours but not for larger tumours where the IFP barrier to 
delivery is significantly higher.252 In these cases, they are able to boost the EPR effect by increasing 
blood pressure to overcome tumour IFP.253 
Retention in tumours is also mediated in part by the properties of the extracellular matrix. The 
dense extracellular matrix present in desmoplastic tumours directly impairs the movement of 
antibodies through the interstitium.254 Netti et al. show that this resistance can be mitigated by 
treatment with collagenase.254   
Tumour cells have high demands for nutrients and amino acids. To meet these demands, 
macropinocytosis is upregulated in certain tumour cells to bring in large amounts of protein from the 
extracellular fluid that can be degraded into amino acids.255 This mass internalization and quick 
protein degradation is ideal for the intracellular release of ADC payloads. Ha et al. propose that new 
ADCs can be targeted against macropinocytosis markers to achieve a degree of tumour-selective 
exposure.256  
Broadly speaking, the location and size of solid tumours are important for predicting exposure to 
ADCs. Considering basic physiology, a melanoma on the skin would receive less exposure than a 
carcinoma in the liver after IV administration. An ideal solid tumour target for ADC therapy would be 
located in highly perfused tissue (e.g. liver, spleen, kidney, intestine, etc.). An inverse relationship 
between tumour size and antibody uptake per gram of tumour has been well established.257-263 The 
highest antibody uptake per gram of tumour is seen in mouse xenografts weighing less than 200mg 
(range of tumour sizes studied: 30 – 1600mg), though this measurement cannot be easily extrapolated 
to humans.257,261,262 The binding site barrier discussed above further hinders ADC penetration 
throughout solid tumour tissues.104,128   
The physicochemical nature of the interstitial space in the tumour microenvironment poses an 
additional pharmacokinetic barrier for ADCs. Large tumours often have hypoxic regions and acidic 
interstitial fluid due to the lack of functional blood vessels and altered metabolism, and linkers may 
be unstable in these conditions. Moreover, the altered pH may affect or even compromise binding of 
ADC to the target.   
Aside from physicochemical differences, the interstitial space in a solid tumour is often infiltrated 
with tumour-associated macrophages, dendritic cells, B cells, T cells and other members of the 
immune system. While it was originally thought that phagocytosis of ADCs into these non-target 
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cells would be a hindrance, adequate tumour cell-killing may still be achieved through the bystander 
effect. Furthermore, exposure of these immune cells to cytotoxic payloads has been shown to drive a 
beneficial anti-tumour immune response.264 
2.9 Conclusion 
The field of ADC development is expanding rapidly with contributions from many different research 
streams. The pharmacokinetic design and evaluation of the numerous ADCs in the clinical pipeline 
must be carefully thought out to ensure that ADCs reaching regulatory approval are both safe and 
effective. Due to the complexity of ADC pharmacokinetics and pharmacodynamics, the clinical value 
of a traditional pharmacokinetic assessment is low without a mechanistic understanding of disposition 
and elimination. This review serves as a consolidation of investigations from a multitude of 
disciplines into one foundation of pharmacokinetic understanding so that maximum value can be 
obtained from clinical trial data. 
2.10 Study Highlights 
In the context of this thesis, this chapter presents broad considerations on the mechanistic 
determinants of antibody pharmacokinetics in adults. In 2017, much of the concepts for antibodies 
had already been reviewed. This manuscript was written to expand that knowledge to cover antibody-




Population PBPK Modeling for Inter-Individual Variability in 
Trastuzumab Pharmacokinetics 
3.1 Abstract 
In this work we proposed a population physiologically-based pharmacokinetic (popPBPK) framework 
for quantifying and predicting inter-individual pharmacokinetic variability using the anti-HER2 
monoclonal antibody (mAb) trastuzumab as an example. First, a PBPK model was developed to 
account for the possible mechanistic sources of variability. Within the model, five key factors that 
contribute to variability were identified and the nature of their contribution was quantified with local 
and global sensitivity analyses. The five key factors were the concentration of membrane-bound 
HER2 (𝐴𝑔), the convective flow rate of mAb through vascular pores (𝐹2), the endocytic transport 
rate of mAb through vascular endothelium (𝐶𝐿𝑢𝑝), the degradation rate of mAb-HER2 complexes 
(𝐾𝑑𝑒𝑔
𝐴𝑔
) and the concentration of shed HER2 extracellular domain in circulation (𝐸𝐶𝐷). 𝐹2 was the 
most important parameter governing trastuzumab distribution into tissues and primarily affected 
variability in the first 500 hours post-administration. 𝐴𝑔 was the most significant contributor to 
variability in clearance. These findings were used together with population generation methods to 
accurately predict the observed variability in four experimental trials with trastuzumab. To explore 
anthropometric sources of variability, virtual populations were created to represent participants in the 
four experimental trials. Using populations with only their expected anthropometric diversity resulted 
in under-prediction of the observed inter-individual variability. Adapting the populations to include 
literature-based variability around the five key parameters enabled accurate predictions of the 
variability in the four trials. Cancer increased variability in distribution and may increase the rate of 
extravasation or clearance of trastuzumab. The successful application of this framework demonstrates 
the utility of popPBPK methods to understand the mechanistic underpinnings of pharmacokinetic 
variability. 
3.2 Introduction 
With respect to pharmacokinetics, it is an impossible challenge to create one drug molecule that will 
be safe and effective for all people. A more realistic approach is to predict which subgroups of 
patients may be at risk of poor safety or efficacy. For this approach, the characteristics that may 
 
48 
predispose an individual to high or low exposure must be determined. In other words, we must 
determine the key factors that contribute to inter-individual pharmacokinetic variability.   
Using conventional “top-down” pharmacokinetic (PopPK) modeling we can identify general 
pharmacokinetic differences between individuals based on covariates such as age, sex, size, ethnicity, 
organ function and disease progression. The main limitation of the PopPK method is that we cannot 
determine the impact of a covariate until it has been measured in a study population and the resulting 
clinical pharmacokinetic data has been analyzed.   
In contrast, “bottom-up” population physiologically-based pharmacokinetic (popPBPK) modeling 
enables us to simulate the impact of covariates with virtual populations. General covariates identified 
through PopPK methods (e.g., ethnicity) may be surrogates for variability in underlying physiologic 
processes (e.g., genetic variant of a transporter). If a PBPK model accounts for all significant 
physiologic processes that affect the pharmacokinetics of the drug, then it follows that the total 
variability observed in pharmacokinetic data should be the output of inter-individual variability 
around each key process or parameter. This approach to quantifying variability is knowledge-driven 
rather than data-driven.   
In this work we propose a framework for quantifying and predicting inter-individual 
pharmacokinetic variability. We demonstrate the utility of popPBPK modeling to complement 
conventional PopPK methods with a study of the anti-HER2 monoclonal antibody, trastuzumab. Key 
factors that contribute to variability will be identified and interpreted in tandem with a previous 
PopPK analysis by Bruno et al.125 Conclusions will enhance our understanding of the mechanistic 
underpinnings of variability and prompt new questions about patient subgroups that may be at risk of 
poor safety or efficacy. 
3.3 Methods 
The primary aim of the research was to determine the factors that contribute to inter-individual 
variability in trastuzumab pharmacokinetics for both healthy volunteers and breast cancer patients 
using a population PBPK model.  
3.3.1 Part One: Mean Analysis 
1. Model Development: construction of an in silico whole-body PBPK model to describe the 
pharmacokinetics of trastuzumab in a mean individual. 
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2. Model Parameterization: estimation of model parameters based on existing literature. 
3. Model Fitting: optimization of uncertain parameters by fitting the model to the mean 
concentration-time profiles in experimental data. 
4. Model Evaluation: evaluation of the optimized model for a mean individual by predicting the 
mean concentration-time profiles from additional experimental data. 
3.3.2 Part Two: Variability Analysis 
5. Uncertainty and Sensitivity Analysis: identification of key parameters that contribute to inter-
individual variability, characterization of their contribution and assessment of parameter 
correlation. 
6. Population Simulation: development of a virtual population of unique individuals with 
literature-based variability around key parameters and simulation of plasma concentration-
time data for the virtual population using the optimized model.   
7. Analysis: comparison of the simulated inter-individual variability with the inter-individual 
variability observed in experimental data. 
3.3.3 Software: 
A MATLAB extension called SBToolbox2 was used to automate the simulation of the system of 
ordinary differential equations and model analysis.265 The population generation tool was based in 
MATLAB and followed generally the method of Willmann et al.266 Clinical data from literature was 
digitized using Plot Digitizer v2.6.8 by Joseph Huwaldt (plotdigitizer.sourceforge.net). 
3.4 Results 
3.4.1 Model Development 
An in silico whole body model to describe the pharmacokinetics of trastuzumab in a mean individual 
was developed based on the platform model for a monoclonal antibody (mAb) by Shah and Betts.135  
A schematic for the structure of the model is shown in Figure 9. Figure 10 illustrates the mechanistic 
processes affecting mAb pharmacokinetics within each tissue compartment. Previous PBPK models 
by Cao and Jusko, Li et al., and Glassman and Balthasar have successfully characterized the nonlinear 




Figure 9. A schematic for the whole body PBPK model showing the connection of anatomical 








Shedding of the HER2 extracellular domain (𝐸𝐶𝐷) was modeled as proposed by Li et al. with the 
following modifications:268   
1. 𝐸𝐶𝐷 concentrations were assumed constant (rate of synthesis equal to rate of degradation) 
2. The concentration in the interstitial space was assumed equal to the measured concentration 
in plasma  
3. mAb-𝐸𝐶𝐷 complex distribution was assumed to be similar to mAb distribution, and pinocytic 
uptake was lumped into a general degradation term for a circulating immune complex (𝐾𝑑𝑒𝑔
𝐸𝐶𝐷) 
Antigen kinetics were determined from existing mechanistic models for HER2 trafficking that 
incorporated in vitro measurements.269-274 Derivation of the antigen degradation term (𝐾𝑑𝑒𝑔
𝐴𝑔
) can be 
found in Appendix A. The concentration of membrane-bound HER2 antigen was kept constant (rate 
of synthesis equal to rate of degradation) because trastuzumab binding does not induce internalization 
or degradation of the receptor.109,119,268-270,275,276 The model can apply to both healthy volunteers and 
breast cancer patients by toggling a tumour compartment on and off. The tumour compartment was 
connected by blood and lymph flow to the whole-body circulation for cancer simulations. Model 
equations can be found in Appendix A. 
3.4.2 Model Parameterization 
Reference values for anatomical parameters were obtained from BioDMET documents and can be 
found in Appendix A.50,266 The volumes of the organ sub-compartments (plasma space, endosomal 
space and interstitial space) were calculated for each organ based on the fractions used in the platform 
model.135 Lymph flow in each organ, aside from the lung, was set to 0.2% of plasma flow.135 Lymph 
flow in the lung was set to 3% of total body lymph flow in agreement with Gill et al.77   
Experimental plasma concentration-time data was collected from seven pharmacokinetic studies 
with trastuzumab and its biosimilars. Biosimilars are pharmacokinetic equivalents of trastuzumab and 
were included because of the sparse data available for trastuzumab. Table 5 lists the trials and 




Table 5. Experimental pharmacokinetic datasets collected for use with the PBPK model. 











Morita et al.277 6 35 M Healthy Volunteers 8d 22.7 (6.8) 
Wisman et al.278 6 46 M Healthy Volunteers 8d 25 (6.8) 
Wynne et al.279 6 6 M Healthy Volunteers 8d 23 (19-26) 
Yin et al.280 6 32 M Healthy Volunteers 8d 35.3 (9.2) 
Tokuda et al.281 1, 2, 4, 8 16 F Breast Cancer 19.9 51 (32-64) 
Baselga et al.282 8 then 6 q3wb 98 F Breast Cancer 30 53.8 (23-84) 
Cobleigh et al.283 4 then 2 q1wc 213 F Breast Cancer 9.33 50 (28-81) 
Leyland-Jones et al.284 8 then 6 q3wb 32 F Breast Cancer 20 53 (31-70) 
FTMB 
Wisman et al.278 0.5, 1.5, 3, 6 64 M Healthy Volunteers 8d 25 (6.8) 
DMB-3111 
Morita et al.277 6 35 M Healthy Volunteers 8d 22.9 (3.2) 
PF-05280014 
Yin et al.280 6 34 M Healthy Volunteers 8d 34.5 (10.7) 
a Number of patients 
b Every 3 weeks thereafter 
c Every 1 week thereafter 
d Value not reported; assumed from literature285,286 
When using the model to simulate the mean concentration-time profile with one representative 
virtual individual, anatomical parameters were scaled from the reference values so that the virtual 
individual’s characteristics matched the mean height, weight, body mass index (BMI), body surface 
area (BSA), gender, cancer status and ECD level of individuals in the experimental trial. A tumour 
with a volume of 20mL was added to the representative individual for simulations of trials with breast 
cancer patients. Tumour parameters were extracted from a previous model for trastuzumab and are 




Table 6. Mechanistic parameters used in the model including literature-based estimates and the 
reported variance for the parameter, expressed as a coefficient of variation (CV%) 
Parameter Description Units Estimate CV% 
𝜎𝑉  Vascular reflection coefficient - 0.85-0.99a 135 See 𝐹2 
𝜎𝐼𝑆 Lymph reflection coefficient - 0.2135 - 
𝐶𝐿𝑢𝑝 Rate of endocytic transport per L 
endosomal space 
L/h/L 0.0366135 25162,287 
𝐹2 (h) Convective flow scaling factor (healthy) - 1135 25140 




𝐹𝑐𝑅𝑛 Accessible FcRn in endosomal space nM 49800135 1577,109,135 
𝐹𝑅 Fraction that recycles to vascular space - 0.715135 5162 
𝐾𝑑𝑒𝑔
𝐹𝑐𝑅𝑛 Degradation rate of FcRn-unbound mAb 1/h 42.9135 15135 
𝐾𝑜𝑛
𝐹𝑐𝑅𝑛 Association rate for FcRn binding 1/nM/h 0.8288 10289 
𝐾𝑜𝑓𝑓
𝐹𝑐𝑅𝑛 Dissociation rate for FcRn binding 1/h 618.4288 10289 
𝐾𝑜𝑛
𝐴𝑔








 Degradation rate of HER2 and mAb-
HER2 complexes 
1/h 0.0789270,273 33.3270 
𝐴𝑔 Accessible membrane-bound HER2 nM 1.6292 100293,294 
𝐴𝑔𝑇𝑢𝑚𝑜𝑢𝑟 Accessible HER2 on tumour cell 
membrane 
nM 25 × 𝐴𝑔293 100293 
𝐾𝑜𝑛
𝐸𝐶𝐷 Association rate for ECD binding 1/nM/h 1291 5  
𝐾𝑜𝑓𝑓
𝐸𝐶𝐷 Dissociation rate for ECD binding 1/h 0.1291 5  
𝐸𝐶𝐷 ECD in plasma and interstitial space nM Trial-specific 100282 
𝐾𝑑𝑒𝑔
𝐸𝐶𝐷 Degradation rate of mAb-ECD 
complexes 
1/h 0.0144122,123 25122 
𝐵𝑀 Body mass kg Trial-specific 12266 




The concentration of HER2 in normal tissues was measured to be 10,000 receptors/cell.292 The 
following calculation was applied, assuming 3.27∙1013 cells/body and a cellular volume of 53.6 


















However, HER2 is a membrane-bound protein and the concentration of HER2 (𝐴𝑔) for the model 
input must be in terms of interstitial volume (𝑉𝐼𝑆) to enable stoichiometric binding of mAbs in the 
interstitial space. There are also limitations to HER2 accessibility. First, one third of HER2 receptors 
are internalized in the cell and inaccessible for binding while two thirds are present on the 
membrane.269,270 Furthermore, accessibility is impaired by dimerization. Up to 95% of membrane-
bound HER2 is homo- and heterodimerized with members of the HER family.269,270 The HER2 
extracellular domain is approximately 100kDa and trastuzumab is 145.5kDa in size.296 Dimer 
linkages occur between the respective subdomain II regions of monomers. Trastuzumab binds to 
subdomain IV, which is closest to the membrane and is overshadowed by subdomain II.296 An 
analysis of crystal structures suggests that subdomain IV is blocked when HER2 is dimerized by a 
linkage across subdomain II.296 Therefore in our model, the concentration of membrane-bound HER2 
available for high affinity binding in each organ was assumed to be the concentration of monomers 
only (~5% of membrane-bound HER2) and was calculated by: 







 𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒-𝑏𝑜𝑢𝑛𝑑 × 0.05 𝑚𝑜𝑛𝑜𝑚𝑒𝑟𝑠 
3.4.3 Model Fitting 
SBtoolbox2 was used to globally fit the model for a mean individual to the mean plasma 
concentration-time profiles for trastuzumab in the datasets from Wisman et al. and Yin et al. with a 
simulated annealing method (see Table 5).278,280 Glassman and Balthasar identified that the rate of 
convective flow through pores and the rate of endocytic transport (𝐶𝐿𝑢𝑝) are drug-specific and 
require fitting.109 A scaling factor (𝐹2) was used for the fit to describe the convective flow through 
pores according to: 
𝐶𝑜𝑛𝑣𝑒𝑐𝑡𝑖𝑣𝑒 𝐹𝑙𝑜𝑤 =  𝐹2 × (1 − σ𝑉) × 𝐿 
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The fitted values for 𝐹2 and 𝐶𝐿𝑢𝑝 were 3.35 and 0.0188 L/h/L respectively. Figure 11 shows two 
model-fitted profiles using data from Wisman et al. and Yin et al.278,280 The optimized model for a 







Figure 11. A comparison of the model-fitted profile for a mean individual (solid line) with the 
experimental data (diamond) in healthy males from Wisman et al. (A) and Yin et al. (B)278,280 
3.4.4 Model Evaluation 
The remaining datasets for trastuzumab and its biosimilars in Table 5 were used to validate the 
optimized model for mean individuals. Figure 12 shows a comparison of the observed mean plasma 
concentrations to the model-predicted mean plasma concentrations for all evaluation datasets, which 
include a variety of dose levels and administration protocols. Predictions for mean individuals were 
strong with an R2 of 0.967 when simulating mean pharmacokinetic profiles for both healthy males 
and females with breast cancer. The model trended toward an overestimation of trastuzumab plasma 
concentrations at levels below 200 nM and an underestimation of trastuzumab plasma concentrations 







Figure 12. Model-predicted vs. observed concentrations for healthy males (circle) and females with 
breast cancer (diamond). The observed concentrations come from the experimental trials listed in 
Table 5 that were not used for model building. 
With a validated model in place that adequately predicts mean concentration-time profiles, we 
turned our attention to analyze variability. Analyses were done with parameter values as determined 
for the validated model, which include the fitted values for 𝐹2 and 𝐶𝐿𝑢𝑝. No changes were made to 
the mean parameter values. 
3.4.5 Uncertainty and Sensitivity Analysis 
A local sensitivity analysis that accounts for the variability around each parameter that is seen in a 
general population allows for an assessment of the importance of each parameter in defining total 
inter-individual variability (see Table 6). The sigma-normalized sensitivity coefficient (𝑆𝑝
𝜎) is a 
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measure of the anticipated percent change in AUC with a perturbation of one standard deviation (𝜎𝑝) 
in the mean parameter value (𝑝).  The sigma-normalized sensitivity coefficient was calculated by: 
𝑆𝑝
𝜎 =  |
𝐴𝑈𝐶(𝑝 ± 𝜎𝑝) − 𝐴𝑈𝐶(𝑝)
𝐴𝑈𝐶(𝑝)
| × 100% 
Key parameters that contribute to inter-individual variability were identified by 𝑆𝑝
𝜎  ≥ 1. If a 
parameter has a sigma-normalized sensitivity coefficient of 1, then an individual possessing a 
parameter value that is one standard deviation higher or lower than the mean value will have an AUC 
that is 1% different than the mean AUC of the population. We deem that this difference is the cut-off 
for declaring a parameter important for accounting for interindividual variability. The literature-
defined variability in terms of a coefficient of variation (CV) for each parameter is listed in Table 6.  
Of note, the CV for FcRn is based on the variability in PBPK model estimates to date and the CV for 
𝐹2 was dependent on cancer status. Figure 13 shows that the five key parameters are the rate of 
endocytic transport (𝐶𝐿𝑢𝑝), the rate of convective flow through pores (𝐹2), the concentration of 
membrane-bound HER2 accessible for binding (𝐴𝑔), the degradation rate of HER2 and mAb-HER2 
complexes (𝐾𝑑𝑒𝑔
𝐴𝑔
) and the concentration of ECD (𝐸𝐶𝐷). The magnitudes of the effects of the key 
parameters on the model remain similar whether the parameters are increased or decreased by one 
standard deviation. Body mass (𝐵𝑀) was included in this analysis for comparative purposes. The 
result suggests that physically varying body mass (changing organ size and flow rates) has a minor 
effect on plasma concentrations when dosing is normalized to body mass (mg/kg). 
 
Figure 13. Sigma-normalized local sensitivity coefficients (𝑺𝒑
𝝈) determined for each mechanistic 
parameter in the model, and body mass (see Table 6). Key parameters were identified by 𝑺𝒑
𝝈 ≥ 𝟏 
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The sigma-normalized local sensitivity of the model to each key parameter over the entire time 
series was analyzed in Figure 14. The convective flow through pores (𝐹2) was the most important 
parameter governing trastuzumab distribution into tissues and primarily affected variability in the first 
500 hours post-administration. The concentration of HER2 (𝐴𝑔) was the most significant contributor 
to variability in clearance. 𝐾𝑑𝑒𝑔
𝐴𝑔
 plays a significant role in elimination as expected. The effects of 
𝐸𝐶𝐷 are small overall. 
 
Figure 14. The effect of each key parameter on plasma concentration over time when perturbed by ± 
one standard deviation, expressed as the absolute difference in plasma concentration between the 
perturbed simulation and the nominal simulation at every time point. 
Next, we carried out a global variance-based sensitivity analysis to quantify the contribution of 
select key parameters (𝐶𝐿𝑢𝑝, 𝐹2, 𝐾𝑑𝑒𝑔
𝐴𝑔
, 𝐴𝑔, 𝐸𝐶𝐷 and 𝐹𝑐𝑅𝑛) to total variability in terms of the effect 
on plasma AUC. 𝐹𝑐𝑅𝑛 was included as an insensitive parameter for a comparative control. The 
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global sensitivity analysis quantifies the variability attributed to each key parameter individually (first 
order effects) as well as the total variability caused by the parameter when additionally considering its 
interactions with every other input parameter (total effects). We used Sobol’s method as proposed by 
Saltelli et al, which is described in Appendix A.297,298 
Figure 15A shows that together, the first order effects of parameters 𝐶𝐿𝑢𝑝, 𝐹2 and 𝐴𝑔 account for 
most of the total variability observed when the six parameters in Table 7 are allowed to vary both 
individually and in possible combination with each other. Figure 15B contrasts the first order effects 
for each parameter with the total global effects, which occur when each parameter varies individually 
and in combination with the others. The first order effect of each parameter accounts for the vast 
proportion of its total effect. The difference between the total effect and first order effect sensitivity 
measure determines the degree of interaction between each parameter and the others. The difference 
between the total effects and first order effects are small, signifying a small degree of interaction 







Figure 15. Panel (A) shows that the first order effects of 𝑨𝒈, 𝑭𝟐 and 𝑪𝑳𝒖𝒑 make up most of the total 
variability. Panel (B) shows that the differences between the first order effects (solid fill) and total 




Table 7. A summary of the inputs and the results for Sobol’s global sensitivity analysis 







𝐶𝐿𝑢𝑝 0.0188 L/h/L 25 0.11 0.14 




-1 33.3 0.02 0.06 
𝐴𝑔 1.6 nM 100 0.57 0.60 
𝐸𝐶𝐷 0.3 nM 100 ~0 0.02 
𝐹𝑐𝑅𝑛 49800 nM 15 ~0 0.01 
 
Lastly, it is important to assess the identifiability of the key parameters which gives a measure of 
the confidence we can have that the values in the model are the true values. A parameter is 
identifiable within a model if it is theoretically possible to learn the true value after observing the 
model for an infinitely long time. SBtoolbox2 was used to create a parameter correlation matrix based 
on the method by Jacquez and Greif (Figure 16).299 Elements in the matrix that are close to 1 (white) 
indicate that it is not feasible to identify the true value of the corresponding parameters 
independently. Elements that are close to 0 (black) indicate that there is no correlation between the 
corresponding parameters and thus these parameters should be independently identifiable. As Figure 
16 indicates, 𝐾𝑑𝑒𝑔
𝐴𝑔
 and 𝐴𝑔 are correlated, meaning that we may be able to achieve a similar output 
profile with different combinations of values for these parameters. 𝐶𝐿𝑢𝑝 is also moderately correlated 
to these parameters. The information from Figure 14 strengthens the understanding of these 
correlations. Figure 14 shows that the three parameters affect the model in similar ways over similar 
time periods. However, the peak effect of 𝐶𝐿𝑢𝑝 on the pharmacokinetic profile occurs earlier than the 
peak effects for 𝐾𝑑𝑒𝑔
𝐴𝑔
 and 𝐴𝑔. Therefore, 𝐾𝑑𝑒𝑔
𝐴𝑔
 and 𝐴𝑔 are highly correlated to each other. The 
correlations of 𝐶𝐿𝑢𝑝 to 𝐾𝑑𝑒𝑔
𝐴𝑔
 and 𝐴𝑔 are weaker, but significant. This result stresses the importance of 




Figure 16. Matrix presenting the correlation between key parameters. A white colour suggests a 
strong correlation, while a black colour suggests no correlation between two parameters. 
3.4.6 Population Simulations 
Virtual populations with variability in anthropometric parameters (body mass, height, blood flow and 
hematocrit) similar to the anthropometric variability in each experimental sample were created using 
a population generation tool previously developed in the Edginton lab. Briefly, individuals for a 
population are randomly generated according to height and the associated standard deviation reported 
for the patient sample in the experimental trial. Organ masses are randomly generated from truncated 
distributions to prevent extreme outliers, and the resulting body mass and the BMI are calculated. If 
the calculated BMI is outside of the range provided for the patient sample in the experimental trial, 
this virtual individual is discarded. The resulting virtual population should have approximately the 
same mean and standard deviation for BMI, height and body mass as the patient sample.   
Virtual individuals were used as inputs for the model and the simulated variability for the virtual 
population was compared to the actual observed variability in the datasets from Wisman et al., Morita 
et al., Baselga et al. and Cobleigh et al.277,278,282,283 Figure 17 shows the minimal impact of 
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anthropometric variability alone on inter-individual variability in the presence of body-mass 
normalized dosing (mg/kg). As mentioned before, the model trended toward an over-prediction of 
trastuzumab plasma concentrations at levels below 200 nM in patients with cancer (Figure 12). These 
overestimations are compounded after multiple weekly low doses in the trial by Cobleigh et al., 
resulting in a significant over-prediction of the mean trough level until plasma concentrations reach 
steady state (Figure 17D).283 
Next, individuals in the virtual populations were modified to have a normal or lognormal 
distribution around key model parameter values (𝐹2, 𝐶𝐿𝑢𝑝, 𝐴𝑔, 𝐾𝑑𝑒𝑔
𝐴𝑔
 and 𝐸𝐶𝐷) according to the 
coefficients of variation in Table 6. The distributions for 𝐴𝑔 and 𝐸𝐶𝐷 were lognormal to encompass 
the wide spread of values seen in the literature.282,293,294 Since these five key parameters are the most 
important for describing variability, they should – in theory – capture most of the experimental 
variability together. The simulated variability was compared to the experimental variability in the 
datasets from Wisman et al., Morita et al., Baselga et al. and Cobleigh et al. in Figure 18.277,278,282,283  
Overall, the framework enabled adequate predictions of the inter-individual variability in clinical 
trials by decomposing total variability into literature-based variability around each of the key 
parameters a priori (Figure 18). However, the population model under-predicted variability in the first 
72 hours for healthy males (Figure 18A, Figure 18B) and in the first cycles before steady state for 
females with breast cancer (Figure 18C, Figure 18D). While the mean plasma concentration is over-
predicted in the simulation for the trial by Cobleigh et al., an adequate prediction for the magnitude of 













Figure 17. Plasma concentration vs. time profiles for a virtual population created with variability in 
anthropometric parameters alone. The resulting variability (shaded fill) was compared to the observed 
inter-individual variability (solid error bar) in Wisman et al. (A), Morita et al. (B), Baselga et al. (C) 















Figure 18. Plasma concentration vs. time profiles for a virtual population created with variability in 
anthropometric parameters plus literature-defined variability around the five key parameters (𝑭𝟐, 
𝑪𝑳𝒖𝒑, 𝑨𝒈, 𝑲𝒅𝒆𝒈
𝑨𝒈
 and 𝑬𝑪𝑫). The resulting variability (shaded fill) was compared to the observed 
inter-individual variability (solid error bar) in Wisman et al. (A), Morita et al. (B), Baselga et al. (C) 







Using the population PBPK modeling framework, five key parameters that contribute to inter-
individual variability in trastuzumab pharmacokinetics were identified. In other words, patients who 
are outliers with respect to these five key parameters:  
1. The concentration of membrane-bound HER2 accessible for binding (𝐴𝑔) 
2. The rate of convective flow of mAb through vascular pores from plasma to interstitial space 
(𝐹2) 
3. The rate of endocytic transport of mAb into vascular endothelial cells (𝐶𝐿𝑢𝑝) 
4. The degradation rate of HER2 and mAb-HER2 complexes (𝐾𝑑𝑒𝑔
𝐴𝑔
) 
5. The concentration of shed HER2 ECD in the plasma and interstitial space (𝐸𝐶𝐷) 
may be at risk for poor safety or efficacy with trastuzumab. 
The next task is to assess the clinical relevance of each parameter. Can these parameters be 
measured in patients and if not, how are these parameters related to more measurable characteristics?  
In a review of inter-individual variability for all mAbs, Gill et al. highlighted ways that physiologic 
processes affecting mAb pharmacokinetics could be correlated to general covariates such as age, 
body mass, ethnicity and disease state.300 We expand on those insights here for trastuzumab. 
Total concentrations of HER2 vary widely in healthy and cancer populations and can be measured 
with the HERmark assay.292 This assay can also measure the concentration of HER2 homodimers, 
which enables a prediction for the concentration of HER2 that is accessible for mAb binding (𝐴𝑔).294 
In the era of personalized medicine, measured levels of HER2 in normal tissues may be appropriate 
grounds for dose adjustments. 
The rate of convective flow of mAb through pores (𝐹2) is difficult to measure directly. However, 
Parving and colleagues have demonstrated that the flow of plasma proteins through capillaries can 
change proportionally to blood pressure and can be altered by liver cirrhosis, diabetes, congestive 
heart failure and inflammatory skin conditions.140-144,146-148,301 The measured transcapillary escape rate 





Table 8. Values reported for the transcapillary escape rate (TER) of albumin and IgG in patients with 
various conditions 




Healthy140 3.0 (0.7) 5.2 (1.0) 
Hypertensiona 140 4.7 (1.0) 7.8 (0.9) 
Short-Term Type 1 Diabetesb 142  5.5 (1.0) 
Long-Term Type 1 Diabetesc 143 4.4 (1.0) 7.4 (1.1) 
Liver Cirrhosis141 8.4 (0.8) 7.4 (1.9) 
Chronic Right Heart Failure144  8.3 (1.6) 
Inflammatory Skin Disease301  8.6 (1.1) 
Cancer146-148  5.5 – 12.1d 
a mean arterial blood pressure: 193/119 mmHg 
b mean duration: 2.6 years 
c mean duration: 20 years with microangiopathy 
d range of reported medians in 3 studies 
 
The presence of cancer impacts the TER and therefore likely increases the 𝐹2 parameter.146-148 
Cancer is an inflammatory disease that alters many homeostatic functions in the body. The TER of 
albumin is up to 2-fold faster in patients with cancer than healthy patients. Furthermore, the liver is a 
common site of metastasis and damage may increase the TER and 𝐹2 similar to cirrhosis.282   
When 𝐹2 increases there is a shift in distribution from plasma to tissue, while the final plasma 
trough concentrations remain similar (Figure 14). Therefore, we anticipate that patients with the 
conditions listed in Table 8 may experience greater tissue exposure along with possibly increased 
efficacy and toxicity. For example, a cancer patient with diabetes who is receiving trastuzumab may 
have greater penetration of the drug into heart tissue and may be at an increased risk for cardiotoxicity 
compared to a cancer patient without diabetes, even while trough concentrations are within normal 
therapeutic ranges for both patients. The results of a recent meta-analysis by Leung and Chan may 
support this hypothesis.302 They identify hypertension and diabetes (among other factors) as 
significant risk factors for cardiotoxicity in elderly females being treated with trastuzumab.302 
The rate of endocytic transport (𝐶𝐿𝑢𝑝) of mAb into vascular endothelial cells is not well 
understood in modeling as estimates vary 10-fold between groups.109,135 It is the gateway by which the 
mAb participates in FcRn binding and recycling. Genetic factors likely play the largest roles for 
determining 𝐶𝐿𝑢𝑝 for an individual.
287,300 Genotypic testing of FcRn, caveolin or other proteins 
involved in endocytosis may prove clinically relevant for dose adjustments. 
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Although not directly measurable, the degradation rate of HER2 and mAb-HER2 complexes (𝐾𝑑𝑒𝑔
𝐴𝑔
) 
is correlated with the internalization rate.269,271 Hendriks showed that the internalization rate of HER2 
depends on the presence of the epidermal growth factor (EGF) ligand and the relative concentrations 
of HER1-4 on the cell membrane.269 The degradation rate may also be subject to genetic 
polymorphisms of the HER2 protein. Genotypic testing of HER2 may be useful for dosing to improve 
safety and efficacy.   
The role of 𝐸𝐶𝐷 as a predictor for response to trastuzumab therapy or tumour progression is still 
unknown. Carney et al. indicate that an increasing ECD level is a marker for poor prognosis, while a 
number of smaller studies show that an early increase in ECD level before trastuzumab treatment can 
predict a good response.303-310 Because of the uncertainty and the overall small effect on variability, 
the clinical utility of ECD for predicting safety and efficacy is low. 
Next, we compare our results from the popPBPK framework to existing results from a PopPK 
study by Bruno et al. in patients with metastatic breast cancer.125 The group modeled the 
pharmacokinetics with a non-linear mixed effects model using two compartments.125 Variability in 
patient body mass, the number of metastatic sites and the concentration of serum extracellular domain 
were determined to be the most important factors for predicting the observed variability, but together 
failed to predict the large variability in the data.125 In the following analysis, we do not endeavour to 
contrast the work of Bruno et al. Rather we strive to gain a mechanistic understanding of their 
findings and of the overall variability in trastuzumab pharmacokinetics through PBPK modeling 
approaches. 
First, they showed that the volume of distribution for trastuzumab changes as a function of body 
mass, ranging from 2.5L at 49 kg to 3.7L at 96 kg.125 These volumes correspond to the predicted 
plasma volume changes as a function of body mass (65 mL blood/kg for females, hematocrit 0.36-
0.48). Body mass-normalized dosing eliminates significant inter-individual variability, as shown in 
Figure 17.  
Bruno et al. also demonstrated that patients with four or more metastatic sites had an 18% lower 
steady state exposure than those with up to three metastatic sites.125 In our model, patients with a total 
tumour volume of 80 mL had a 1.75% lower AUC than patients with a total tumour volume of 20 
mL. The covariate effect cannot be reproduced through mechanistic PBPK modeling. This result 
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suggests that the impact of more metastatic sites on clearance is not due to the physical effects of the 
tumour burden alone, but rather due to the increased disease burden on the whole body.   
Because of its effects on clearance and volume of distribution, Bruno et al. predicted a 12% lower 
steady state exposure in a patient with a serum ECD level greater than 200 ng/mL compared to a 
patient with a serum ECD level of 8 ng/mL.125 Our mechanistic model predicts an 8.3% lower AUC 
in a patient with a serum ECD level of 200 ng/mL compared to a patient with a serum ECD level of 8 
ng/mL and a 12.0% lower AUC for a patient with a serum ECD level of 300 ng/mL. Therefore, it is 
likely that the overall effect of ECD on trastuzumab clearance is directly mechanistic in nature. In 
other words, the effect of ECD on clearance and volume and distribution as quantified by Bruno et al. 
can be fully attributed to the physical mechanism where trastuzumab binds to ECD in the plasma or 
the interstitial space and is then cleared as an immune complex. 
A current challenge with virtual populations is a lack of information on inter-variability in the 
vascular and interstitial fractions of internal organs. Such information would be able to characterize 
the variability in peak concentrations, which is under-estimated in this work. 
Some modeling limitations were encountered. First, the model was built using data from healthy 
males and the same mean parameter values were extrapolated to females with breast cancer.281 While 
the model predictions were acceptable, improvements could be made by adjusting mean 𝐹2 values 
based on disease state. Figure 19 shows how increasing the mean 𝐹2 value by 50% for females with 
breast cancer relative to healthy males improves the accuracy of the model predictions for the mean 
data. Disease-specific mAb modeling using adjustments in the 𝐹2 parameter will be warranted in the 
future. However, at the moment there is no reliable way to proactively assign a mean 𝐹2 value for a 




Figure 19. Panel (A) shows the model-predicted profiles and the experimental data in breast cancer 
patients from Tokuda et al.281 Panel (B) shows the improved predictions when the mean 𝑭𝟐 value is 
increased by 50% to model the physiologic burden of cancer. 
Further, there are limitations surrounding our assumptions for ECD kinetics that could be improved 
with additional physiologic data in the future. The concentration of ECD in the interstitial space is 
largely uncertain. Moreover, we assume that the convective flow of the mAb-ECD complex is the 
same as naked mAb. The mAb-ECD complex is much larger than the naked mAb and it is likely 
restricted by pore size to a greater degree. Data are not available to inform these two parameters at the 
present time. 
Aside from the platform model by Shah and Betts, other recent models incorporate the competition 
of endogenous IgG for FcRn.59,109,289 The overall effect is that the accessible concentration of FcRn 
decreases. Because the platform model was parameterized without endogenous IgG independently 
characterized, adding this feature would compromise the internal validity of the other model 
parameter estimates. Shah and Betts state that it is an advantage that they have removed the 
characterization of endogenous IgG from their model.135 Figure 13 shows that the sensitivity of our 
model to accessible FcRn concentrations is relatively low in comparison to the key parameters and 
thus adding an FcRn modifier (i.e. endogenous IgG) would have little impact on model outcomes. 
The model could be improved by adding tissue-specific values for FcRn, though full measurements 








Finally, mass balance of fluid flow through the endosomal compartment requires the assumption 
that exactly half of the fluid taken up via endocytosis leaves endothelial cells via exocytosis, while the 
other half is sorted intracellularly for lysosomal processing before passively exiting the compartment.  
In the model equations, the fluid flow entering the endosomal compartment is 2 × 𝐶𝐿𝑢𝑝 L∙h
-1, while 




A popPBPK framework for quantifying inter-individual pharmacokinetic variability was proposed, 
tested and evaluated. Five key factors that contribute to inter-individual variability in trastuzumab 
pharmacokinetics were identified and the nature of their contribution was quantified with local and 
global sensitivity analyses. The clinical relevance of each of the five key parameters was explored. 
Simulations of plasma concentrations for virtual populations incorporating variability around each of 
the key parameters successfully predicted the inter-individual pharmacokinetic variability seen in 
experimental trials. The utility of popPBPK modeling to complement conventional PopPK methods 
was demonstrated. Overall, our understanding of inter-individual variability in trastuzumab 
pharmacokinetics has been enhanced with knowledge about the underlying key mechanistic 
processes. We look to the clinical research community to apply this information as they formulate 
dosing strategies for patient subgroups that may be at risk for poor safety or efficacy with mAb drugs. 
3.7 Study Highlights 
This study represents one of the early applications of whole body PBPK modeling to describe the 
pharmacokinetics of monoclonal antibodies in humans. The methods shown herein – both for mean 
model parameterization and population simulation – are performed in adults as workflow examples 
before the concepts are scaled to children. We also begin to discover the importance of modeling the 




PBPK Modeling vs. Allometric Scaling to Predict the 
Pharmacokinetics of Infliximab in Pediatric Patients 
4.1 Abstract 
The comparative performances of physiologically-based pharmacokinetic (PBPK) modeling and 
allometric scaling for predicting the pharmacokinetics of large molecules in pediatrics are unknown. 
Therefore, both methods were evaluated for accuracy in translating knowledge of infliximab 
pharmacokinetics from adults to children. PBPK modeling was performed using the base model for 
large molecules in PK-Sim v7.4 with modifications in Mobi. Eight population pharmacokinetic 
models from literature were reconstructed and scaled by allometry to pediatrics. Evaluation data 
included seven pediatric studies (~4 – 18 years). Both methods performed comparably with 66.7% 
and 68.6% of model-predicted concentrations falling within two-fold of the observed concentrations 
for PBPK modeling and allometry, respectively. Considerable variability was noted among the 
allometric models. Therefore, pediatric clinical trial planning would benefit from using approaches 
that require predictions depending on the specific question i.e., PBPK modeling and allometry. 
4.2 Introduction 
Physiologically-based pharmacokinetic (PBPK) modeling and allometric scaling are the two most 
common methods for translating knowledge of adult pharmacokinetics (PK) to the pediatric space for 
the planning of pediatric clinical trials.312 While drug developers and regulatory agencies alike 
maintain high confidence in both methods for small molecule drugs, little is known about the 
performance and utility of either method for large molecule drugs.70 Here we evaluate the two 
approaches for the prediction of large molecule PK in pediatric patients with infliximab as a working 
example, since plenty of adult and pediatric data are available in published literature for the exercise. 
The practice of allometry applies an empiric and inherently simple method to perform body-
weight-based scaling of adult PK parameters that have been derived from population pharmacokinetic 
(PopPK) studies (i.e. clearance and volume of distribution).313 The accuracies of allometric models 
have been demonstrated with numerous small molecule drugs for children older than two years of 
age, when distribution and clearance processes have achieved adult performance.15,314 Below this 
threshold empirical adjustments for maturation and ontogeny are required and the resulting functions 
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are not translatable between molecules.315,316 In keeping with this observation, our evaluation of 
allometric scaling in the large molecule space first includes studies with children older than 4 years of 
age, when the mechanisms governing PK are thought to have reached full maturity.34 
Physiologically-based pharmacokinetic (PBPK) models have long been recognized for offering 
translational utility by maintaining mechanistic approaches to distribution and clearance.12 They 
enable PK predictions in unique populations or unknown exposure scenarios based on known 
physiological and anatomical characteristics, but are considerably more complex to develop. PBPK 
models must first be calibrated, informed and evaluated with PK data in adults before their 
predictions can become reliable in the pediatric space. The practice of PBPK modeling to support 
pediatric clinical trial planning in the context of small molecule drugs has achieved critical mass with 
regulatory support from both the US Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA).12 In contrast to allometric models, PBPK models can employ physiologic 
knowledge of growth and maturation to account for the ontogeny of key distribution and clearance 
processes in young children, even neonates and pre-term infants.317  
The same confidence must yet be earned for large molecule drugs. The mechanisms governing the 
PK of large molecules are not at all similar to those of small molecules.318 Platform PBPK models for 
large molecules in adults have emerged in the last 7 years and to date only one minimal PBPK 
modeling effort has been made to characterize PK in children.66,135,319 We continue the exploration 
with a whole-body approach to the PK of infliximab in children since a large amount of pediatric PK 
data is available for this purpose in published literature. The assessment of pediatric PBPK modeling 
in older children and adolescents must be completed prior to considering children less than 4 years of 
age for proper evaluation of size-dependent scaling alone without additionally considering age-
dependent factors, namely the maturation and ontogeny of key distribution and clearance 
mechanisms.34  
Infliximab is a chimeric monoclonal antibody directed against tumour necrosis factor alpha (TNF) 
that is used to treat inflammation associated with many autoimmune conditions, such as inflammatory 
bowel disease, rheumatoid arthritis, psoriasis, ankylosing spondylitis and Kawasaki disease. It is most 
often dosed at 5 mg/kg by a 2-hour intravenous infusion at 0, 2 and 6 weeks for induction of 
remission and then every 8 weeks thereafter for maintenance of remission, though standard regimens 
may vary slightly among disease states and clinical treatment centres. 
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The drug exhibits complex but generally linear pharmacokinetics due to its large size, antibody-
based design and low target burden. Two-compartment models are often used to describe its time-
course in the adult body. The drug possesses an extensive plasma residence time due to poor 
permeability across blood vessel walls, with a mean plasma half-life of 9.5 days. High affinity 
interactions with the neonatal Fc receptor (FcRn) in endothelial, epithelial and hematopoietic cells 
further protect the drug from intracellular degradation. Infliximab neutralizes soluble TNF in most 
extracellular fluid domains, but most importantly in the interstitial spaces of inflamed organs. From 
the interstitial space, the lymphatic system recirculates infliximab via the thoracic duct to the venous 
blood, where the distribution cycle can begin again. Over time, and in part due to its make-up with 
portions of murine protein, the body may mount an immune response against infliximab. At sufficient 
titres, anti-drug antibodies (ADAs) can render infliximab undetectable in plasma. 
Monoclonal antibodies are a rapidly expanding drug class and pediatric investigations are well 
underway. The FDA has recently highlighted the gaps in modeling and simulation efforts to support 
pediatric drug approvals.70 By completing this work we aim to assess the confidence with which 
PBPK modeling and/or allometric scaling can be applied in the context of pediatric drug development 
and clinical trial planning. 
4.3 Methods 
4.3.1 Software 
PBPK models were built and evaluated using the base model for large molecule drugs in PK-Sim and 
Mobi v7.4 (www.open-systems-pharmacology.org) with minor modifications.66 PK data in scientific 
literature was digitized using Plot Digitizer v2.6.8 by Joseph Huwaldt (plotdigitizer.sourceforge.net). 
MATLAB R2018b and the Intiquian toolbox (IQMTools v1.2.2.2) by Henning Schmidt were used for 
reconstruction of PopPK models, allometric scaling and graphical presentation of results. 
4.3.2 Pharmacokinetic Data 
After a comprehensive literature search, seven pediatric PK trials were located and the data was 
digitized for evaluation of the pediatric PK predictions between PBPK modeling and allometric 
scaling (Table 9).28,29,320-326 The datasets encompass children with inflammatory bowel disease or 
juvenile idiopathic arthritis almost exclusively between 4 and 18 years of age with infliximab doses 
ranging from 1 – 10 mg/kg IV. 
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4.3.3 Adult PBPK Model Development 
PBPK modeling enables a mechanistic representation of drug disposition in virtual individuals with 
known anatomical and physiological properties. Virtual adults and children for the analysis were 
generated using PK-Sim v7.4. Algorithms for the generation of virtual individuals in PK-Sim are 
reported elsewhere.266 In the PBPK modeling process, one virtual individual (whether adult or child) 
was created to represent the mean individual in each PK study. Each virtual individual had the same 
age, height, weight, sex and disease state as the mean individual in the corresponding real-world 
study along with all associated anatomical and physiological characteristics. Maturation was assumed 
not to have an impact on these characteristics in children older than 4 years of age. 
 In agreement with pediatric PBPK model development workflows for small molecules, an adult 
PBPK model was constructed for infliximab first to gain confidence in the global parameterization 
before scaling the model to pediatric individuals. 
The base model for large molecule drugs in the software package has been described previously.66 
Fifteen organs were included in the model structure to represent a virtual human, and each organ 
compartment was further divided into plasma, endosomal, interstitial and cellular sub-compartments. 
The base model featured two-pore extravasation, endothelial uptake, salvage by FcRn and lymphatic 
recycling. The model structure was adapted in Mobi v7.4 to include target-mediated interactions with 











Inflammatory Bowel Disease 
Candon et al.320 Induction with 5 20 10.5 [0.5 – 
15] 
NA 
Hyams et al.28,29,321 Induction with 5 then 5 q8w 
and q12w with dose 
escalation to 10 
112 13.3 ± 2.5 43.8 ± 14.6 
Hamalainen et al.322 Induction with 5 then 5 q8w 37 14 [5.6 – 18] 43.5 [19.6 – 
67.1] 
Baldassano et al.323 1, 5 and 10 single dose 21 15.1 [8 – 17] 49.1 
Singh et al.324 Induction with 5 then 5 q8w 58 11.4 [6.6 – 
18.4] 
NA 
Adedokun et al.325 Induction with 5 then 5 q8w 
and q12w with dose 
escalation 
60 14.5 [6 – 17] 50.8 (36.3 –
59.4) 
Juvenile Idiopathic Arthritis 
Ruperto et al.326 Induction with 3 or 6 then 3 
or 6 q8w 
122 11.2 [4 – 18] NA 
Data presented as mean or median and [range], (interquartile range) or ± standard deviation 




Table 10. Model parameters 
Parameter Final Value 
Infliximab 
Molecular weight 149100 kDa 
Hydrodynamic radius 5.34 nm66 
Rate of uptake into endosomal space (𝑘𝑢𝑝) 0.35 min
-1 
Dissociation constant for FcRn binding (𝐾𝐷
𝐹𝑐𝑅𝑛) 727 nM288 
Dissociation constant for TNF binding (𝐾𝐷
𝑇𝑁𝐹) 30 pM327 
Dissociation constant for ADA binding (𝐾𝐷
𝐴𝐷𝐴) 500 pM328 
TNF 
TNF maximum plasma concentrationa (𝑇𝑁𝐹𝑜𝑟𝑔𝑎𝑛) 0.5 pM
329-331 
TNF factor for autoimmune disease 2329,330,332,333 
TNF degradation rate (𝑘𝑑𝑒𝑔
𝑇𝑁𝐹) 0.0231 min-1 334,335 
mAb-TNF complex degradation rate (𝑘𝑑𝑒𝑔
𝑚𝐴𝑏−𝑇𝑁𝐹) 0.0231 min-1 
ADA 
















IgG maximum plasma concentrationa (𝐸𝑚𝑎𝑥
𝐼𝑔𝐺
) 136 nM  












mAb-ADA complex degradation rate (𝑘𝑑𝑒𝑔
𝑚𝐴𝑏−𝐴𝐷𝐴) 0.48 day-1 337 
Inflamed Organ 
Inflammation factor for inflamed pores (𝐼𝐹𝜎) 1.569,338,339 
TNF factor for inflamed organ 3340,341 
a Zero order synthesis rates were calculated by multiplying the degradation rate by the maximum 
concentration of the molecule 







Infliximab binds to TNF in circulation with high affinity and the complex is later eliminated by the 
immune system.342 In the PBPK model, TNF was present in all plasma and interstitial spaces with a 
relative expression of 1 across all organs. The natural synthesis (𝑘𝑠𝑦𝑛
𝑇𝑁𝐹) and turnover (𝑘𝑑𝑒𝑔
𝑇𝑁𝐹) of TNF 
were represented with zero order and first order rate constants, respectively. TNF molecules were 
non-circulating and stationary within each sub-compartment. Binding of infliximab to TNF caused 
the formation of a complex, which was eliminated from the system by a first order degradation rate 
(𝑘𝑑𝑒𝑔
𝑚𝐴𝑏−𝑇𝑁𝐹). 
In PopPK studies, infliximab is often noted to exhibit faster clearance in individuals with severe 
inflammation, possibly mediated through higher TNF concentrations, vascular hyperpermeability or 
cachexia. In the PBPK model, the presence of autoimmune disease was represented with a global 2-
fold increase in TNF concentrations.329,330,332,333 In inflamed organs, local TNF concentrations were 
further increased by a factor of 3.340,341  
Large molecule drugs abide by permeability-rate-limited distribution and are subject to vascular 
hyperpermeability in inflamed organs. To represent this effect, the pore sizes in inflamed organs were 
increased proportional to an inflammation factor in agreement with previous minimal PBPK models 
of inflammatory conditions by Jusko and colleagues, who observed the requirement for lower 
vascular reflection coefficients in inflamed organs.69,338,339 The large intestine was inflamed in patients 
with inflammatory bowel disease, the bone was inflamed in patients with rheumatoid arthritis and 
ankylosing spondylitis, the skin was inflamed in patients with psoriasis and the lung was inflamed in 
patients with non-small cell lung cancer (NSCLC). 
Immunogenicity is a key determinant of infliximab elimination. Results are conflicting due to 
inconsistency in ADA assays, though up to 60% of patients may express an immunogenic response 
against infliximab over the course of one year of therapy.343 ADA molecules (IgM, IgG) bind to 
infliximab to form a complex, neutralizing its therapeutic potential and eventually resulting in 
degradation. In the PBPK model, ADA molecules (IgM, IgG) were synthesized, released and 
contained within the plasma of venous and arterial blood, similar to the assumptions made by Chen et 
al.344 Mean ADA synthesis and degradation rates in the adult population were parameterized 
according to Ren et al., who quantified the typical immune response after first-dose exposure to four 
therapeutic proteins with a PopPK modeling approach.336 In the absence of additional data, the zero 




). The typical ADA 
profile featured an initial period of IgM synthesis, a lag phase and finally a sustained IgG response. 
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The group noted differences in IgG degradation rates between healthy and autoimmune individuals, 
which were implemented in the model.336 Mechanistically, binding of infliximab to IgM or IgG 
caused the formation of a complex, which was eliminated from the system by a first order degradation 
rate (𝑘𝑑𝑒𝑔
𝑚𝐴𝑏−𝐴𝐷𝐴).  
Two parameters in the adult PBPK model were uncertain and required optimization: the rate of 
uptake into endosomal space (𝑘𝑢𝑝) and the zero order molar synthesis rate of ADA molecules against 
infliximab (𝑘𝑠𝑦𝑛
𝐼𝑔𝐺
), which was mediated via the maximum concentration of IgG parameter (𝐸𝑚𝑎𝑥
𝐼𝑔𝐺
). 
Optimization was carried out in Mobi using a Monte-Carlo approach to exploring the parameter 
space. The parameters were optimized separately in two steps. First, 𝑘𝑢𝑝 was optimized to ADA-
negative PK data available in 4 studies (Table 11). Following this step, 𝐸𝑚𝑎𝑥
𝐼𝑔𝐺
 was optimized to PK 
data available from 20 studies in healthy and diseased individuals (Table 11). Therefore, 𝐸𝑚𝑎𝑥
𝐼𝑔𝐺
 
represents the mean immunogenic response across the general adult population, including both ADA-
positive and ADA-negative individuals. 
Model accuracy following optimization was assessed statistically by the squared Pearson 
correlation coefficient (Pearson R2), the absolute average fold error (AAFE) across all data points, the 
root mean squared error (RMSE) and the percent of model-predicted concentrations falling within 
two-fold of the corresponding observed concentrations. An external evaluation of the final adult 
model was not performed because the purpose of the model was to extrapolate knowledge of adult PK 
to pediatrics, and this workflow maximizes learning from adult datasets. 
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Table 11. Datasets used for adult PBPK model building 






Datasets with an ADA-Negative Subset (Model Building Step 1) 
Yoo et al.345 Rheumatoid Arthritis Induction with 3 then 3 q8w 304 50 [21 – 74] 68 [36 – 136] 
Brandse et al.346 Ulcerative Colitis Induction with 5 19 36 (27 – 44) 70 (61 – 75) 
Shin et al.347 Healthy 5 single dose 53 39.4 ± 9.9 79.1 ± 8.3 
Takeuchi et al.348 Rheumatoid Arthritis Induction with 3 then 3 q8w 47 53.8 ± 13.4 53.4 ± 10.1 
Additional Datasets (Model Building Step 2) 
Lambert et al.349 Healthy 5 single dose 41 28.5 [18 – 45] 74.7 [62.3 – 88.6] 
Udata et al.350 Healthy 10 single dose 48 [18 – 55] NA 
Park et al.351 Healthy 5 single dose 71 41 [18 – 55] 78.1 [55.4–99.9] 
Maini et al.352 
St. Clair et al.353 
Rheumatoid Arthritis Induction with 3 and 10 then 3 and 10 q4w 
or q8w 
197 53 [19 – 80] NA 
Park et al.354,355 Ankylosing Spondylitis Induction with 5 then 5q8w 110 38 [18 – 66] 76.0 (45.5–122.7) 
Gottlieb et al. 356,357 Psoriasis Induction with 5 and 10 17 43 [21 – 69] 91.5 [61 – 165] 
Gottlieb et al. 357,358 Psoriasis Induction with 5 then 5 q8w 215 44.4 ± 13.3 93.5 ± 21.1 
Adedokun et al.359 Ulcerative Colitis Induction with 5 and 10 then 5 and 10 q8w 484 40 (30 – 52) 77 (66 – 89) 
Rutgeerts et al.360 Crohn’s Disease 5, 10 and 20 single dose then 10 q8w 37 34 [20 – 64] 66 [40 – 102] 
Cornillie et al.361 Crohn’s Disease Induction with 5 then 5 and 10 q8w 284 36.8 [18 – 76] NA 
Rahman et al.362 Rheumatoid Arthritis Induction with 3 then 3q8w  220 54 (44 – 62) 69.3 (60.1 – 81.0) 
Hibi et al.363 Behcet Disease Induction with 5 then 5 q8w 11 37.6 ± 7.4 67.8 ± 17.9 
Jatoi et al.364 NSCLC 5 on weeks 0, 2, 4, 8, 12 4 72.25 NA 
Choe et al.365 Rheumatoid Arthritis Induction with 3 then 3 q8w 160 52.6 ± 11.7 71.9 ± 16.5 
Bortlik et al.366 Crohn’s Disease Induction with 5 then 5 q8w 84 31 [17 – 62] NA 
Krzysiek et al.367 Ankylosing Spondylitis Induction with 5 then 5 q6w 93 39.5 ± 12.0 NA 
Torii et al.357,368,369 Psoriasis  Induction with 5 then 5 q8w 35 46.9 ± 13.0 68.5 ± 13.4 
Sorrentino et al.370 Crohn’s Disease 3 and 5 q8w 11 37.8 NA 
Kavanaugh et al.371 Rheumatoid Arthritis 5, 10 and 20 single dose 21 45.5 ± 12.3 NA 
Data presented as mean or median and [range], (interquartile range) or ± standard deviation 
‘Induction’ refers to intensive dosing at weeks 0, 2 and 6 before regular maintenance dosing 
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4.3.4 Pediatric Extrapolation 
After establishing confidence in the performance of the adult PBPK model, it was then translated to 
the pediatric space. In simple terms, the virtual adult individual was replaced with a pediatric 
individual with all associated anatomical and physiological parameters to explore the a priori PK 
predictions of the model in children. Physiological parameters related to disease pathology and 
immunogenicity were kept constant between adults and children, with some literature to inform this 
decision.320,331,372 Observed PK data from seven pediatric clinical trials were available for evaluation 
of the predictions (Table 19). As above, prediction accuracy was assessed by four metrics: Pearson 
R2, AAFE, RMSE and the percent of model-predicted concentrations falling within two-fold of the 
corresponding observed concentrations in children.  
Allometric scaling offers a simple and empirical approach to translating the statistical knowledge 
gained from an adult PopPK study to a pediatric population by acknowledging differences in body 
weight. Many adult PopPK models for infliximab exist in published literature. In a typical drug 
development case only one model would exist, built after collation of PK data from two or three small 
studies. For this exercise, a total of eight adult PopPK models were reconstructed from literature for 
application of allometric scaling (Table 12).  
Each PopPK model was constructed, scaled and evaluated independently. First, values for 
clearance (𝐶𝐿𝑎𝑑𝑢𝑙𝑡), inter-compartmental clearance (𝑄2𝑎𝑑𝑢𝑙𝑡), volume of distribution in the central 
compartment (𝑉1𝑎𝑑𝑢𝑙𝑡) and volume of distribution in the peripheral compartment (𝑉2𝑎𝑑𝑢𝑙𝑡) were 
extracted for the typical adult individual in each study (Table 12). The typical adult had mean or 
median covariate status for age, height, weight, sex, disease status, immunomodulator use and 
inflammatory biomarker concentration where applicable. The four PK parameters were then scaled by 
allometry from the typical adult to the typical child in each of the pediatric PK studies designated for 
evaluation (pediatric body weights presented in Table 19). Allometric scaling was implemented as 
described by Tod, Jullien and Pons.313 Mathematically, 


























Pediatric PK predictions were only made in the context of the same or similar disease states. Seven 
PopPK models developed in adults with inflammatory bowel disease were used to make pediatric PK 
predictions for children with inflammatory bowel disease and one PopPK model developed in adults 
with rheumatoid arthritis was used to make pediatric PK predictions for children with juvenile 
rheumatoid arthritis. Pediatric PK profiles were simulated with the updated parameters and compared 
to the mean pediatric observed concentrations from literature (Table 19). Once again, the accuracy of 
PK profile prediction through allometric scaling was assessed by the same four statistical metrics for 
direct comparison to the PBPK model-driven predictions (Pearson R2, AAFE, RMSE and percent of 
model-predicted concentrations falling within 2-fold of the corresponding observed concentrations). 
Table 12. Adult infliximab PopPK studies used for allometric scaling 












Inflammatory Bowel Disease 
Fasanmade et al.27 580 37.5 ± 11.9 71.1 ± 18.3 15.27 6.09 3.58 1.29 
Fasanmade et al.373 482 41.2 ± 13.9 78.8 ± 18.4 16.96 297.5 3.29 4.13 
Ternant et al.374 33 33 [19 – 53] 67 [44 – 
110] 
12 5.4 2.9 1.9 
Dotan et al.375 54 35.6 [20 – 70] NA 15.8 5.08 2.37 1.37 
Aubourg et al.376 133 NA 60 [41 – 
120]  
14 83 2.6 4.5 
Buurman et al.377 42 44 [19 – 80] 75 [51 – 
145] 
8.29 2.58 4.94 3.13 
Brandse et al.378 332 38.6 ± 13.9 72.3 ± 16.3 14.96 2.9 4.72 2.4 
Rheumatoid Arthritis 
Ternant et al.379 84 58 [27 – 84] 65 19 180 2.3 3.6 
Data presented as mean or median and [range], (interquartile range) or ± standard deviation 
CL = clearance, Q2 = intercompartmental clearance, V1 = volume of distribution in the central 
compartment, V2 = volume of distribution in the peripheral compartment. 
 
4.4 Results 
A comprehensive PBPK model was developed using the base model for large molecule drugs in PK-
Sim and Mobi v7.4 with modifications to feature the effects of inflammation and target-mediated 
interactions with TNF and ADA molecules. The adult model was then scaled to represent children by 
updating all anatomical and physiological parameters accordingly. Additionally, eight two-
compartment PopPK models from literature were reconstructed and scaled by allometry to the 
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pediatric space according to the methods proposed by Tod, Jullien and Pons.313 Equipped with these 
tools, the performances of PBPK modeling and allometric scaling for the prediction of infliximab PK 
in children and adolescents were systematically evaluated. 
4.4.1 Adult PBPK Model Development 
In the first optimization step (the ADA negative scenarios), the final value for 𝑘𝑢𝑝 was 0.35 min
-1 
(Figure 20). In the second optimization step, the final value for  𝐸𝑚𝑎𝑥
𝐼𝑔𝐺
 was 136 nM. The adult PBPK 
model well-characterized the observed PK profiles from all datasets used in both optimization steps 
achieving a Pearson R2 of 0.90, an AAFE of 1.16 and an RMSE of 30.9. Notably, 88.4% of the 
model-predicted infliximab concentrations were within 2-fold of the corresponding observed 
concentrations. Figure 21 shows sample PK profiles in healthy subjects, ankylosing spondylitis and 
rheumatoid arthritis, and a comparison of the model-predicted vs. observed concentrations across all 
studies. The possible effect of inflammation on clearance was modestly under-estimated for 
inflammatory bowel disease and psoriasis patients, though a significant portion of this observed data 
was obtained from non-responder subsets. Non-responders have lower trough concentrations than 
responders, possibly due to higher TNF concentrations, ADA positivity or severely inflamed, 
damaged or leaky organs.  
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Figure 21. Sample fitted infliximab PK profiles in healthy subjects, ankylosing spondylitis and rheumatoid arthritis, and a comparison of model-
predicted vs. observed infliximab concentrations (NSCLC = non-small cell lung cancer) after the second optimization step. References to observed 
data are provided in Table 11. 
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4.4.2 Evaluation of Pediatric Predictions 
Both methods performed similarly for predicting the mean PK in children obtained from studies that 
included individuals almost exclusively between the ages of 4 and 18. Figure 22 displays a plot-by-
plot comparison of allometrically-derived PK profiles, PBPK profiles and the mean pediatric 
observed concentrations from literature. Considerable differences were noted among the profiles 
derived from allometric scaling that stemmed from variable PK parameter values from the eight adult 
PopPK models. Visually, the pediatric PBPK model was more proficient for predicting peak 
concentrations after infusion and volume of distribution in the central compartment, while the 
allometrically-derived models performed better for predicting trough concentrations.  
Across all allometric models, model-predicted concentrations were within 2-fold of the observed 
concentrations 68.6% of the time, while the best allometric model enabled predictions within 2-fold 
of the observed concentrations 84.3% of the time (Table 13).378 The PBPK model performed similarly 
overall, achieving predictions within 2-fold of the observed concentrations 66.7% of the time (Table 
13). No discernable correlations were detected between the sample size of a PopPK study (N) and the 
accuracy of its pediatric predictions. The Pearson R2 and RMSE values identified trends in model 
performance but no conclusions could definitively be made about overall model performance from 
these metrics. 
Finally, Figure 23 compares the model-predicted and observed infliximab concentrations across all 
pediatric studies. Low concentrations were over-predicted by both methods, though there is 
uncertainty in these data values with regard to the lower limits of quantification for the assays in the 




Figure 22. Comparison of pediatric PBK modeling and allometric scaling for the prediction of infliximab PK in children with inflammatory bowel 
disease or juvenile idiopathic arthritis; data digitized from seven pediatric studies (Table 19).  
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Figure 23. Model-predicted vs. observed infliximab concentrations in pediatrics. 
 
Table 13. Statistical evaluation of pediatric PK model performance 
Model N AAFE R2 RMSE 2-Fold Error 
Inflammatory Bowel Disease 
Fasanmade et al.27 580 0.77 0.977 8.1 60.8% 
Fasanmade et al.373 482 1.09 0.964 9.7 76.5% 
Ternant et al.374 33 1.35 0.980 10.1 80.4% 
Dotan et al.375 54 0.60 0.957 21.4 51.0% 
Aubourg et al.376 133 1.36 0.973 8.5 82.4% 
Buurman et al.377 42 2.82 0.913 17.0 47.0% 
Brandse et al.378 332 1.18 0.970 14.0 84.3% 
Rheumatoid Arthritis 
Ternant et al.379 84 0.83 0.987 20.7 66.7% 
All Allometric Models 
  1.25  13.7 68.6% 
PBPK Modeling 





The evaluations of PBPK modeling and allometric scaling for prediction of small molecule PK in 
children have been extensive.15,314 Both methods are often reported to achieve predictions within 2-
fold of the observed values up to 90% of the time for children older than 2 years of age. However, 
this evaluation has not yet been performed in the context of large molecule drugs. With infliximab as 
a case example, we demonstrate that PBPK modeling and allometric scaling in their current states 
provide similar pediatric PK predictions for children older than 4 years of age in known exposure 
scenarios. There is significant room for improvement in the large molecule space, as neither method 
in this example achieved the accuracies reported in small molecule evaluations (66.7% and 68.6% of 
model-predicted concentrations falling within 2-fold of the observed concentrations for PBPK 
modeling and allometric scaling, respectively). Refinement of allometric exponents for large 
molecule drugs and investigations into the relevance of pediatric physiology for predicting PK in 
young children are required to advance the predictive accuracy of these methods.34 
A closer inspection of model performances may offer guidance about the utility of each method for 
specific purposes (Figure 22). The pediatric PBPK model performed stronger than the allometrically-
derived models for the prediction of peak drug concentrations after infusion (Figure 23), suggesting 
that volume of distribution in the central compartment for children is most reliably estimated by 
physiological methods. Clearance in children older than 4 years of age was modestly underestimated 
by PBPK modeling, suggesting that there may be mild effects of maturation on anatomical and 
physiological parameters that govern elimination. Allometric scaling may more reliably estimate 
trough concentrations and clearance in known exposure scenarios. Lastly, allometric scaling was 
performed for eight different PopPK models in a small fraction of the time that was required to 
develop the pediatric PBPK model (~100 hours) and would be preferred when time is a constraint.  
The findings from this study can be generalized to the pediatric PBPK modeling and allometric 
scaling of monoclonal antibodies with similar FcRn affinity and a low target burden to guide drug 
development and selection of first-in-pediatric doses. Antibodies with a high target burden often 
exhibit nonlinear kinetics and there is yet no reliable method for scaling the TMDD component of a 
non-linear PopPK model by allometry, especially when disease pathology may vary between adults 
and children. PBPK modeling would be highly desired in this case. 
Wide variability was noted in the predictions among the eight allometric models and the accuracy 
among the models was independent of adult study sample size (Figure 22)(Table 12, Table 13). This 
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observation draws attention to the need for optimal sampling in the design of adult PopPK studies to 
increase confidence when applying allometric scaling. Without dense sampling and variable exposure 
scenarios, fundamental model structures cannot be determined. In the case of infliximab, estimates for 
PK parameters are highly variable among the eight models and are often poorly defined due to 
inadequate mid-profile sampling. Limited sampling analyses for large molecule drugs are beginning 
to be used to guide the sampling times for appropriate derivation of pivotal PK parameters, some of 
which govern curve shape.380  
PBPK modeling for large molecules is gaining traction in academia, industry and regulatory 
agencies. Here we present the first evaluation of a whole-body PBPK model for a large molecule drug 
in pediatrics and the first PBPK model to incorporate immunogenicity. Infliximab is one of the oldest 
monoclonal antibodies and there is an abundance of PK data available for model parameterization, yet 
the drug has often been avoided due to uncertainty around modeling immunogenicity, which is a key 
driver of its elimination. The immunogenic response is a modelling challenge because ADA assays 
often do not quantify concentrations, only titres of ADA molecules.24 As a first step toward 
quantifying the response, the ADA-negative PK data for infliximab available in literature combined 
with the parameterization of the time-course of ADA formation in humans by Ren et al. have enabled 
the first mechanistic representation of the immunogenic response to a therapeutic drug product.336 
Figure 24 displays the simulated profile of mean ADA formation following first dose administration 
in a typical population of adults with inflammatory bowel disease. The first phase is IgM formation, 
and the second phase is IgG formation. Not yet addressed mechanistically is the impact of concurrent 
drug therapy with immuno-modulators on ADA formation and clearance. 
The adult PBPK model showed a modest under-prediction of clearance in inflammatory bowel 
disease, though a significant portion of this observed data was extracted from subsets including only 
non-responders to treatment. As previously mentioned, this result is expected since non-responders 
often have higher ADA concentrations, higher TNF levels and more severely inflamed tissues. Loss 
of infliximab into the feces is an alternate explanation for the error.381 
For therapeutic proteins, the observation that children receive lower exposures than adults with the 
same weight-based doses has been reported before.34 Drug developers are beginning to anticipate this 
phenomenon and derive pediatric-specific doses according to age or weight using PBPK modeling or 
allometric scaling.56,70 The results of this study highlight the degree of error that can be expected 
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when only adult information is used to predict pediatric PK in maturation-independent age groups for 
the purposes of deriving age or weight-tiered doses with therapeutic proteins.56  
 
Figure 24. Simulated profile of mean ADA formation following first dose administration in a typical 
population of adults with inflammatory bowel disease 
To summarize, the methods of PBPK modeling and allometric scaling were comprehensively 
evaluated in this work for their accuracy in translating infliximab pharmacokinetic knowledge from 
adults to children. Both methods performed comparably, yet neither method achieved the prediction 
accuracy that is recorded in studies with small molecule drugs. Considerable variability was noted 
among the predictions made by the eight allometric models and accuracy was not driven by the 
sample sizes from the parent PopPK studies. Therefore, a comprehensive pediatric clinical trial 
planning approach would benefit from both PBPK modeling and allometric scaling, being cognizant 
that PBPK modeling may be more appropriate for predicting peak concentrations and allometric 




4.6 Study Highlights 
At present, pediatric drug development for large molecules is poorly supported by modeling and 
simulation. The comparative performances of physiologically-based pharmacokinetic (PBPK) 
modeling and allometric scaling for the prediction of large molecule pharmacokinetics in children are 
unknown. 
This study addressed which method(s) for pediatric PK prediction could be used reliably in 
pediatric drug development and clinical trial planning for large molecules. 
With infliximab as an example for the evaluation, PBPK modeling and allometric scaling had 
comparable accuracy in known exposure scenarios. Two-thirds of the model-predicted concentrations 
fell within two-fold of the observed concentrations. PBPK modeling was more accurate for predicting 
peak drug concentrations, while allometry was more accurate for predicting trough drug 
concentrations. 
No pediatric PBPK modeling has been completed to support regulatory submissions to the FDA for 
a monoclonal antibody.70 We highlight the opportunity for PBPK modeling to be used in tandem with 
allometry to contribute to this growing field of drug development. 
Since a PBPK model with size-dependent anatomy alone failed to predict the elimination of 
infliximab in children, and since the disease physiology and exposure-response relationships are 
known to be similar between adults and children, we put forward the hypothesis that there are age-
dependent physiological factors that must be considered when extrapolating PK even to adolescents 





Pediatric Physiology in Relation to the Pharmacokinetics of 
Monoclonal Antibodies 
5.1 Abstract 
Dose designs for pediatric trials with monoclonal antibodies (mAbs) are often extrapolated from the 
adult dose according to weight, age or body-surface area. While these methods account for the size 
differences between adults and children, they do not account for the maturation of processes that may 
play a key role in the pharmacokinetics and/or pharmacodynamics of mAbs. With the same weight-
based dose, infants and young children typically receive lower plasma exposures when compared to 
adults. In this review, the mechanistic features of mAb distribution, elimination and absorption are 
explored in detail and literature-based hypotheses are generated to describe their age-dependence. 
This knowledge can be incorporated into a physiologically-based pharmacokinetic (PBPK) modeling 
approach to pediatric dose determination.   
5.2 Introduction 
Increasing numbers of pediatric clinical trials are being performed under the pediatric regulations 
provided by the U.S. Food and Drug Administration and by the European Medicines Agency, which 
mandate and grant incentives to drug manufacturers for pursuing pediatric research. Dose designs for 
pediatric trials are often extrapolated from the adult dose according to weight, age or body-surface 
area (BSA). While these methods account for the size differences between adults and children, they 
do not account for the maturation of processes that may play a key role in pharmacokinetics and/or 
pharmacodynamics.382 The therapeutic consequences are most pronounced for infants, who are small, 
immature and vulnerable to toxicity from dosing errors.383 An alternative tool for dose determination 
in pediatric trials that explicitly accounts for age-related changes in anatomy and physiology is the 
physiologically based pharmacokinetic (PBPK) model. These mechanistic mathematical models 
attempt to recapitulate the anatomy and physiology of the human, at all stages of life, by 
compartmentalizing tissues and organs with knowledge of their size, composition and blood flow and 
connecting them to each other to simulate in vivo drug disposition. These models have utility in many 
areas of drug development, with pediatrics being a frequent use.12,384 
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Pharmacokinetic differences between adults and children have been linked to developmental 
differences in tissue composition, blood flow rates, enzyme and plasma protein concentrations and 
glomerular filtration rates.14 These developmental differences can be incorporated into PBPK models 
to make predictions of pharmacokinetics in children and numerous examples of pediatric PBPK 
models for small molecules are published.14,384-387 One use of the pediatric PBPK model is in the 
planning of pediatric clinical trials where it can be used to guide dosing regimen design, ensure 
efficient blood sampling times and potentially reduce the number of children required for the 
studies.388  
In the last two decades there has been an explosion of large molecule drugs registered for use in 
children, a significant portion of which are monoclonal antibodies (mAbs).80 They offer new avenues 
for targeted therapies against proteins that are involved in disease pathology. Most mAbs are 
structurally similar to endogenous IgG and share similar pharmacokinetic properties. For example, 
unlike small molecule drugs, many mAbs possess long plasma half-lives in part due to recycling by 
the neonatal Fc receptor (FcRn).2 Consequently, we must endeavour to explore these new drivers of 
large molecule pharmacokinetics as they relate to children and cannot rely on our previous 
understanding of the factors related to small molecule pharmacokinetics.   
A number of mAb therapies have been investigated in children for immunology, oncology, 
infectious disease and hematology. The general pharmacokinetic differences between adults and 
children (< 18 years) are reviewed by Edlund et al. and Zhang et al. and are most prominent in infants 
and young children, suggesting that maturation plays a key role.4,80 Every mAb with published 
investigations that include infants (< 2 years) is listed in Table 14 (current as of January, 2018). 
Overall, infants and young children achieve lower plasma exposure than adults when the same 
weight-based doses are given.3,4,80,389-391 Weight-normalized plasma clearance is faster and peak 
concentrations following an intravenous dose are lower.3,4,80,389-391 BSA-based dosing regimens are 
less common and may cause higher exposures in infants.3,4,42,80,389-391 The same general patterns are 
observed for other large molecule therapies that do not share the same IgG structure such as 
darbepoetin alfa, factor VII, recombinant factor VIII, and recombinant factor IX when administered 




Table 14. Pharmacokinetic studies with monoclonal antibodies involving infants (< 2 years) 
Generic 
Name 
Target Indication Dose Age 
(years) 
Year Ref. 
Basiliximab IL-2R𝝰 Prophylaxis of transplant rejection 10 – 20 mg IV 1 – 15 2002 397 
Prophylaxis of transplant rejection 10 – 20 mg IV 1 – 16 2002 398 
Prophylaxis of transplant rejection 10 mg IV 1 – 12 2010 399 
Prophylaxis of transplant rejection 10 – 20 mg IV 1 – 16 2002 400 
Bevacizumab VEGF Solid tumour 5 – 15 mg/kg IV 0.5 – 21 2016 42 
CNS tumour 10 mg/kg IV < 3 2017 401 
Solid tumour 5 – 15 mg/kg IV 1 – 21 2008 402 
Retinopathy of prematurity 0.25 – 0.625 mg IVT < 1 2015 403 
Retinopathy of prematurity 0.25 – 0.5 mg IVT < 1 2012 404 
Cetuximab EGFR Solid tumour 75 – 250 mg/m2 IV 1 – 12 2009 405 
Daclizumab IL-2R𝝰 Prophylaxis of transplant rejection 1 mg/kg IV 0.9 – 5 2008 406 
Dinutuximab GD2 Neuroblastoma 25 mg/m2 IV 1.2 – 7.3 2014 407 
Neuroblastoma 20 – 40 mg/m2 IV 1 – 14 2009 408 
Eculizumab C5 Atypical hemolytic-uremic syndrome 300 – 900 mg IV 0.4 – 17 2016 409 
Gemtuzumab 
Ozogamicin 
CD33 Acute myeloid leukemia 0.2 – 0.3 mg/kg IV 0 – 2 2004 410 
Infliximab TNF𝝰 Kawasaki disease, Crohn’s disease, 
ulcerative colitis, juvenile 
rheumatoid arthritis 
5 mg/kg IV 0.2 – 17 2012 411 
Kawasaki disease 5 mg/kg IV 0.2 – 6 2008 412 
Crohn’s disease 5 – 10 mg/kg IV 0.5 – 1 2006 320 
MEDI8897 RSV-F Respiratory syncytial virus infection 10 – 50 mg IM 0 – 2 2017 413 
Motavizumab RSV-F Respiratory syncytial virus infection 15 mg/kg IM < 2 2010 414 
Respiratory syncytial virus infection 3 – 15 mg/kg IM < 2 2009 415 
Respiratory syncytial virus infection 15 mg/kg IM < 2  2010 416 
Respiratory syncytial virus infection 3 – 30 mg/kg IV < 2 2009 417 
Respiratory syncytial virus infection 15 mg/kg IM < 2  2011 418 
Respiratory syncytial virus infection 15 mg/kg IM < 0.5 2015 419 
Pagibaximab LTA Coagulase-negative staphylococci 
infection 
10 – 90 mg/kg IV Neonate 2009 52 
Coagulase-negative staphylococci 
infection 
60 – 90 mg/kg IV Neonate 2011 420 
Coagulase-negative staphylococci 
infection 
10 – 90 mg/kg IV Neonate 2010 421 
Palivizumab RSV-F Respiratory syncytial virus infection 15 mg/kg IM < 2 2012 35 
Respiratory syncytial virus infection 3 – 15 mg/kg IV < 2 1998 422 
Respiratory syncytial virus infection 5 – 15 mg/kg IV < 2 2004 423 
Respiratory syncytial virus infection 5 – 15 mg/kg IM < 2 1998 424 
Respiratory syncytial virus infection 15 mg/kg IM < 0.5  2014 425 
Respiratory syncytial virus infection 15 mg/kg IM < 2   2010 416 
Rituximab CD20 Opsoclonus-myoclonus syndrome 375 mg/m2 IV 1.3 – 17 2010 426 
SB 209763 RSV-F Respiratory syncytial virus infection 0.25 – 10 mg/kg IM < 0.5  1999 427 
Urtoxazumab Stx2 Hemolytic-uremic syndrome due to 
infection by Shiga-like toxin-
producing E. Coli 
1 – 3 mg/kg IV 1 – 15 2010 428 
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5.3 A Physiological Approach to Pharmacokinetics 
A number of reviews describe the mechanistic processes governing the disposition of antibody-
based drugs in the body (Figure 25).2,429,430 The distribution of a protein-based drug is limited to the 
extracellular fluid. Uptake into cells generally leads to degradation. After intravenous administration 
into the plasma, mAbs can cross the vascular wall and enter the interstitial space of certain organs by 
extravasation through pores or (to a lesser extent) by transcytosis through the vascular endothelium. 
The rate of extravasation is tissue-specific and dependent on pore-size, vascular surface area and 
capillary permeability.136 For mAbs, cellular uptake does not always lead to degradation. Inside 
endothelial, epithelial and hematopoietic cells, mAbs can bind reversibly with the neonatal Fc 
receptor (FcRn) during endosomal sorting, which protects them against lysosomal degradation.431 
From the interstitial space, mAbs can be drained through the lymphatic system and re-enter venous 
circulation. Transit within the interstitial space and through lymphatic circulation is slow, erratic and 
driven by convective flow. Drainage of interstitial fluid into the lymph helps to ensure that the 
interstitial spaces in tissues are not permanent traps for circulating mAbs. Catabolism by non-specific 
proteases in circulation may make a minor contribution to total elimination. Renal excretion is 
assumed negligible because the molecular weight exceeds 70 kDa.64 Because mAbs are protein 
molecules, an immunogenic response and subsequent development of anti-drug antibodies may 
occur.23 A full immunogenic response can render the drug near-undetectable in plasma.320   
In cases of high target abundance and accessibility, mAbs may exhibit target-mediated drug 
disposition, meaning that the kinetics of the target directly impact the kinetics of the drug.19 If the 
target is free and soluble, mAbs may contact it anywhere in the extracellular fluid. After binding, the 
neutralized mAb-target complex would circulate until it is cleared by the activation of complement 
and subsequent removal by phagocytosis. This phagocytosis could be mediated in part through 
binding to Fc-gamma receptors (FcγR) on the surface of macrophages. If the target is bound to the 
cell membrane, mAbs must often reach the interstitial space to contact it. After binding, the mAb-
target complex may be internalized into the cell and degraded, initiating a major route of elimination 
for the drug. When a mAb is subject to significant target-mediated elimination, the in vivo 
pharmacokinetics can be noticeably non-linear (clearance can decrease with increasing doses).19,20      
A physiological approach to mAb pharmacokinetics must be taken to ensure safe and effective dose 
design in the pediatric clinical trials to come. This review seeks to formulate hypotheses about the 
age-related differences in physiology that may be responsible for the observed pharmacokinetic 
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differences between adults and children. The major focus is on neonates (< 1 month) infants (< 2 
years) and young children (2 – 6 years), where the pharmacokinetic differences are most prominent. 
 
Figure 25. The main physiologic processes governing the disposition of mAbs. After IV 
administration, mAbs cross the vascular wall by extravasation or by transcytosis through the vascular 
endothelium. During this transcytosis, mAbs may bind reversibly with the neonatal Fc receptor 
(FcRn), which protects them from lysosomal degradation. If the target is membrane-bound, mAbs 
must reach the interstitial space in order to facilitate target binding. The mAb-target complex on the 
cell surface can be internalized and degraded. If the target is free and soluble, mAbs may contact the 
target anywhere in the extracellular fluid. The mAb-target complex will circulate until it is cleared by 
the activation of complement and subsequent phagocytosis. Phagocytosis of these complexes could be 





As mentioned, the distribution of mAbs is limited to the extracellular fluid in the body due to their 
poor permeability across cellular membranes and vulnerability to intracellular catabolism. Therefore, 
it is possible to estimate the volume of distribution in different species or individuals based on known 
reference values for extracellular fluid volume and body composition. Table 15 summarizes the 
developmental biology of circulatory and hydrostatic parameters from infancy until adulthood. While 
the extracellular fluid volume fraction falls rapidly after birth, plasma volume rises incrementally. 
The net effect is that the proportion of total body volume available for distribution is higher in infants 
than in older children and adults.   
Table 15 also highlights the fast rate of blood perfusion throughout the infant body in the first 6 
months of life (cardiac output). On a per kilogram basis, young infants receive higher volumes of 
blood to tissues over time.14,432 Consequently, distribution to tissues may occur faster in infants up to 
6 months of age when compared to adults. However, the distribution of large molecules to tissue 
spaces is largely rate limited by permeability across capillary walls, rather than perfusion.   























Birth 70/55 140 0.6 [0.174/kg] 85  53 40 45 
1 month 85/52 120 0.7 [0.152/kg] 80 44 45 40 
2 months 90/50 120 0.8 [0.139/kg] 80 44 45 32 
3 months 90/50 120 0.9 [0.137/kg] 75 34 50 30 
6 months 90/52 120 1.1 [0.134/kg] 75 34 50 29 
12 months 90/55 120 1.3 [0.131/kg] 80  36 50 26 
18 months 90/55 110 1.5 85 37 55 23 
24 months 90/55 110 1.7 85 37 55 20 
6 years 95/57 100 3.5 80 38 50 19 
12 years 110/65 85 4.7 75 39 46 18 













a calculated from blood volume and hematocrit 
ECW = extracellular water 
 
99 
A number of mAbs have been recently approved or are in development for infectious disease 
prevention in neonates.35,52,413,414,428 Therefore it is important to consider circulatory physiology 
during the fetal-to-neonatal circulatory transition period. In hours to days after birth, the neonatal 
circulatory system undergoes drastic structural changes.438 Briefly, the placenta is replaced by the 
lungs as the location of gas exchange and the corresponding shift from a parallel circuit to a series 
circuit in the heart is accompanied by the closing of the ductus arteriosus, the foramen ovale and the 
ductus venosus. The pulmonary arteries dilate and the left ventricle strengthens as they each begin to 
accommodate the flow and volume of the entire cardiac output. These changes occur progressively 
and perfusion to the lungs and peripheral organs may not be strong in the first week of life. Generally 
speaking, there may be irregular distribution when mAbs are administered during the fetal-to-neonatal 
circulatory transition period. 
While the rates of extravasation of therapeutic mAbs in children and adults have not been 
measured, there is data available for other plasma proteins, such as albumin.439-450 Albumin and IgG 
are both plasma proteins that follow similar patterns of distribution and bind with high affinity to 
FcRn. The TER is measured by calculating the rate of disappearance of labelled albumin from plasma 
over time. The TER of IgG is typically 40% lower than the TER of albumin across a variety of 
disease states, as summarized by Malik et al.68 Therefore, the transcapillary escape rate (TER) of 
albumin in infants and children can be used as a surrogate to explore how the rate of extravasation of 
IgG molecules into tissues may change with age.449 Overall, the rate of extravasation of plasma 
proteins is approximately 3 times higher in healthy neonates than adults (Table 16). To make 
hypotheses about how these differences progress after birth and when adult extravasation rates are 
reached, the mechanism behind the increased rate of extravasation must be elucidated. 
Extravasation of plasma proteins through pores occurs dynamically by filtration, convection and 
sieving.150 The rate of extravasation is a function of capillary permeability – which itself is affected 
by the capillary pore size – and the vascular surface area available for plasma protein exchange. 
According to the Starling equation, capillary permeability and net flux of fluid is governed by 
competing hydrostatic (blood pressure, blood flow rate, fluid volumes, etc.) and colloidal osmotic 
(protein concentration gradients) fluid pressures on either side of the capillary wall:150 
𝑃𝑒 = 𝑃𝑐 − (𝑃𝑡 + 𝑃𝑜) 
where 𝑃𝑒 = effective filtration pressure, 𝑃𝑐 = capillary hydrostatic pressure, 𝑃𝑡 = opposing hydrostatic 
pressure, 𝑃𝑜 = net colloid osmotic pressure 
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Mollison et al.439 < 1 d Healthy and hemolytic disease 20 EB 
Steele440 < 1 d Healthy 15.5 IHSA 
Jegier et al.441 < 1 d Healthy 19 IHSA 
Cassady et al.442 < 1 d Healthy 12.8 EB 
Parving et al.443  < 1 d Born to diabetic mothers 18.4 IHSA 
Ingomar et al.444 < 1 d Healthy 22.6 EB 
Ingomar et al.445 < 1 d Born to diabetic mothers 17.5 EB 
Ingomar et al.445 < 1 d IRDS 20.4 EB 
Ingomar et al.445 < 1 d Birth asphyxia 25.6 EB 
Linderkamp et al.446 < 2 d Premature 23 IHSA 
Linderkamp et al.446 < 2 yr Critically ill 11.3 IHSA 
Tassani et al.447 < 14 d Transposition of the Great Arteries 25.3 EB 
Parving et al.448  Adult Healthy 5.6 IHSA 
Rossing et al.449 Adult Healthy 5.4 IHSA 
Wasserman and 
Mayerson450 
Adult Healthy 4.9 IHSA 
TER – Transcapillary escape rate 
EB – Evan’s blue dye 
IHSA – Iodinated human serum albumin 
 
Hydrostatic pressure drives the movement of fluid out of capillaries and colloidal osmotic pressure 
draws fluid back into capillaries according to protein concentration gradients. The Landis model of 
fluid exchange suggests that net flux of fluid is out of capillaries at the arterial end of the capillary 
bed when hydrostatic pressure is highest and into capillaries at the venous end of the capillary bed 
when interstitial colloid osmotic pressure is able to overcome the diminishing hydrostatic pressure.451 
The movement of mAbs is expected to follow this flux, though there is significant resistance due to 
the large size and charge of the molecules. This model with filtration at the arterial end of the 
capillary bed and reabsorption at the venous end of the capillary bed is a simple approximation and 
both processes may not always be occurring.451 For example, in renal tubular capillaries, the colloid 
osmotic pressure from the interstitial fluid is weak and cannot drive reabsorption because the renal 
tubular absorbate is being continuously flushed.451 In addition, there are many dynamic factors to 
consider, such as the impact of transient vasoconstriction and vasodilation that may dictate the 
degrees of filtration and reabsorption.451 
The developmental biology of transcapillary fluid balance has been explored in maturing animals, 
but there is limited data in human infants.452-455 Where data is sparse, extrapolations of capillary 
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permeability in all tissues can be made by examining capillary permeability in the glomeruli. In 
animals, the net filtration rate of fluid across capillaries increases with age and approximately in 
proportion to the changes in arterial and venous pressures (Table 15).452-455 This change is driven by 
discordant increases in the opposing forces of extravasation; although colloid osmotic pressure 
increases with age, hydrostatic pressure increases to a greater degree (Figure 26).454 Even though 
plasma protein concentrations are much higher in adults than immature animals, colloid osmotic 
pressure only increases modestly with age due to the balance of protein concentrations that is 
maintained between the plasma and extracellular fluid. 
 
Figure 26. The ontogeny of filtration pressures in newborn guinea pigs until 7 weeks of age.454 𝑃𝑒 = 
effective filtration pressure (solid line), 𝑃𝑐 = capillary hydrostatic pressure, 𝑃𝑡 = opposing hydrostatic 
pressure, 𝑃𝑜 = net colloid osmotic pressure; 𝑃𝑒 = 𝑃𝑐 − (𝑃𝑡 + 𝑃𝑜) 
  Similar patterns of age-dependent capillary permeability and net filtration rate are observed in 
human infants. As evidence, the glomerular filtration rate of human infants per unit of kidney weight 
increases with age until reaching adult values after 6 months.456,457 The mechanism of this change 
appears consistent between humans and animals. Though capillary hydrostatic pressure cannot be 
measured directly in humans, there is sufficient data regarding the modest age-dependent increase in 
colloid osmotic pressure that occurs during the first year of life to support this hypothesis.458-463 Based 
on the ontogeny of glomerular filtration in humans and the maturation rates of factors in 
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transcapillary fluid balance observed in animals, we expect that capillary permeability to plasma 
proteins modestly increases with age until reaching adult values by six months.   
The second component of extravasation is the capillary surface area available for plasma protein 
exchange. Neonatal tissues have high demands for oxygen and other nutrients after birth and during 
the subsequent period of rapid growth. To meet these demands, infants have a vast and dense 
capillary surface area available for fluid, oxygen, solute and protein exchange, most notably in the 
peritoneum, muscle and skin.464-466 Further, infants have the largest skin surface area per unit volume, 
where capillary networks are dense.466 Though capillary density is increased, the endothelial surface 
area is not compromised.464 Capillary density decreases with age until puberty and then rises steadily 
throughout adulthood, though never reaching the extremes seen in infancy (Figure 27).464,467 There is 
significant variability in capillary density at birth, and it can be even further elevated in preterm 
neonates or in those born to hypertensive mothers.468,469 
 
Figure 27. Median peritoneal capillary density in humans with interquartile ranges464 
Finally, it is important to note that capillary endothelial structure is unique to each tissue. For 
example, the brain is largely impermeable to plasma proteins because of the tight intercellular 
junctions present between endothelial cells at the blood-brain barrier, while the liver, spleen and 
kidneys are highly permeable to plasma proteins due to the presence of sinusoidal or fenestrated 
capillaries.136 These central organs are proportionally larger in infants, which may explain the faster 
rate of mAb distribution to tissues in infants when compared to adults.443 For example, the liver 
 
103 
makes up 4% of the total body mass of infants, while in adults it makes up 2.5% of total body mass.50 
The ratio of “leaky” (liver, spleen, heart, lung, kidney, bone marrow, small intestine) to “tight” (brain, 
muscle, skin, adipose, large intestine, stomach, thymus, pancreas, bladder) tissue mass decreases by 
30% from birth to adulthood and may partially explain the age-dependent pattern of weight-
normalized clearance that is observed (Table 17). All things considered, the conclusion is that despite 
modestly lower capillary permeability, the overall rate of extravasation into tissues is higher in infants 
than in adults because infants have proportionally larger capillary surface area per unit volume 
available for plasma protein exchange and proportionally larger central organs, where sinusoidal or 
fenestrated capillaries are present.  
Table 17. Ratio of leaky to tight tissue mass in humans from birth until adulthood50,136 
Age 
(years) 







a Leaky tissues: liver, spleen, heart (no blood), lung (no blood), kidney, bone marrow (active only) 
and small intestine. 
b Tight tissues: brain, muscle, skin, adipose (separable), large intestine, stomach, thymus, pancreas 
and bladder 
5.5 Elimination 
Elimination of mAbs occurs predominantly through intracellular proteolysis and to a lesser extent, 
extracellular proteolysis (serum proteases, other non-specific interactions).  
Uptake into cells that leads to intracellular degradation is accomplished by endocytosis, 
phagocytosis and in some cases, receptor-mediated endocytosis.103,186,470-472 The major cell types 
implicated are endothelial and hematopoietic cells, including macrophages.473 At present there is no 
evidence that these cellular uptake functions are different between adults and children. However, 
there is convincing evidence that the relative abundances of these major cell types are higher in 
children. As mentioned, children have high capillary density, particularly in muscle, skin and 
peritoneal tissues. This vascular network provides a greater number of vascular endothelial cells per 
unit volume for non-specific endocytosis and degradation of protein products. Moreover, reference 
values for complete blood counts show that there are also high numbers of circulating hematopoietic 
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cells in children, even up to an average of 3-fold higher than adult numbers shortly after birth (Table 
18).474-478 These high levels of circulating leukocytes and macrophages will contribute to the observed 
cellular uptake and clearance of protein products in children. Tissue-specific macrophages are also 
thought to be sites of mAb degradation and Fc-mediated recycling.479 Tissue-specific macrophages 
can be detected very early during development in the fetal liver, spleen red pulp and bone marrow, 
and are known to be some of the first fully functioning cell types in the fetus.480,481 Little is yet known 
about the relative abundance of tissue-specific macrophages in children. 
Table 18. Summary of reference ranges for circulating leukocyte concentrations in children 
Age Leukocyte Concentrationa 474-478 
(109 cells/L plasma) 
Preterm 13.0 (5.0 – 21.0)b 
Term 18.0 (11.0 – 28.0) 
1 – 3 months 10.6 (7.2 – 18.0) 
3 – 6 months 9.2 (6.7 – 14.0) 
6 – 12 months 9.1 (6.4 – 13.0) 
1 – 2 years 8.8 (6.4 – 12.0) 
2 – 6 years 7.1 (5.2 – 11.0) 
6 – 12 years 6.5 (4.4 – 9.5) 
12 – 18 years 6.0 (4.4 – 9.1) 
Adult 6.0 (4.0 – 9.0) 
a Data reported as median (10th – 90th percentile) 
b Premature infants who are small for gestational age may have leukocyte concentrations that are up 
to 50% lower than those who are appropriate for gestational age482,483 
 
With regard to extracellular proteolysis, the comparative proteolytic activities of adult and infant 
sera against immunoglobulin are unknown.484 Major protein modification pathways which may affect 
IgG stability and activity in serum include asparagine deamidation, methionine oxidation, Fc glycan 
interactions with mannosidases and reduction of disulfide bonds.484 Certainly there is an opportunity 
for further investigation into the stability of IgG in infant serum. 
Specific phagocytosis of IgG is mediated in part through contact with the FcγR family, named 
because they bind to the Fc region of IgG. These receptors are expressed in cells of the mononuclear 
phagocyte system and facilitate the antibody-dependent functions of the immune system, such as 
antibody-dependent cell-mediated cytotoxicity and the elimination of antibody-target complexes.485 
However, studies in mice and monkeys show no significant impact of FcγR binding on the 
pharmacokinetic profile of mAbs.168,169,486 While there may be small differences in FcγR receptor 
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expression and activity between neonatal leukocytes and adult leukocytes,487 the overall contribution 
to the age-dependence of elimination is expected to be low. 
The effects of FcRn on the pharmacokinetics of mAbs in adults or infants are mediated by five 
factors:488-491  
1. FcRn expression per cell 
2. Relative abundance of FcRn-expressing cells 
3. Affinity of FcRn for IgG 
4. Concentration of endogenous IgG  
5. Inflammation, which may alter the expression or function of FcRn 
Organ-specific RT-PCR data from a study in rats reveals that FcRn expression varies from birth to 
puberty with sudden peaks and fluctuations.492 A grouped representation of the FcRn expression in all 
organs is presented in Figure 28. This preliminary data suggests that FcRn expression may increase 
with age until the end of puberty (40 days of age for a rat). No consistent pattern of ontogeny can be 
determined after this point because there is considerable inter-individual and inter-organ variability. 
 
Figure 28. Grouped representation of the relative expression of FcRn mRNA in rat tissues. Tissue 
mRNA data was collected from the lung, intestine, heart, spleen, liver, kidney, skin and muscle 
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tissues of maturing rats (1-63 days old).492 The red square denotes the median and the error bars mark 
the first and third quartiles. 
Further investigations in immature rats with immunohistochemical staining show that FcRn is 
largely localized in epithelial cells and macrophages rather than endothelial cells, where expression is 
heterogeneous or sparse.492 Cianga et al. discover a similar profile in human neonatal tissues.493 
However, these results may be limited by the poor sensitivity of immunohistochemical methods. If 
FcRn concentrations in vascular endothelium are indeed crucial to IgG homeostasis in humans, then a 
low concentration in infants may contribute to the increased weight-normalized clearance of mAbs 
that is observed.473,489,490   
In addition to possible low FcRn concentrations, there are relatively high concentrations of 
endogenous IgG in infants available to compete for FcRn binding in the first month after birth. 
Placental transfer of maternal IgG occurs late in gestation and maternal IgG lingers for up to two 
months, based on a maximal plasma half-life of 28 days.494 Maternal IgG transferred through breast 
milk also contributes to these levels. Endogenous IgG competes with exogenous mAb for binding to 
FcRn and this displacement would increase intracellular degradation of the mAb. Serum endogenous 
IgG levels in infants are relatively high at birth but fall in the first 3 months of life and then gradually 
rise to adult values before puberty (Figure 29).495-497   
With the available data, it can be hypothesized that the increased weight-normalized clearance that 
is observed in infants and young children is related to a high relative abundance of circulating 
macrophages and vascular endothelial cells for cellular uptake, and a possible low level of FcRn 
expression in vascular endothelial cells (Figure 28). This effect may be more pronounced in the first 
month of life, when maternal IgG is present in relatively high amounts and may compete with 





Figure 29. Plasma concentrations of IgG subclasses from birth to adulthood in human children.497 
5.6 Absorption 
Of the mAbs administered to infants, only a few are given by an extravascular route (Table 14). The 
mAbs for respiratory syncytial virus prophylaxis are given intramuscularly and the mAbs for 
retinopathy of prematurity are given intravitreally. While subcutaneous (SC) administration is 
preferred in adults for systemic biotherapeutics, intramuscular (IM) administration may be preferred 
in infants due to the ease of injection to the vastus lateralis muscle. In patients of all ages, absorption 
is slow with a time to maximal plasma concentration (Tmax) ranging from 1.7 – 13.5 days.498 Both 
experimental evidence and mechanistic models in adults predict that while the rate and extent of 
absorption are largely comparable between the IM and SC routes for mAbs, the IM route may be 
associated with a higher Cmax and shorter Tmax.498,499 For mAbs, bioavailability after extravascular 
administration ranges from 52 – 80%.498,500   
There is moderate inter-individual variability in both the rate and extent of mAb absorption 
following extravascular administration due to factors related to body weight, gender, age, activity 
level, disease state, respiratory rate, and blood pressure.2 There may also be variability in protein 
absorption depending on which injection site is used (e.g., abdomen, thigh, arm),501 though the current 
evidence with mAbs in humans conflicts with the prevailing notions in the field of SC 
biotherapeutics.499,502-505   
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Mechanistically, absorption to the systemic circulation after either IM or SC administration occurs 
via two major pathways: immediate absorption into blood via fluid recirculation in the capillary beds 
of the local injection site, or slow lymphatic drainage and recirculation, which is the dominant 
pathway.76,78,498 Sensitivity analyses with mechanistic models of SC mAb absorption suggest that the 
absorption rate is largely dependent on the lymph flow rate, which has been approximated to be 0.2% 
of the plasma flow rate in adults.78,135,498 The extent of absorption and overall bioavailability are 
governed by the degree of pre-systemic elimination in the lymphatic system, the lymphatic transit 
time and the FcRn binding affinity.498,506 Pre-systemic elimination is attributed to proteolytic 
degradation, endocytosis into endothelial and epithelial cells or phagocytosis into cells of the MPS 
that are present throughout the lymphatic system.479,498   
Some data exist to inform predictions of the rate and extent of mAb absorption in infants and 
young children. One population pharmacokinetic (PopPK) study to date with palivizumab suggests 
that the rate of absorption after IM administration is two to three times faster in infants than adults 
and that the extent of absorption or bioavailability is similar between the two groups.35 However, the 
results are limited due to the sparse nature of the pediatric data that was used, which included few 
data points in the early phases following administration. A fast rate of absorption in comparison to 
adults was also reported in a small study of SC adalimumab with five patients whose ages were 6, 9, 
10, 13 and 13 years.507 Studies with other large proteins, such as darbepoetin alfa, similarly suggest 
that absorption is more rapid in children 3 – 16 years of age with extravascular dosing.392   
To potentially explain this observation of higher absorption rate in children as compared to adults, 
we examine the factors of lymph flow rate and extracellular fluid volume.  Infants have a high 
fraction of extracellular fluid volume (Table 15) and enhanced tissue hydration when compared to 
adults.508,509 This translates to a large fluid reservoir available for dispersion and absorption of protein 
therapeutics shortly after extravascular administration. Infants have greater cutaneous, subcutaneous 
and muscle perfusion due to the high density of capillaries present and immature vasomotor control, 
which improves access to the systemic circulation.508,509  
When normalized for body weight, both local and whole body lymph flows are high in infants, 
which drives a fast rate of drug absorption.510 In animal studies, newborn lambs had thoracic duct 
flow rates that were three times higher than the rates in adult sheep (7.4 vs. 2.3 mL∙h-1∙kg-1).511 
Locally, lymph flows from subcutaneous tissue and from the lungs have been measured to be higher 
in newborn anesthetized animals than in their adult counterparts.512,513     
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With respect to the extent of absorption, or bioavailability, it appears as if this property is similar to 
adults given the same route of administration.35,392 Considering that the rate of absorption appears to 
be faster in young children, for bioavailability to remain similar, pre-systemic elimination must be 
higher. This elimination may be attributable to greater proteolytic degradation or phagocytosis by 
hematopoietic cells during lymphatic transport.479   
The exact pathways of systemic absorption after intravitreal (IVT) administration are unknown.  
Two VEGF-inhibitors, bevacizumab (mAb) and ranibizumab (Fab) are known to reach systemic 
circulation after IVT administration in premature infants.403,404,514 In adults, the systemic absorption of 
bevacizumab is significantly greater than the systemic absorption of ranibizumab.515 FcRn is present 
in endothelial cells in the eye and may be responsible for the improved absorption of bevacizumab 
over ranibizumab, which does not bind FcRn.516 FcRn binding may therefore be an important process 
governing systemic absorption after IVT administration. More research is required to elucidate the 
pathways of systemic absorption in the eye and how they may differ between premature infants and 
adults.   
In summary, it is likely that the processes governing absorption are the most consistent between 
adults and children. There may be a faster rate of absorption and greater extent of pre-systemic 
elimination in children, but the same overall bioavailability. 
5.7 Conclusion 
A number of physiologic mechanisms may be responsible together for the unique pharmacokinetic 
profiles that are seen with mAbs in infants and young children. In particular, the faster rate of weight-
normalized plasma clearance observed in children may be due to a higher burden of circulating 
hematopoietic cells, lower concentrations of FcRn in vascular endothelial cells, and/or high levels of 
maternal IgG that may compete for FcRn binding shortly after birth. The faster rate of extravasation is 
driven by a higher ratio of “leaky” to “tight” tissue mass and a greater capillary surface area per unit 
volume available for plasma protein exchange in young children. While overall bioavailability may 
appear similar, it is important to recognize that the rate of absorption can be much faster in children, 




5.8 Study Highlights 
This review explores the age-dependence of the physiologic processes governing the disposition of 
monoclonal antibodies in infants. 
1. The fraction of extracellular fluid volume in the body decreases with age and provides large 
weight-normalized volumes of distribution in infants.   
2. Extravasation of antibodies into tissues occurs quickly in infants as they have a large 
capillary surface area per unit volume available for plasma protein exchange and a large 
proportion of “leaky” tissues, where capillary permeability is highest.   
3. A fast rate of lymph flow in infants drives a fast rate of absorption after extravascular 
administration. 
4. Infants have higher circulating concentrations of hematopoietic cells, which may contribute 
to extensive cellular uptake and fast elimination. 
5. Intracellular metabolism and elimination may be increased due to low expression of FcRn – 
the neonatal salvage receptor – and the relatively high concentration of endogenous IgG 





Integration of Ontogeny into a PBPK Model for Monoclonal 
Antibodies in Premature Infants 
6.1 Abstract 
An understanding of pediatric pharmacokinetics (PK) is essential for first-in-pediatric dose selection 
and clinical trial design. At present there is no reliable way to scale the PK of monoclonal antibodies 
and IgG drug products from adults to young children or to premature infants – a vulnerable 
population with a rapidly growing drug development pipeline.  
In this work, pediatric PBPK models are constructed in PK-Sim and Mobi to explore the PK of 
pagibaximab, palivizumab, MEDI8897 and intravenous immunoglobulin (IVIG) in preterm infants. In 
addition to considering ontogeny in pediatric organ volumes, organ composition, blood flow rates and 
hematocrit, advanced ontogeny is applied for three key parameters: capillary surface area, 
hematopoietic cell concentration and lymph flow rate. The role and importance of each parameter for 
determining pediatric clearance and volume of distribution at steady state are quantitatively assessed 
with a local sensitivity analysis. In addition, the uncertainty around parameters with limited 
information in pediatrics is addressed (e.g. free FcRn concentration). 
The full ontogeny parameterization yields pediatric PK predictions that are within 1.5-fold 
prediction error over 90% of the time for preterm infants, with an absolute average fold error of 1.05. 
This result suggests that many of the key factors related to ontogeny are appropriately addressed.  
Overall, this study makes a first step toward developing a platform pediatric PBPK model for 
monoclonal antibodies and IgG drug products by solidifying existing parameterizations, integrating 
new concepts and drawing attention to unmet needs for physiologic knowledge in children. 
6.2 Introduction 
Monoclonal antibodies (mAbs) have solidified their position as the world’s most popular class of 
drugs both on the market and in the drug development pipeline. The list of therapeutic applications is 
extensive and continues to grow, now featuring opportunities in a host of pediatric-specific disease 
states such as Kawasaki disease,517 infectious syndromes of prematurity,420,518 atypical hemolytic 
uremic syndrome,409 and pediatric cancers.407  
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In pediatric drug development, safety is of utmost importance for first-in-pediatric (FIP) dose 
selection. However, if the FIP dose is too conservative, consequences may include exposing sick 
children to ineffective doses, wasting research expenditures or requiring additional children to be 
unnecessarily enrolled in the study. Conventionally, FIP doses are determined by establishing 
confidence in pharmacokinetics (PK), safety and efficacy in adults and then translating this 
knowledge to children by allometric scaling or physiologically-based pharmacokinetic (PBPK) 
modeling.312  
Our recent work addresses the comparative performances of both methods for predicting infliximab 
PK in children between 4 and 18 years of age.60 In the case of small molecule drugs, allometric 
scaling and PBPK modeling often achieve predictions within 2-fold error over 90% of the time for 
children over 2 years of age, when maturation and ontogeny do not critically influence drug 
disposition.15,314 Below the age of two years there is more uncertainty. Allometric scaling with age-
dependent exponents can match PBPK modeling in pediatric PK prediction for very young children, 
but the age-dependent exponents have to be learned with similar compounds in advance.315,316,519  
At present there is no reliable way to scale the PK of mAbs from adults to younger children or to 
premature infants – neither PBPK modeling nor allometric scaling have been evaluated. At this stage 
of life, children are physiologically very different from adults and consequently achieve lower plasma 
exposures than adults when the same weight-based doses are given.34 Our recent review highlights the 
key physiological drivers of this phenomenon in pediatrics.34 The US Food and Drug Administration 
has stressed the importance of incorporating these physiological parameters into a PBPK modeling 
framework to support pediatric drug development for mAbs and Fc-fusion proteins.70 To date, only 
one effort has been made to explore the PK of mAbs in pediatrics with a minimal PBPK modeling 
approach.319 
In the same way as for small molecule drugs,14 reviewing the literature34 and integrating a 
quantitative understanding of pediatric physiology into a PBPK model are first steps toward the 
development of a platform pediatric PBPK model that can be used for FIP dose selection and drug 
development in the future. Here we synthesize literature-based ontogeny profiles for key 
physiological parameters relevant to mAb disposition, integrate them into pediatric PBPK models for 
four drug products in premature infants and quantify their impact on PK with a sensitivity analysis. 
Premature infants are first considered because they are the most different from the adult population 





All PBPK models were constructed in PK-Sim and Mobi v8.0 using the base model for large 
molecules and therapeutic proteins (www.open-systems-pharmacology.org).66 PK data from literature 
in the form of concentration-time profiles were digitized with PlotDigitizer v2.6.8 by Joseph 
Huwaldt. MATLAB R2018b was used for data analysis and graphical presentation of results. 
6.3.2 Pharmacokinetic Data 
Adult and pediatric concentration-time profiles featuring intravenous (IV) and intramuscular (IM) 
administrations were extracted from literature for pagibaximab, palivizumab, MEDI8897 and IVIG 
(Table 19). No adult PK data were available for palivizumab. 
6.3.3 Virtual Individuals 
As inputs to the PBPK models, virtual adults and premature infants were created in PK-Sim and Mobi 
v8.0 according to previously published algorithms.14,266,317,520 For each real-world PK study (Table 
19), a virtual individual was created for simulation with postnatal age, gestational age (if premature), 
height, weight and sex parameters according to the mean individual in that study. Additional 
physiological parameter adjustments were made for virtual premature infants to account for the 
ontogeny of key processes governing mAb disposition, as will be discussed. 
6.3.4 Adult PBPK Model Development 
The base model for large molecules and therapeutic proteins in PK-Sim features two-pore 
extravasation, endocytosis into vascular endothelium, binding to FcRn and lymph recirculation.66 
Intramuscular administration was implemented by applying the bioavailable dose (𝐷𝑜𝑠𝑒 ∙ 𝐹) as a 
bolus to the interstitial space of the muscle compartment. Modifications were made to address the 
contribution of hematopoietic cells to cellular uptake, as will be discussed. Target-mediated drug 
disposition and immunogenicity were considered negligible. The same model structure was used for 




Table 19. Pharmacokinetic data for PBPK modeling 




3 mg/kg IV 
10 mg/kg IV 
Healthy 
adults 
8 34.7 [24-50] 
years 
- 77.9 [61-113] kg 
Weisman et 
al. 420 
60 mg/kg IV 


















4.9 ± 0.74 kg 
Sáez-Llorens 
et al.424 








Griffin et al.521 3000 mg IV 
1000 mg IV 
300 mg IV 
300 mg IM 
100 mg IM 
Healthy 
adults 
102 31 ± 7.8 
years 
- 78 ± 14.9 kg 
Domachowske 
et al.522  
50 mg IM 
25 mg IM 
10 mg IM 
Premature 
infants 
71 6.5 months 32 – 35 weeks 6.8 ± 1.9 kg 
Intravenous Immunoglobulin (IVIG) 
Andresen et 
al. 523 
600 mg/kg IV Healthy 
adults 
30 26 [18-43] 
years 
- 66 [52-86] kg 
Chirico et al. 
524 
500 mg/kg IV  Premature 
infants 




Noya et al.  
525 
500 mg/kg IV 
750 mg/kg IV 




21 [1-5] days 29.1 [26-33] 
weeks 
1.1 [0.75-1.5] kg 
Noya et al.  
526 
500 mg/kg IV 
750 mg/kg IV 
Premature 
infants 
20 [1-5] days 28.9 [26-35] 
weeks 
1.1 [0.75-1.5] kg 






Adult models were constructed with drug-specific parameterizations for each molecule (Table 20). 
While the data for IVIG actually includes several brands of the product, the physicochemical 
parameters were assumed the same across all brands because no data was available to inform any 
product-specific differences. The affinities of pagibaximab and MEDI8897 for the neonatal Fc 
receptor (𝐾𝐷
𝐹𝑐𝑅𝑛) and the bioavailable fractions in the muscle interstitium (𝐹) for MEDI8897 were not 
available in literature and required optimization. The optimization was carried out in PK-Sim using a 
Monte-Carlo approach for exploring the parameter space. The bioavailable fraction of palivizumab in 
muscle interstitium was assumed the same as for MEDI8897 since no adult concentration-time data 
was available to perform an optimization and the molecules have similar parent derivations.  
Table 20. Drug-specific parameters inputted into the PBPK model 
Parameter Pagibaximab Palivizumab MEDI8897 IVIG 
Molecular Weight 146.1 kDa   150 kDa 
Hydrodynamic 
Radius 
5.34 nm 5.34 nm 5.34 nm 5.34 nm 






(assumed same as 
MEDI8897) 
0.85 - 
Shaded parameters were optimized against the PK data from healthy adults 
Success of the PBPK models for mechanistically representing the PK of the mAbs in adults was 
confirmed by comparing model predictions to observed concentration-time data from literature with a 
visual predictive check (Table 19). 
6.3.5 Integration of Ontogeny 
Adult parameters in the final models were adapted to pediatrics with careful consideration of 
physiological literature to date.34 To begin, organ volume, organ composition, blood flow rate and 
hematocrit parameters were updated with values for preterm infants.14,266,317,520  
Infant organs – particularly adipose and muscle tissues – are more “watery” than adult organs and 
provide large volumes of distribution (mL/kg) for protein-based drugs. The extracellular fluid fraction 
in the infant body decreases from 0.45 at birth to 0.18 in adulthood.34,437 In addition, central “leaky” 
and macrophage-bearing organs such as the liver and spleen make up a large portion of the neonatal 
body when compared to adults (12.9% in infants vs. 9.8% in adults).34 Virtual children are created by 
default in PK-Sim with these properties already accounted for.14 
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Moving forward, advanced ontogeny was considered in two additional domains: extravasation and 
lymph flow, and cellular uptake. Table 21 summarizes how advanced ontogeny was integrated into 
the PBPK model for premature infants. 
Table 21. Summary of advanced ontogeny parameters in the PBPK model 
Age Capillary Density  
464,467,468,527,528 
(Fraction of Adult) 
Lymph Flow Rate 
34,511,513,529,530 
(Fraction of Adult) 
Leukocyte Concentrationa  
474-478,482 
(109 cells/L plasma) 
Preterm 1.6 2.0 13.0 (5.0 – 21.0)b 
Term 1.3 2.0 18.0 (11.0 – 28.0) 
1 – 3 months 1.1 2.0 10.6 (7.2 – 18.0) 
3 – 6 months 1.0 2.0 9.2 (6.7 – 14.0) 
6 – 12 months 0.9 2.0 9.1 (6.4 – 13.0) 
1 – 2 years 0.8 - 8.8 (6.4 – 12.0) 
2 – 6 years 0.8 - 7.1 (5.2 – 11.0) 
6 – 12 years 0.9 - 6.5 (4.4 – 9.5) 
12 – 18 years 1.0 1.0 6.0 (4.4 – 9.1) 
Adult 1.0 1.0 6.0 (4.0 – 9.0) 
a Data reported as median (10th – 90th percentile) 
b Premature infants who are small for gestational age may have leukocyte concentrations that are up 
to 50% lower than those who are appropriate for gestational age483,531 
 
The neonatal extravasation rate of IgG is three times faster than the adult extravasation rate as 
approximated by the transcapillary escape rates (TER) of plasma proteins34 and the filtration capacity 
in skeletal muscle.532 This phenomenon is governed by three factors: 
1. “Leaky” organs (e.g., liver and spleen) are proportionally larger in children.34 
2. Infant organs – particularly skin, muscle and adipose tissues – have dense capillary networks, 
providing greater surface areas for extravasation to occur.34,464,467,468 
3. Neonatal lymph flow is two times faster than adult lymph flow as approximated from animal 
studies.34,511,513,529,530 
Table 21 demonstrates the ontogeny profile for capillary density that was constructed from five 
definitive studies in humans representing the body of literature on the topic.464,467,468,527,528 Similar data 
is available in animals.533-535 For reference, the data and derivation are provided in Appendix B. In 
humans, the profile follows a U-shaped function with increasing age such that capillary density is 




The convective flow terms in the two-pore equation66 were updated with a surface area scaling 
factor (𝐹2) to reflect that both convection and diffusion across capillary walls should increase in 
proportion to capillary surface area. 
















    
Lymph flow (𝐿) was doubled for preterm infants according to studies in newborn 
lambs.34,511,513,529,530 Lymph flow is the key driver of the rate of absorption after IM administration. 
The major route of mAb elimination is by cellular uptake and lysosomal degradation. Intracellular 
binding to the neonatal Fc receptor (FcRn) can protect the drug and prolong the plasma half-life. 
Animal studies have identified that vascular endothelial cells and hematopoietic cells (more 
specifically, leukocytes and macrophages) are the two major cell types contributing to cellular uptake 
and FcRn-mediated salvage.473,490,536 Therefore, it is important to consider the concentrations of these 
cell populations in infants as compared to in adults. 
The ontogeny of vascular endothelial cell concentration follows the ontogeny of capillary surface 
area, as previously discussed (Table 21). In a similar pattern, leukocyte cell concentrations – 
parameterized for the virtual child as a fraction of the adult concentration (𝐹1) – are high at birth but 
decline with age (Table 21).474,477  
In the base model for large molecules in PK-Sim, the vascular endothelial cell and leukocyte cell 
spaces are lumped together into one endosomal compartment. For this analysis, the endosomal 
compartment was split and attributed equally to vascular endothelial and leukocyte cell spaces 
according to observations from animal knock-out studies which suggest that each cell population 
contributes equally to mAb uptake and recycling.473,490,536 
The availability of FcRn for intracellular salvage is a key determinant of plasma half-life. Some 
preliminary data may suggest lower FcRn concentrations in children, though no definitive argument 
can yet be made.34,319,492,493,537 Three studies have examined FcRn expression in neonatal subjects 
relative to adults.492,493,537 In rats, RT-PCR revealed a general trend across all organs of low FcRn 
mRNA expression at birth relative to adults,492 though the intestine may be an exception.537 
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Physiologically this is plausible because FcRn expression in the intestine is important for the neonatal 
absorption of maternal IgG when breastfeeding. In humans, Cianga et al. discovered low and 
heterogeneous expression of FcRn in neonatal carcasses, especially in vascular endothelium.493 
Volumes of organs of the mononuclear phagocyte system, such as the liver and spleen are of 
special consideration in relation to whole-body cell uptake rates because they house numerous 
leukocyte cell populations. The liver and spleen are proportionally larger in infants and this difference 
may contribute to more extensive cellular uptake of circulating mAbs. Again, these organ volumes for 
preterm infants are implemented appropriately in PK-Sim by default. 
6.3.6 Dynamic Simulation of Growth 
IgG-based molecules exhibit long plasma half-lives and the consequence is that even single dose PK 
trials for these drug products must be extended for weeks at a time. When modeling the PK of these 
long half-life products in preterm infants, the anatomy and physiology parameters in the model must 
be considered dynamic, rather than static, as the infants’ bodies grow rapidly across the simulation 
time.  
By selecting the “allow aging” option in PK-Sim, organ volume, organ composition, blood flow 
rate and hematocrit parameters for virtual preterm infants update at discrete intervals according to the 
data highlighted by Claassen et al.317 Aging was manually implemented for capillary surface area, 
lymph flow rate and hematopoietic cell concentrations according to the intervals in Table 21.  
In the absence of other data, preterm infants were assumed to possess the same capillary density 
and hematopoietic cell concentrations as term infants after 1 month of postnatal age. 
6.3.7 Sensitivity Analysis 
A local sensitivity analysis was performed for parameters relevant to ontogeny to quantify their 
impact on clearance and volume of distribution. Simulations were run for a mean premature infant (3 
days old, 29 weeks gestational age) receiving a single dose of pagibaximab 60 mg/kg IV. Parameters 
related to ontogeny were varied by ±10% and the resulting percent changes in clearance (𝐶𝐿 =
𝐷𝑜𝑠𝑒 ÷ 𝐴𝑈𝐶) and volume of distribution at steady state (𝑉𝑆𝑆 =
𝐷𝑜𝑠𝑒×𝐴𝑈𝑀𝐶
𝐴𝑈𝐶2
) were presented as 
sensitivity coefficients. The sensitivity analysis also directs attention to the parameters that are 
important to refine when developing a platform pediatric PBPK model and the degree of error that 
could be expected when those parameters are misinformed. 
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6.3.8 Pediatric Pharmacokinetics Assessment 
The pediatric PK data from literature – both the concentration-time profiles and the calculated PK 
parameters – were compared to the predictions simulated by the full pediatric PBPK models. Model 
performance was assessed with a visual predictive check and by calculation of the absolute average 
fold error around each data point (AAFE), the root mean squared error (RMSE) and the percent of 
model-predicted plasma concentrations falling within 2-fold, 1.5-fold and 1.33-fold prediction error. 
Fold error at each datapoint was calculated as the predicted concentration divided by the observed 
concentration. 2-fold prediction error was defined as the range between 0.5- and 2.0 fold error. 1.5-
fold prediction error was defined as the range between 0.667- and 1.5-fold error. Finally, 1.33-fold 
prediction error was defined as the range between 0.75- and 1.33-fold error. 
6.4 Results 
6.4.1 Adult PBPK Model Development 
High confidence was established in the adult scenario for each drug except for palivizumab before 
approaching the pediatric scenario. Visual predictive checks for the optimized adult PBPK models 
revealed close fits with observed concentration-time data from literature (Figure 30).  
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Figure 30. Performance of the final adult PBPK models for representing the observed pharmacokinetic data from literature for three antibody 
products.53,521,523 
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6.4.2 Sensitivity Analysis 
The sensitivity analysis confirmed the importance of the advanced ontogeny parameters for predicting 
pediatric PK and gave insight into the roles that they play in defining clearance and VSS (Figure 31). 
In the current structure and under the given assumptions, the sensitivity analysis reveals that high 
hematopoietic cell concentrations (𝐹1) in children may be responsible for the increased clearance in 
children but have a minimal effect on VSS. The capillary surface area (𝐹2) is important for defining 
both clearance and VSS in children since the parameter speeds extravasation and increases the volume 
of vascular endothelium available for cellular uptake. A fast lymph flow rate (𝐿) in children mildly 
decreases VSS due to faster recirculation from the interstitium to the venous blood. This parameter is 
most important when modeling mAb absorption after intramuscular or subcutaneous administration. 
 
Figure 31. Results of the local sensitivity analysis reported as the percent changes in clearance and 
volume of distribution that were dictated by ±10% changes in input parameters relevant to ontogeny. 
𝑭𝟏 = hematopoietic cell concentration ontogeny factor, 𝑭𝟐 = capillary surface area ontogeny factor, 𝑳 
= lymph flow rate, 𝑭𝒄𝑹𝒏 = free FcRn concentration in endosomal space, 𝑽𝑳𝒊𝒗𝒆𝒓 = liver volume, 
𝑽𝑻𝒐𝒕𝒂𝒍
𝑬  = whole-body endosomal volume, 𝒌𝒖𝒑= rate of cellular uptake, 𝒓𝒑𝒐𝒓𝒆 = capillary pore radius, 
𝑷 = capillary permeability. 
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Clearance in the pediatric model is most sensitive to the rate of cellular uptake (𝑘𝑢𝑝) and there is no 
information available yet to assess potential differences in this parameter between adults and children. 
Vascular endothelial cells and leukocytes will be of interest for in vitro investigations. A fast rate of 
cellular uptake in children would increase clearance and vice versa. Interestingly, cellular uptake 
parameters have some relevance for predicting VSS due to the mechanism where mAbs can be 
sequestered in endosomal spaces. 
The sensitivity analysis also shows that if FcRn concentrations in children were lower than in 
adults as hypothesized elsewhere34 – the difference would dictate a moderate increase in clearance.  
Capillary pore radius (𝑟𝑝𝑜𝑟𝑒) and capillary permeability (𝑃) are important contributors to describe 
extravasation and VSS. Measurements of osmotic and hydrostatic pressures across capillary walls 
suggest that net capillary permeability in children is only slightly lower than in adults, but increases 
with age.34 Conflicting observations are made showing increased permeability of new vessels formed 
by angiogenesis during wound healing, though the applicability to the developing blood vessels in 
children may be low.538 A comprehensive quantitative expression of the ontogeny of capillary 
permeability is unlikely to be of significant importance for pediatric PK prediction since the effects 
on extravasation are strongly antagonized by the ontogeny of capillary surface area (𝐹2). 
Finally, proper parameterizations for the volumes and compositions of centrally vascularized, 
permeable and hematopoietic cell-bearing organs (such as 𝑉𝐿𝑖𝑣𝑒𝑟) are shown to have some importance 
for predicting both pediatric clearance and VSS. 
6.4.3 Pediatric Pharmacokinetics Assessment 
After integration of ontogeny into the final pediatric PBPK models, PK predictions were strong for 
the four mAbs in premature infants from 1 day to 24 months of age (Figure 32). Across the observed 
drug concentrations, 93% of the corresponding model-predicted concentrations fell within 2-fold 
prediction error, 90% fell within 1.5-fold prediction error and 80% fell within 1.33-fold prediction 
error. This result suggests that many of the key factors related to ontogeny are appropriately 
addressed. Much of the error was driven by a failure to predict concentrations in the terminal phase of 
the IVIG profiles. Extravasation was also under-predicted after the first dose for pagibaximab. The 




Figure 32. Performance of the final pediatric PBPK models for representing observed pharmacokinetic data from literature for pagibaximab, 
palivizumab, MEDI8897 and intravenous immunoglobulin (IVIG) in premature infants.420,424,522,524-526
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Observed data in the terminal phase of the IVIG profiles should be interpreted with caution, as the 
reported values in the data for exogenous IgG are likely lower than the real values. In the literature, 
exogenous IgG concentrations are calculated as: 
[𝐼𝑔𝐺𝑒𝑥𝑜] = [𝐼𝑔𝐺𝑇𝑜𝑡𝑎𝑙] − [𝐼𝑔𝐺𝑒𝑛𝑑𝑜] 
However, endogenous IgG (𝑰𝒈𝑮𝒆𝒏𝒅𝒐) is only measured at baseline in the first few days after birth. 
Endogenous IgG is shown to decrease from that point over the first two months of life for preterm 
infants.539 The consequence of using the baseline measurement for endogenous IgG in the equation is 
that the terminal phase data points for exogenous IgG have low confidence and may be significantly 
under-reported. This phenomenon drives the decreasing predictive performance of the pediatric 
PBPK model over time for IVIG. 
6.5 Discussion 
Preterm infants are gaining increased therapeutic attention in drug development for mAbs and IgG 
products against infectious syndromes of prematurity (e.g. HIV, respiratory syncytial virus, 
cytomegalovirus, staphylococcal sepsis). The US FDA recently highlighted the need for pediatric 
PBPK modeling efforts to support drug development and clinical trial design for this vulnerable 
population, as is commonly done in the context of small molecules.70 In response, we begin the first 
whole-body PBPK modeling assessment of mAbs in preterm infants, with pagibaximab, palivizumab, 
MEDI8897 and IVIG as working examples.  
In this work, literature-based ontogeny for organ volumes, organ composition, blood flow rates, 
hematocrit, hematopoietic cell concentration, capillary surface area and lymph flow rates were 
integrated into a PBPK model for mAbs in premature infants. The importance of each parameter for 
determining clearance and VSS was assessed quantitatively with a local sensitivity analysis. 
Furthermore, attention was drawn to other key parameters that are important to refine in the process 
of developing a platform PBPK model for mAbs and IgG products in premature infants. With over 
90% of model-predicted concentrations falling within 1.5-fold prediction error, we can be confident 
that many of the important factors related to ontogeny have been appropriately addressed. 
For the most part, analyses of the accuracy of PBPK modelling for predicting the PK of small 
molecule drugs in preterm infants report area-under-the-curve (AUC) and clearance as primary 
outcomes of interest.540 However, it is the trough concentrations and the half-life that drive FIP dose 
selection for mAbs, especially those targeted against infectious antigens.420,424,522 For these products, 
clinicians seek a dosing regimen that sustains a trough concentration above a target value. In doing 
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so, the patient achieves stronger immunity against the infectious antigen (RSV, HIV, bacterial 
antigens, etc.). Nevertheless, reporting the prediction error around AUC and clearance was not 
possible in this work because the observed values were rarely reported in the clinical studies and a 
manual non-compartmental analysis would be highly inaccurate with only three data points available 
for calculation. 
This work also serves as an update on the state-of-the-art understanding of pediatric physiology in 
relation to mAb PK.34 We refine this content with a quantitative presentation of the ontogeny of 
capillary surface area derived from five definitive studies.464,467,468,527,528 Furthermore, knock-out 
animal studies473,490,536 and recent PBPK models for FcRn inhibitors541 highlight the important role 
that cells of hematopoietic origin may play in the cellular uptake, FcRn-mediated salvage and 
elimination of mAbs. The effects of a high concentration of hematopoietic cells at birth have been 
incorporated into the pediatric PBPK model for mAbs and characterized with a sensitivity analysis, 
showing that this parameter drives clearance but not VSS. 
The ontogenies of FcRn expression and endogenous IgG concentrations have yet to be addressed. 
They both moderate the availability of the free FcRn parameter. Previous minimal PBPK modeling 
work by Hardiansyah and Ng fully attributed the unique elimination profile of mAbs in children to 
altered FcRn expression.319 However, similar patterns of pediatric exposure are observed for other 
protein-based drugs that do not bind to FcRn, such as erythropoietin stimulating agents and 
coagulation factor concentrates.392-396 This observation suggests that the mechanisms responsible for 
fast elimination of mAbs in children are not attributable to FcRn ontogeny alone, or perhaps even at 
all. Here we uncover the impacts of ontogeny in foundational physiological parameters before 
considering the ontogeny of FcRn expression, which bears a high degree of uncertainty. 
The conventional approach for using PBPK modeling to make a PK prediction in pediatric patients 
involves first evaluating the foundational model structure and parameters in adults before scaling 
select parameters to represent pediatrics according to known physiology.387 For large molecules 
administered to patients in whom there is no ligand present, the drug-specific parameters are actually 
quite simplistic and a prediction of pediatric PK could be made without evaluating the parameters in 
the adult population first. For IVIG and palivizumab, no optimization or learning was performed at 
the adult modelling step. Unexpectedly, the a priori pediatric predictions are strong for palivizumab. 
There are opportunities for further refinement of the parameterization. The capillary surface area 
ontogeny factor (𝐹2) in the model is applied in the same way to every organ in the absence of organ-
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specific data. The measurements from literature come from the abdominal peritoneum, buccal 
mucosa, skin, muscle and nail folds,464,467,468,527,528 but are generalized to the central organs as well. 
Organ-specific estimates for the ontogeny of capillary surface area could be obtained from future 
animal studies. 
Furthermore, the base model for large molecules and therapeutic proteins in PK-Sim does not 
explicitly include a hematopoietic cell compartment in addition to a vascular endothelial cell 
compartment, such as in the models put forward by Li and Balthasar541 or Aborig et al.542 Instead, the 
impacts of cellular uptake by vascular endothelial cells and hematopoietic cells are lumped together 
into one endosomal compartment. To correctly account for the ontogeny of this cell population we 
have split the relative contributions to cellular uptake equally between vascular endothelium and 
hematopoietic cells in the absence of specific data, though this fraction may vary among specific 
organs (e.g. spleen542).  
While it is yet to be explored, PBPK modeling may even offer adequate pediatric PK predictions 
for molecules that are subject to target-mediated drug disposition and nonlinear elimination. As 
already mentioned, children and especially premature infants typically achieve much lower plasma 
exposures to biologic drugs than adults with the same mg/kg doses.80 Since a PBPK model accounts 
for target-binding and nonlinear elimination mechanistically, such an approach would theoretically be 
able to classify when the drug would enter the linear clearance range in children.  
At present, the PBPK modeling approach to pediatric PK assessment is limited by its inability to 
characterize or predict the variability in the PK data. In adults, population PBPK modeling has been 
proposed, which attributes overall PK variability to inter-subject variability in key physiological input 
parameters.68  This approach enables a reproduction of the observed PK variability in clinical trials 
when simulations are conducted iteratively with parameter sets representing many virtual individuals 
as inputs.68 The inter-subject variabilities in key parameters related to ontogeny and the correlations 
between them in children are not yet known for large molecules, but may be the subject of future 
research.  
All models were constructed in the open-source software, PK-Sim and Mobi v8.0, enabling drug 
developers and academics to easily access and apply this parameterization. The parameterizations for 
full term infants and young children (1-4 years) were not evaluated explicitly in this work since 
limited or no data was available in literature for objective evaluation. Therefore, caution should be 




Overall, this work describes a literature-based integration of ontogeny into a PBPK model for mAbs 
in premature neonates coupled with a comprehensive assessment of the role that each parameter may 
play in the prediction of clearance and volume of distribution at steady state. It sets the stage for the 
development of a platform pediatric PBPK model by solidifying parameterizations for organ volumes, 
organ composition, blood flow rates and hematocrit, deriving parameterizations for hematopoietic cell 
concentration, capillary surface area and lymph flow, and drawing attention to unmet needs for 
physiologic knowledge in children. 
6.7 Study Highlights 
This manuscript integrates the ontogeny factors discovered in the literature review (Chapter 5) within 
a PBPK modeling framework to extrapolate monoclonal antibody pharmacokinetics from adults all 
the way down to preterm infants. This extrapolation was performed with the best knowledge that was 
available at that time (2019) to parameterize the PBPK model structure and the ontogeny profiles of 
relevant physiological factors in very young children. Assumptions about the role of hematopoietic 






Model-Based Assessment of the Contribution of Hematopoietic 
Cells to the Pharmacokinetics of Monoclonal Antibodies 
7.1 Abstract 
The role of hematopoietic cells and in particular, monocytes and macrophages in the 
pharmacokinetics of monoclonal antibodies (mAbs) is currently not well understood. Uptake of mAbs 
into hematopoietic cells is of potential importance for anticipating the changes in pharmacokinetics 
that may occur when hematopoietic cells are present in relatively high concentrations in special 
populations, such as in children. A complicating factor is that children may also have lower 
availability of the neonatal Fc receptor (FcRn) for mAb protection. In this work, a minimal 
physiologically-based pharmacokinetic (PBPK) model is used to characterize mAb uptake into 
hematopoietic cells and associated FcRn-mediated recycling in the context of site-specific FcRn 
deletion and variable endogenous and exogenous IgG levels using data from mice. The model unifies 
experimental data from three studies in unique mouse models with site-specific FcRn deletion in 
macrophages or endothelial cells together with clodronate liposomes to achieve macrophage 
knockdown. The final model was verified by testing its predictive performance against experimental 
data describing the interaction between therapeutic mAb, endogenous IgG, high-dose exogenous IgG 
and FcRn in mice. A sensitivity analysis revealed the plasma AUC was highly sensitive to endothelial 
cell parameters, but had near-nil sensitivity to macrophage parameters, even in the scenario with 90% 
FcRn depletion. Overall, the model confirms the assertion that macrophages are indispensable for IgG 
homeostasis. In this regard, macrophages serve as highly efficient protectors of IgG in plasma, 
interstitial fluid and lymph. They are not, as previously thought, sinks for mAb degradation. In mice 
with normal FcRn expression, model simulations suggest that less than 2% of an intravenously 
administered dose is eliminated in macrophages, while endothelial cells are predicted to dominate 
mAb elimination. We conclude that it is very unlikely that a high concentration of circulating 
monocytes can contribute to explaining the fast weight-based clearance of mAbs in very young 





It is well known that Immunoglobulin G (IgG) and its therapeutic derivatives, termed monoclonal 
antibodies (mAbs) have long plasma residence times in the body spanning weeks to months.2 The 
major route of elimination is by cellular uptake and subsequent endosomal catabolism.2 Two major 
cell populations have been identified to be responsible for this uptake based on proximity to plasma 
and innate pinocytic or phagocytic activity – (1) vascular endothelial cells and (2) hematopoietic 
cells.473 Fighting to protect IgG from catabolism in these cells is the neonatal Fc receptor (FcRn), a 
salvage protein that binds to IgG in the acidic conditions of endosomes and recycles back to the 
extracellular surface.2 In the body, vascular endothelial cells make up the capillary walls and 
therefore have extensive access to mAb in plasma. Hematopoietic cells are present in plasma (e.g., 
monocytes), and are also located throughout the extravascular space and the lymph nodes.479  
In 2018, data was presented from Richter et al. highlighting the contribution of hematopoietic cell 
uptake and FcRn-mediated recycling to mAb disposition in mice with site-specific FcRn 
knockouts.479,536 The original conclusions from the work were that: 
1. Hematopoietic cells and endothelial cells contribute about equally to the FcRn-mediated 
protection of mAbs 
2. Hematopoietic cells and endothelial cells contribute about equally to the clearance of mAbs 
3. Clearance of mAbs by endothelial cells occurs predominantly from plasma, while clearance 
of mAbs by hematopoietic cells occurs predominantly in the extravascular space 
4. After extravascular administration, pre-systemic elimination or ‘first pass catabolism’ of 
mAbs occurs in hematopoietic cells 
Based on these observations, our group hypothesized in 2019 that a higher concentration of 
circulating hematopoietic cells in very young children may explain in part why children have faster 
weight-based clearance of mAbs than adults.65 It was revealed later in 2019 by Challa et al. that it was 
a specific hematopoietic cell subtype – the macrophages – that were predominantly responsible for 
the Fc-mediated recycling of mAbs.490 Therefore our hypothesis evolved to consider that a higher 
concentration of monocytes (the circulating phagocytes) in children may contribute to this faster 
weight-based clearance. Indeed, monocytes are present at three to five times higher concentrations in 
infant blood when compared to adult blood, while tissue-resident macrophages are known to remain 
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largely constant in their abundance and activity throughout infancy to adulthood, even from the fetal 
stage.478,480,543  
Complicating factors are the degree of FcRn expression and the circulating concentrations of 
endogenous IgG that may compete with therapeutic mAb for FcRn-mediated protection. With very 
limited evidence, it has been hypothesized that children may have lower FcRn concentrations in 
vascular endothelial and/or hematopoietic cells, which implies poor protection of mAbs in vivo and 
fast clearance.34,63,492,493 The available FcRn is potentially further compromised by high 
concentrations of circulating IgG in the three months after birth from maternal sources.34 Therefore it 
becomes of importance to understand the quaternary quantitative relationship between monocyte and 
macrophage concentrations, FcRn expression, endogenous IgG concentrations and mAb clearance. 
In the presented work, a mechanistic model is developed using data from mice that characterizes 
mAb uptake into hematopoietic cells and associated FcRn-mediated recycling in the context of site-
specific FcRn deletion and variable endogenous and exogenous IgG levels. The overall aim is to 
provide evidence towards accepting or rejecting the hypothesis that high concentrations of blood 




PBPK modeling was performed in MATLAB R2020a (Mathworks, Natick, MA) using the extension 
IQM Tools v1.2.2.2 by Henning Schmidt (Intiquan, www.intiquan.com). All datasets were digitized 
from literature using PlotDigitizer v2.6.8 by Joseph Huwaldt (plotdigitizer.sourceforge.net). 
Anatomical parameter values for a mouse were extracted from PKSim v9.1 (www.open-systems-
pharmacology.org). 
7.3.2 Pharmacokinetic Data 
The first dataset for model building was from Garg et al.91 In these experiments, C57BL/6J wild-type 
and global FcRn-knockout mice (GKO) were administered 8 mg/kg of mAb 7E3 by intravenous 
injection. Elimination of 7E3 was dramatically faster in GKO mice compared to controls. In an 
additional experiment, 7E3 was co-administered with 1 g/kg intravenous immunoglobulin (IVIG) to 
partially saturate FcRn, and elimination was moderately increased. This data was reserved for model 
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verification as it reflects the complex interplay between therapeutic mAb, endogenous IgG, 
exogenous IgG and FcRn.  
The second dataset for model building was from Challa et al.490 There were three populations of 
mice to consider: C57BL/6J wild-type mice, GKO mice, and macrophage-specific FcRn knockout 
mice (MKO). Mice were administered 10-15 µg of 125I-labelled mAb D1.3 and whole-body 
radioactivity was measured at specific time points using an Atom Lab 100 dose calibrator. GKO mice 
exhibited the shortest whole-body mAb half-life (35.5 hours), followed by MKO (41.9 hours) mice 
and then wild-type mice (247.6 hours). In another set of experiments, macrophages in wild-type and 
GKO mice were knocked down by two 1.5 mg doses of clodronate liposomes injected 18 hours 
before and 30 hours after mAb administration. In wild-type mice, macrophage knockdown with 
clodronate did not significantly impact the whole-body mAb half-life. In GKO mice, however, 
macrophage knockdown increased the whole body mAb half-life (54 vs. 39 hours). Mice with 
endothelial-specific FcRn knockout were not successfully validated and so that data was excluded 
from this analysis. However, fast elimination was also observed in that mouse model. 
The final dataset for model building was synthesized from experiments by Akilesh et al. and was 
digitized from the manuscript by Richter et al.479,536 In these experiments, C57BL/6J wild-type mice 
and GKO mice were administered 4 mg/kg of mAb 1B7 by intraperitoneal injection. In addition, 
MKO mice were generated by subjecting C57BL/6 wild-type mice to high doses of radiation and then 
replacing hematopoietic cells with a bone marrow transplant from GKO mice. In similar fashion, 
endothelial-specific FcRn knockout mice (EKO) were generated by subjecting GKO mice to high 
doses of radiation and then replacing hematopoietic cells with a bone marrow transplant from 
C57BL/6 wild-type mice. Total exposures were highest in wild-type control mice, followed by EKO 
mice, MKO mice and then GKO mice.  
7.3.3 Minimal PBPK Model Development 
A minimal PBPK model is defined as one in which the whole body and its physiological mechanisms 
of drug disposition are simplified into one lumped organ compartment to test elementary 
pharmacokinetic hypotheses. For this model, whole body volume parameters for plasma, interstitial 
space and endothelial endosomes were extracted from PK-Sim v9.1 for a virtual mouse with 21 g 
body weight (𝑉𝑃 , 𝑉𝐼𝑆, 𝑉𝐸). In the proposed physiological structure (Figure 33), mAb is deposited in 
the plasma space after intravenous administration. Lymph flow (𝐿) drives convective transport across 
the vascular wall into the interstitial space, with resistance to flow through pores modeled by a 
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vascular reflection coefficient (𝜎𝑉). From the interstitial space, mAb may be returned by lymph flow 
back to the plasma space. Uptake into endothelial cells occurs from plasma (𝐶𝐿𝑢𝑝). Uptake into 
circulating macrophages and Kupffer cells occurs from plasma, and uptake into tissue-resident 
macrophages occurs from interstitial space (𝑃𝑢𝑝). Within endosomes, unbound mAb is subject to 
degradation (𝐶𝐿𝑠𝑝𝑒𝑐 , 𝑃𝑠𝑝𝑒𝑐). However, mAb that binds to the neonatal salvage receptor (𝐹𝑐𝑅𝑛) may 
be recycled back to the extracellular space (𝐶𝐿𝑢𝑝, 𝑃𝑢𝑝). Intracellular binding to FcRn was represented 
with first order binding rates determined from in vitro studies (𝑘𝑜𝑛, 𝑘𝑜𝑓𝑓) and evaluated by Niederalt 
et al.66 One FcRn concentration (nmol/L endosome) was applied consistently for endosomal spaces, 
regardless of cellular origin.91,544 Full notation of the states, variables and parameters are presented in 
Table 22 with model equations following. 
The volumes of three major macrophage populations were derived from literature: circulating 
hematopoietic macrophages (monocytes) (𝑉𝑐𝑖𝑟𝑐
𝑀 ), Kupffer cells lining sinusoids in the liver (𝑉𝑘𝑢𝑝𝑓𝑓𝑒𝑟
𝑀 ) 
and other tissue-resident macrophages (𝑉𝑡𝑖𝑠𝑠𝑢𝑒
𝑀 ), such as splenic red pulp macrophages, alveolar 
macrophages in the lung and Langerhans cells in the pancreas.545 Monocytes are the dominant 
macrophage cell population in blood and make up approximately 2% of the murine white blood cell 
count.545-549 As such, the circulating macrophage volume was calculated based on a murine white 
blood cell count of 9000 cells/µL and employing a 20 µm spherical radius for monocytes.548 Kupffer 
cells make up 10-16% of cells in the murine liver and are largely derived from circulating 
monocytes.543,549-551 With challenges due to their irregular shape, Kupffer cell volume was assumed to 
be the same as that calculated for the monocyte parent. The total Kupffer cell volume in mouse was 
then calculated based on the cellularity of 135 million cells per gram liver tissue.552 Tissue-resident 
macrophage volume was fixed at 2% of non-blood volume according to a previous derivation by 
Aborig & Malik et al.542,553 The endosomal fraction (𝑓𝑒𝑛𝑑𝑜) of 0.2 was assigned the same for 
macrophages as for endothelial cells.66  
Intraperitoneal administration was described by adding a local injection site compartment and 
allowing mAb to enter the plasma compartment by a first order absorption rate constant (𝑘𝑎). This 
process represents the flow of lymph from the local site to the interface of the thoracic duct with the 
subclavian vein. In transit, mAb is subject to pre-systemic elimination. In FcRn transgenic mice, 
Richter et al. observe that EKO mice have similar bioavailability to wild-type mice, but that MKO 
and GKO mice have marked lower bioavailability.479 The exact intraperitoneal bioavailability of 1B7 
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in the wild-type (𝐹𝑊𝑇
𝐼𝑃 ) and macrophage knockout (𝐹𝑀𝐾𝑂
𝐼𝑃 ) scenarios could not be calculated as there 
was no intravenous data for comparison.  
Endogenous IgG is present in parallel within the system and competes with therapeutic mAb for 
binding to FcRn. Each model run requires a baseline phase (0-500 hours) that allows endogenous IgG 
levels in the body to acclimate to steady state, and then a dosing phase, where therapeutic mAb is 
administered. Endogenous IgG levels in plasma of C57BL/6J mice and various knockout mice were 
used for each experiment as measured by Challa et al.490 
In this “middle-out” approach, nine parameters were optimized using a simulated annealing 
temperature-based global optimization method (𝐶𝐿𝑢𝑝, 𝐶𝐿𝑠𝑝𝑒𝑐 , 𝑃𝑢𝑝, 𝑃𝑠𝑝𝑒𝑐 , 𝐿, 𝜎
𝑉 , 𝑘𝑎 , 𝐹𝑊𝑇
𝐼𝑃 , 𝐹𝑀𝐾𝑂
𝐼𝑃 ). Ten 
optimizations were run from randomized start values within physiologically relevant parameter 
bounds to assess identifiability of a unique solution. To absolve potential correlations between uptake 
and degradation, the endosomal degradation rates were optimized using a scaling factor multiplied by 
the uptake rate (𝐶𝐿𝑠𝑝𝑒𝑐 = 𝐶𝐿𝑠𝑝𝑒𝑐
𝑓𝑎𝑐𝑡𝑜𝑟
× 𝐶𝐿𝑢𝑝, 𝑃𝑠𝑝𝑒𝑐 = 𝑃𝑠𝑝𝑒𝑐
𝑓𝑎𝑐𝑡𝑜𝑟
× 𝑃𝑢𝑝). In the beginning of the 
optimization process, it was found that three constants trended to solutions that were lower than those 
physiological plausible (𝜎𝑉, 𝐹𝑊𝑇
𝐼𝑃 , 𝐹𝑀𝐾𝑂
𝐼𝑃 ). Therefore, they were fixed to the lower limit of 










Table 22. State and parameter notation for the minimal PBPK model 
Term Units Definition 
States 
𝐶𝑃 pmol/mL Concentration of mAb in plasma space 
𝐶𝐸 pmol/mL Concentration of unbound mAb in endothelial endosomes 
𝐶𝐸:𝐵𝑜𝑢𝑛𝑑 pmol/mL Concentration of FcRn-bound mAb in endothelial endosomes 
𝐶𝐼𝑆 pmol/mL Concentration of mAb in interstitial space 
𝐶𝑖
𝑀 pmol/mL Concentration of unbound mAb in macrophage endosomes (𝑖 
= circulating. Kupffer or tissue) 
𝐶𝑖
𝑀:𝐵𝑜𝑢𝑛𝑑 pmol/mL Concentration of FcRn-bound mAb in macrophage 
endosomes (𝑖 = circulating, Kupffer or tissue) 
𝐹𝑐𝑅𝑛𝐸 pmol/mL State for the negative value of mAb-FcRn complex 
concentration in endothelial endosomes 
𝐹𝑐𝑅𝑛𝑖
𝑀 pmol/mL State for the negative value of mAb-FcRn complex 
concentration in macrophage endosomes (𝑖 = circulating, 
Kupffer or tissue) 
Parameters 
𝐿 mL/h Organ lymph flow 
𝜎𝑉 - Vascular reflection coefficient 
𝑉𝑃 mL Volume of plasma space  
𝑉𝐸 mL Volume of endothelial endosomes 
𝑉𝐼𝑆 mL Volume of interstitial space  
𝑉𝑖
𝑀 mL Volume of macrophage endosomes (𝑖 = circulating, Kupffer 
or tissue) 
𝐶𝐿𝑢𝑝 mL/h/mL Rate of pinocytosis and exocytosis per mL of endothelial 
endosomes 
𝐶𝐿𝑠𝑝𝑒𝑐 mL/h/mL Rate of degradation in endothelial endosomes 
𝑃𝑢𝑝 mL/h/mL Rate of phagocytosis and exocytosis per mL of macrophage 
endosomes 
𝑃𝑠𝑝𝑒𝑐 mL/h/mL Rate of degradation in macrophage endosomes 
𝐹𝑐𝑅𝑛 pmol/mL Maximum concentration of the neonatal Fc receptor in 
endosomes (constant) 
𝑘𝑜𝑛
𝐹𝑐𝑅𝑛 mL/pmol/h Association rate constant for mAb binding to FcRn 
𝑘𝑜𝑓𝑓
𝐹𝑐𝑅𝑛 h-1 Dissociation rate constant for mAb binding to FcRn 
𝐾𝐷
𝐹𝑐𝑅𝑛 pmol/mL Equilibrium dissociation constant for mAb binding to FcRn 
𝐹𝑊𝑇
𝐼𝑃  - Bioavailabilty of D1.3 from intraperitoneal space in WT and 
EKO mice 
𝐹𝑀𝐾𝑂
𝐼𝑃  - Bioavailability of D1.3 from intraperitoneal space in MKO 
and GKO mice 
𝑘𝑎 h







Equation Set 7.1: Amount of mAb in Plasma 
𝑉𝑃 ×  
𝑑𝐶𝑃  
𝑑𝑡
= −(1 − 𝜎𝑉) × 𝐿 × 𝐶𝑃 + 𝐿 × 𝐶𝐼𝑆 − 𝑃𝑢𝑝 × 𝑉𝑐𝑖𝑟𝑐
𝑀 × 𝐶𝑃 + 𝑃𝑢𝑝 × 𝑉𝑐𝑖𝑟𝑐
𝑀 × 𝐶𝑐𝑖𝑟𝑐
𝑀:𝐵𝑜𝑢𝑛𝑑
− 𝑃𝑢𝑝 × 𝑉𝑘𝑢𝑝𝑓𝑓𝑒𝑟
𝑀 × 𝐶𝑃 + 𝑃𝑢𝑝 × 𝑉𝑘𝑢𝑝𝑓𝑓𝑒𝑟
𝑀 × 𝐶𝑘𝑢𝑝𝑓𝑓𝑒𝑟






Circulating Macrophage Endosomes 









𝑀 + 𝐹𝑐𝑅𝑛) + 𝑘𝑜𝑓𝑓
𝐹𝑐𝑅𝑛 × 𝐶𝑐𝑖𝑟𝑐








𝑀 + 𝐹𝑐𝑅𝑛) − 𝑘𝑜𝑓𝑓
𝐹𝑐𝑅𝑛 × 𝐶𝑐𝑖𝑟𝑐








𝑀 + 𝐹𝑐𝑅𝑛) + 𝑘𝑜𝑓𝑓
𝐹𝑐𝑅𝑛 × 𝐶𝑐𝑖𝑟𝑐








= 𝐶𝐿𝑢𝑝 × 𝐶
𝑃 − 𝑘𝑜𝑛
𝐹𝑐𝑅𝑛 × 𝐶𝐸 × (𝐹𝑐𝑅𝑛𝐸 + 𝐹𝑐𝑅𝑛) + 𝑘𝑜𝑓𝑓





𝐹𝑐𝑅𝑛 × 𝐶𝐸 × (𝐹𝑐𝑅𝑛𝐸 + 𝐹𝑐𝑅𝑛) − 𝑘𝑜𝑓𝑓





𝐹𝑐𝑅𝑛 × 𝐶𝐸 × (𝐹𝑐𝑅𝑛𝐸 + 𝐹𝑐𝑅𝑛) + 𝑘𝑜𝑓𝑓











= (1 − 𝜎𝑉) × 𝐿 × 𝐶𝑃 −  𝐿 × 𝐶𝐼𝑆 − 𝑃𝑢𝑝 × 𝑉𝑡𝑖𝑠𝑠𝑢𝑒




Tissue-Resident Macrophage Endosomes 
 









𝑀 + 𝐹𝑐𝑅𝑛) + 𝑘𝑜𝑓𝑓
𝐹𝑐𝑅𝑛 × 𝐶𝑡𝑖𝑠𝑠𝑢𝑒
𝑀:𝐵𝑜𝑢𝑛𝑑








𝑀 + 𝐹𝑐𝑅𝑛) − 𝑘𝑜𝑓𝑓
𝐹𝑐𝑅𝑛 × 𝐶𝑡𝑖𝑠𝑠𝑢𝑒








𝑀 + 𝐹𝑐𝑅𝑛) + 𝑘𝑜𝑓𝑓
𝐹𝑐𝑅𝑛 × 𝐶𝑡𝑖𝑠𝑠𝑢𝑒
𝑀:𝐵𝑜𝑢𝑛𝑑 + 𝑃𝑢𝑝 × 𝐶𝑡𝑖𝑠𝑠𝑢𝑒
𝑀:𝐵𝑜𝑢𝑛𝑑 
 
Kupffer Cell Endosomes 









𝑀 + 𝐹𝑐𝑅𝑛) + 𝑘𝑜𝑓𝑓
𝐹𝑐𝑅𝑛 × 𝐶𝑘𝑢𝑝𝑓𝑓𝑒𝑟
𝑀:𝐵𝑜𝑢𝑛𝑑








𝑀 + 𝐹𝑐𝑅𝑛) − 𝑘𝑜𝑓𝑓
𝐹𝑐𝑅𝑛 × 𝐶𝑘𝑢𝑝𝑓𝑓𝑒𝑟








𝑀 + 𝐹𝑐𝑅𝑛) + 𝑘𝑜𝑓𝑓
𝐹𝑐𝑅𝑛 × 𝐶𝑘𝑢𝑝𝑓𝑓𝑒𝑟
𝑀:𝐵𝑜𝑢𝑛𝑑






Intraperitoneal Injection Site  
Equation Set 7.7: Amount of mAb in the Intraperitoneal Injection Site (i = wild-type or MKO) 
𝑑𝐴𝐼𝑃  
𝑑𝑡
= −𝐴𝐼𝑃 × 𝑘𝑎 




7.3.4 Minimal PBPK Model Verification 
The final model was verified by evaluating its predictive performance against the dataset from Garg 
et al. that was not used during the model building process.91 In this scenario, mAb 7E3 was 
administered intravenously at 8 mg/kg to C57BL/6J mice along with high dose IVIG (1 g/kg). Strong 
performance in this scenario reflects appropriate characterization of the complex interplay between 
therapeutic mAb, endogenous IgG, exogenous IgG and FcRn in vivo.  
7.3.5 Model Projections 
Simulations were conducted to refine the overall understanding on the contribution of hematopoietic 
cell uptake and FcRn-mediated recycling to mAb pharmacokinetics. The original conclusions 
postulated by Richter et al. were tested by simulating the amount cleared by each of the cell 
populations over time in wild-type and GKO mice.479 
7.3.6 Sensitivity Analysis 
A one-at-a-time (OAT) sensitivity analysis was conducted with the final model to quantify the 
contribution of the three macrophage cell populations (circulating monocytes, Kupffer cells and 
tissue-resident macrophages) to the clearance of mAbs in mice. Separate sensitivity analyses were 
conducted for the wild-type model and for adaptations featuring 50% FcRn depletion and 90% FcRn 
depletion to anticipate the effects if FcRn were partially or near-fully depleted in children. Parameters 
hypothesized to have relevance to the ontogeny of mAb pharmacokinetics were varied individually by 
+50% and –50% of the nominal value and the resulting percent changes in the area-under-the-curve 









To explore if monocyte blood concentration may be a plausible explanation to the observed faster 
weight-normalized clearance of mAbs in young children, the monocyte volume in blood (𝑉𝑐𝑖𝑟𝑐
𝑀 ) was 
increased 5-fold and compared against the nominal profile. 
7.4 Results 
7.4.1 Minimal PBPK Model Development 
A minimal PBPK model was developed that describes mAb extravasation, flow via lymph, uptake 
into endothelial cells, uptake into macrophages, salvage through binding to FcRn and competition 
with endogenous IgG for FcRn in a series of wild-type of site-specific FcRn knockout mouse models. 
The final model fit is presented in Figure 34 and the final parameterization is presented in Table 23. 
The coefficients of variation on estimated parameters among solutions from multiple optimizations 
with randomized start values were less than 0.2%, confirming that the solution is uniquely identifiable 
(Figure 35). The fit analysis is presented in Figure 36. Fold error at every data point was calculated as 
the predicted value divided by the observed value. The absolute average fold error across all 
datapoints was 1.00 and 90.3% of points fell within the 1.5-fold error boundaries (0.667 – 1.5-fold 
error). 
The model fit was poor only when characterizing the plasma profile of GKO mice from Garg et 
al.91 However the fit to this dataset must be balanced against the mild under-fitting of the GKO 
profiles in the other two datasets.479,490,536 Indeed this analysis assumes that all three of the studied 
mAbs (7E3, D1.3 and 1B7) have the same cellular uptake rates, but there is notable heterogeneity in 
cellular uptake among other mAbs that may explain the interstudy variation in observed data for GKO 
mice.554 The subgroup analysis by experiment type confirms that the error in the GKO datasets is 
balanced across the median fold-error of 1, with the Garg et al. dataset being over-estimated and the 




Figure 34. Fitted model performance against observed data in various FcRn knockout mice (WT, 
EKO, MKO, GKO) and macrophage knockdown scenarios (WT+Clod, GKO+Clod). WT = wild-type 
control mice, EKO = endothelial-specific FcRn knoc006Bout mice, MKO = macrophage-specific 
FcRn knockout mice, GKO = global FcRn knockout mice, Clod = co-administration of clodronate 
liposomes to knock down macrophages. Observed data presented from Akilesh et al.,479,536 Garg et 





Table 23. Final parameter values for the minimal PBPK model 
Term Units Value (estimation CV%) Reference 
Fixed Parameters 
𝑉𝑃 mL 0.99 Niederalt et al.66 
𝑉𝐸 mL 0.0051 Niederalt et al.66 
𝑉𝐼𝑆 mL 3.165 Niederalt et al.66 
𝑉𝑐𝑖𝑟𝑐
𝑀  mL 0.00028 Derived 
𝑉𝑘𝑢𝑝𝑓𝑓𝑒𝑟
𝑀  mL 0.0176 Derived 
𝑉𝑡𝑖𝑠𝑠𝑢𝑒
𝑀  mL 0.08 Derived  
𝑘𝑜𝑛
𝐹𝑐𝑅𝑛 mL/pmol/h 0.0522 Niederalt et al.66 
𝐾𝐷
𝐹𝑐𝑅𝑛 pmol/mL 750 Niederalt et al.66 
𝜎𝑉 - 0.65 Fixed during 
estimation 
𝐹𝑊𝑇
𝐼𝑃  - 0.70 Fixed during 
estimation 
𝐹𝑀𝐾𝑂
𝐼𝑃  - 0.45 Fixed during 
estimation 
𝐹𝑐𝑅𝑛 pmol/mL 33000 Garg et al.,91 Li et 
al.544 
Serum IgG in WT mice pmol/mL 8600 Challa et al.490 
Serum IgG in EKO mice pmol/mL 3600 Challa et al.490 
Serum IgG in MKO mice pmol/mL 3200 Challa et al.490 
Serum IgG in GKO mice pmol/mL 850 Challa et al.490 
Optimized Parameters 
𝐶𝐿𝑢𝑝 mL/h/mL 5.05 (0.02%) - 
𝐶𝐿𝑠𝑝𝑒𝑐 mL/h/mL 79.7 (0.07%) - 
𝑃𝑢𝑝 mL/h/mL 0.480 (0.015%) - 
𝑃𝑠𝑝𝑒𝑐 mL/h/mL 0.150 (0.18%) - 
𝐿 mL/h 0.152 (0.04%) - 
𝑘𝑎 h








Figure 35. Box-and-whisker diagram for the estimation data visualizing the spread in the parameter 
estimation results. Parameters presented on y-axis with mean and arithmetic standard deviation. Red 
lines note the median, boxes note the first and third quartiles, error bars note the minimum and 
maximum, and outliers are plotted as single dots (defined as a value further than 1.5 times the 
interquartile range from the median). To normalize the data for the box-and-whisker diagram, the 





Figure 36. Model fit analysis. Fitted values are plotted against observed values for each experiment 
type (colored diamonds). WT = wild-type, EKO = endothelial-specific FcRn knockout, MKO = 
macrophage-specific FcRn knockout, GKO = global FcRn knockout. The solid black line marks the 




7.4.2 Minimal PBPK Model Verification 
The final model was verified with respect to its Fc-receptor mediated interactions by making a 
successful prediction for the plasma concentration-time profile of 7E3 when co-administered with 1 
g/kg IVIG in the study by Garg et al.91 The prediction is presented in Figure 37. 
 
Figure 37. Prediction of 7E3 pharmacokinetics when co-administered with 1 g/kg intravenous 
immunoglobulin (IVIG) to verify the Fc-dependent interactions in the final model. Observed data 




7.4.3 Model Projections 
Simulations with the final model were used to revisit existing hypotheses about the contribution of 
hematopoietic cell uptake and FcRn-mediated recycling to the pharmacokinetics of mAbs in mice. 
The model suggests that in individuals with normal FcRn expression, macrophages largely act as 
protectors of mAb in the body, rather than degraders. Instead, degradation occurs predominantly in 
non-hematopoietic cells. In the wild-type scenario, the model predicts that at 500 hours, 84% of the 
administered mAb dose is eliminated in endothelial cells while 2% is eliminated in macrophages 
(Figure 38). However in the GKO scenario, the model predicts that at 500 hours, 57% of the 
administered mAb dose is eliminated in endothelial cells while 43% is eliminated in macrophages 
(Figure 38). This observation also changes the understanding of the pre-systemic elimination of mAbs 
after extravascular administration. Instead of degraders, hematopoietic cells can be thought of as 
protectors enabling safe transit of mAb through the lymphatic system. When FcRn is knocked out in 








Figure 38. Simulation for percent of injected dose cleared by endothelial cells (dashed line) and 




7.4.4 Sensitivity Analysis 
The OAT sensitivities of the simulated plasma AUC to select model parameters across the wild-type, 
50% FcRn depleted and 90% FcRn depleted scenarios are presented in Figure 39. Across all 
scenarios, the plasma AUC is most sensitive to endothelial clearance parameters, namely the volume 
of endothelial cells (𝑉𝐸), the rate of uptake into endothelial cells (𝐶𝐿𝑢𝑝) and the rate of degradation in 
endothelial cells (𝐶𝐿𝑠𝑝𝑒𝑐). The vascular reflection coefficient between plasma and interstitial space 
had a mild impact on the AUC as it governs the distributional equilibrium between plasma and 
interstitial fluid, and therefore the availability of mAb for uptake into endothelial cells. Parameters 
related to macrophage volume or uptake had virtually no impact on the plasma profile even in the 
scenario with 90% FcRn depletion – circulating monocyte volume least of all (𝑉𝑐𝑖𝑟𝑐
𝑀 ). This result 
suggests that the FcRn-mediated recycling of mAbs in hematopoietic cells is highly efficient. To 
confirm this observation, a simulation was run where the monocyte volume was increased 5-fold from 
its nominal value, and the plasma AUC did not change. Therefore it is very unlikely that a high 
concentration of circulating monocytes may contribute to the fast weight-based clearance in young 






Figure 39. One-at-a-time sensitivity of the simulated plasma AUC to select model parameters in scenarios with normal FcRn expression (blue), 
50% depletion of FcRn (orange) and 90% depletion of FcRn (purple). Parameters were varied by -50% (solid bar) and +50% (empty bar) of the 
nominal value and the resulting percent changes in AUC are reported as sensitivity coefficients. See Table 22 for parameter definitions.  
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7.5 Discussion 
The role of hematopoietic cells and in particular, monocytes and macrophages in the 
pharmacokinetics of mAbs is currently not well understood. Recent mouse PK data with site-specific 
FcRn deletion and macrophage knockdown with clodronate liposomes have been enlightening toward 
this end.479,490,536 In the current work, a minimal PBPK model has been developed to unify the datasets 
and a model-based analysis has been conducted to bring clarity to the issue. A model-based analysis 
is valuable for this exercise because of the degree of experimental complexity. Experiments in mice 
with site-specific FcRn deletion are further complicated by simultaneous macrophage knockdown 
with clodronate liposomes, intraperitoneal administration and experiment-specific endogenous IgG 
concentrations competing for FcRn binding. Overall, the model confirms the assertion by Challa et al. 
that macrophages are indispensable for IgG homeostasis. In this regard, macrophages serve as highly 
efficient protectors of IgG in plasma, interstitial fluid and lymph. They are not, as previously thought, 
sinks for mAb degradation. In fact, model simulations suggest that with normal FcRn expression less 
than 2% of an intravenously administered dose is eliminated in macrophages, while endothelial cells 
are predicted to dominate mAb elimination. The near-nil sensitivity of the models with up to 90% 
FcRn depletion to monocyte and macrophage parameters suggests that it is very unlikely that a high 
concentration of circulating monocytes can contribute to explaining the fast weight-based clearance 
of mAbs in very young children.  
This work inspires new questions about the importance of hematopoietic cell uptake toward the 
biodistribution and organ-specific accumulation of mAbs, especially in the context of an expansion of 
this work to a full body PBPK model. The relative abundance of macrophages in various organs is 
well known in mice.553,555 One full body PBPK model for mAbs has incorporated hematopoietic cell 
uptake as relevant for IgG homeostasis in the context of therapeutic FcRn inhibition, but this 
parameterization was not built with biodistribution data or the knockout data used here.544 The present 
minimal model does not allow significant accumulation of mAb inside endothelial cells or 
macrophages outside of FcRn binding due to the assumption of equal cellular influx and efflux rates. 
Nevertheless, the conceptual strides that have been made toward understanding the role of each cell 
type in the uptake and elimination of mAbs will assist future efforts for modeling organ accumulation 
as potentially dependent on uptake into macrophages. Such expansion is debatably necessary for 
mAbs alone, but certainly necessary for characterizing the PK of other large molecule species that are 




The collected datasets have particular strengths in that they all feature the same foundational mouse 
model that is not immunodeficient and does not have human transgenic FcRn, the C57BL/6 athymic 
nude mouse. The mice were otherwise healthy and did not have tumour xenografts, which increases 
mAb clearance.556,557 The administered mAbs showed linear kinetics and demonstrated negligible 
target binding in mice to avoid the potentially confounding effects of target-mediated drug 
disposition. However, some challenges were met when unifying the datasets under one model 
parameterization. While each study used a unique mAb, none of the studies reported the FcRn affinity 
of their drug product. Different mAbs are also known to show different propensities for extravasation 
and cellular uptake dependent on their charge, glycosylation, and other physicochemical 
properties.554,558,559 In this work, none of these drug-specific parameters were able to be accounted for.  
Finally, it is important to acknowledge that this PBPK model is limited by its structural 
assumptions. All compartments are assumed to be well-stirred and representative of the sum of the 
respective organ sub-compartments across the whole body. Cellular uptake is limited to FcRn-
expressing cells only (endothelial cells and macrophages), and FcRn binding is mathematically 
described with 1:1 stoichiometry, though 2:1 stoichiometry is observed in vitro. Cellular uptake and 
recycling are assumed to occur at equal rates to improve identifiability, though in vitro experiments 
may prove useful for establishing a relationship between these parameters. 
7.6 Conclusion 
The model-based analysis of experimental data in mice suggests that the role of macrophages in IgG 
homeostasis includes highly efficient FcRn-mediated protection but not degradation as previously 
thought. The relevance of this finding for hypotheses related to high concentrations of circulating 
monocytes in pediatrics has been discussed.  
7.7 Study Highlights 
This manuscript revisits the assumptions that were used to perform the pediatric extrapolation in 
Chapter 6 and reveals that a high concentration of circulating hematopoietic cells is likely not 






Conclusions and Future Directions 
With the body of pediatric data growing, it is becoming increasingly possible to scale the 
pharmacokinetics of a mAb from adults to children older than 2 years of age empirically, especially 
one that is administered intravenously and displays linear kinetics in vivo. On the other hand, a 
physiologically-based extrapolation to children will be preferred when accounting for non-linear 
behaviour, when disease pathophysiology impacts pharmacokinetics in children, when scaling to 
infants (where only sparse data exist) or when asking mechanistic research questions. The efforts in 
this thesis have been directed to making a physiologically-based extrapolation a feasible reality for 
drug developers, regulators and academics alike.  
Four hypotheses remain that may account for the observed fast clearance and high volumes of 
distribution in children on a per kg basis. First, high extracellular water fractions in young children 
contribute to a large volume of distribution for mAbs.61,437 Extravasation of mAbs occurs quickly in 
children due to dense capillary networks and proportionally larger central and leaky organs.50,464,560 A 
fast rate of lymph flow drives fast absorption – and even potentially higher bioavailability after 
extravascular administration.36,511 Finally, it cannot be ruled out that the free concentration of the 
neonatal Fc receptor (FcRn) is present in lower concentrations in the endothelial cells and 
macrophages of infants and children, leading to faster clearance.492  
Future research will be directed to the continued testing of these hypotheses and the generation of 
new ones to eventually complete the full picture of mAb absorption, distribution and elimination in 
children. As shown by the results of the last chapter, the mechanistic determinants of mAb disposition 
in humans (even adults) are still not fully understood. Yet to be addressed is the potential for mAbs to 
deposit or adhere to the endothelial glycocalyx, the potential for fast clearance in liver sinusoidal 
endothelial cells, or the drivers of hematopoietic cell uptake and accumulation in the spleen.556,561 To 
make physiologically based tools that can support pediatric clinical trial planning, the final 
parameterizations must be expanded to a population approach, similar to the example shown for 
trastuzumab. Pharmacokinetic variability in peak concentrations remains unaccounted for by the 
current understanding of variability in virtual individuals, and among experts it has been suggested 
that the vascular volume fraction or varying potentials for endothelial adherence in the post-injection 
period may be the key determinants to investigate. Encouragingly, the advances made for mAbs in 
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pediatrics will also contribute to the wider field of all therapeutic protein use in children. Even 
nanoparticles and liposomes share similar disposition patterns in children.562 
Of course, none of this work was done in a vacuum. Multiple research groups contributed literature 
over the same years that together brought about the evolution of this field. Hardiansyah and Ng 
published the first physiologically-based pediatric extrapolation for mAbs in 2018.319 They concluded 
that FcRn concentrations would be higher in children than adults. In 2020, the commercial team at 
SimCyp released a pediatric PBPK model for therapeutic proteins by Pan et al., which has been 
discussed in Chapter 1.63 They attribute the ontogeny in mAb clearance to a lower concentration of 
free FcRn in children. A significant portion of our work would not be possible without the use of the 
generic model for large molecules by Niederalt et al. that was released in 2018.66 Basu et al. 
subsequently trialed the generic model for extrapolation of bevacizumab and palivizumab 
pharmacokinetics to children considering only size-dependent anatomy and physiology.563 Similar to 
our work, they came to the conclusion that immature physiology likely contributes to faster clearance 
even for older children. Temrikar and Meibohm published a notable review of the clinical 
pharmacology of monoclonal antibodies including a summary of the ontogenic hypotheses in 2020, 
who then became our collaborators for the review on pediatric dose selection for therapeutic proteins 
in 2021.25 Now in 2021, the platform PBPK model by Shah and Betts is being translated to pediatrics 
with infliximab as an example.564,565 It has been a privilege to be a part of these pioneering efforts. 
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Appendix A: Supplementary Material for Chapter 3 
Derivation of the Degradation Rate of mAb-HER2 Complexes (𝐾𝑑𝑒𝑔
𝐴𝑔
) 
We denote the amount of mAb bound to HER2 on the cell membrane by 𝐴𝐶𝑀 and the amount bound 
to HER2 in the intracellular space by 𝐴𝐼𝐶. The time-varying rate of mAb binding to HER2 is given by 
𝑣(𝑡). The rate at which the mAb-HER2 complex on the cell membrane is internalized is denoted by 
𝐾𝑖𝑛𝑡
𝐴𝑔
. A fraction (𝐹𝑅𝐴𝑔) of intracellular mAb-HER2 complex is recycled back to the cell membrane 
at a certain rate (𝐾𝑒𝑥𝑖𝑡
𝐴𝑔
). The remaining fraction (1 − 𝐹𝑅𝐴𝑔) is degraded. This process is described by 
the following differential equations: 
 𝑑𝐴𝐶𝑀
𝑑𝑡
= 𝑣(𝑡) − 𝐾𝑖𝑛𝑡
𝐴𝑔
× 𝐴𝐶𝑀 + 𝐾𝑒𝑥𝑖𝑡
𝐴𝑔





× 𝐴𝐶𝑀 − 𝐾𝑒𝑥𝑖𝑡
𝐴𝑔
× 𝐹𝑅𝐴𝑔 × 𝐴𝐼𝐶 − 𝐾𝑒𝑥𝑖𝑡
𝐴𝑔
× (1 − 𝐹𝑅𝐴𝑔) × 𝐴𝐼𝐶 
(A1) 
Let: 
 𝐴𝑇 ≔ 𝐴𝐶𝑀 + 𝐴𝐼𝐶  (A2) 
 
So that (A1) becomes: 
 𝑑𝐴𝐶𝑀
𝑑𝑡
= 𝑣(𝑡) − 𝐾𝑖𝑛𝑡
𝐴𝑔
× 𝐴𝐶𝑀 + 𝐾𝑒𝑥𝑖𝑡
𝐴𝑔
× 𝐹𝑅𝐴𝑔 × (𝐴𝑇 − 𝐴𝐶𝑀) 
𝑑𝐴𝑇
𝑑𝑡
= 𝑣(𝑡) − 𝐾𝑒𝑥𝑖𝑡
𝐴𝑔
× (1 − 𝐹𝑅𝐴𝑔) × (𝐴𝑇 − 𝐴𝐶𝑀) 
(A3) 




 are of the same order and that 𝐹𝑅𝐴𝑔 ≈ 1, it follows that 
𝐾𝑒𝑥𝑖𝑡
𝐴𝑔




. To represent this difference in magnitude, we let 𝑘1 ≔  𝜖 × 𝐾𝑖𝑛𝑡
𝐴𝑔
, 
𝑘2 ≔  𝜖 × 𝐾𝑒𝑥𝑖𝑡
𝐴𝑔
× 𝐹𝑅𝐴𝑔 and 𝑘 = 𝐾𝑒𝑥𝑖𝑡
𝐴𝑔
× (1 − 𝐹𝑅𝐴𝑔), where 𝜖 is a small parameter that makes 










= 𝑣(𝑡) − 𝑘 × (𝐴𝑇 − 𝐴𝐶𝑀) 
The separation of timescales introduced by the small parameter 𝜖 allows us to make an 
approximation.  Since 𝜖 ≈ 0 we can say (informally) that: 
 −𝑘1 × 𝐴𝐶𝑀 + 𝑘2 × (𝐴𝑇 − 𝐴𝐶𝑀) ≈ 0 (A5) 
 
This step can be shown formally using a standard application of Tikhonov’s theorem. Therefore, we 
obtain 𝐴𝐶𝑀 ≈  𝑘2 × 𝐴𝑇 (𝑘1 + 𝑘2)⁄ and, from (A4), the following approximation holds over time: 
𝑑𝐴𝑇
𝑑𝑡




















is the rate of degradation of mAb-HER2 complexes. 
A final numerical value of 0.0789 was calculated using the kinetic parameter values determined by 





In the following equations, the subscript 𝑖 represents a specific organ tissue compartment being 
considered.  For all organ tissue compartment equations except the lung and liver, subscript 𝑗 refers to 
the lung.  For the lung equations, subscript 𝑗 refers to the plasma compartment concentration.  The 
liver plasma space is described separately in equations 7 and 8. Table A1 below defines any equation 
terms that are undefined in the main body of the work. 
Table A1 A listing and description of the previously undefined parameters used in the model 
equations. For all other parameter definitions, see Table 6 in the main body of the work. 
Term Units Definition 
𝑃𝐿𝑄𝐿𝑢𝑛𝑔 L/h Total body plasma flow 
𝐿𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒 L/h Total body lymph flow 
𝑃𝐿𝑄𝑖 L/h Plasma flow into and out of each organ 
𝐿𝑖 L/h Lymph flow into and out of each organ 
𝐶𝑃𝑙𝑎𝑠𝑚𝑎 nM Concentration of mAb in plasma space 
𝐶𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒 nM Concentration of mAb in lymphatic system 
𝐶𝑖
𝑃 nM Concentration of mAb in organ plasma space 
𝐶𝑖
𝐸𝐵𝑜𝑢𝑛𝑑 nM Concentration of mAb in endosomal space bound to FcRn 
𝐶𝑖
𝐸𝑈𝑛𝑏𝑜𝑢𝑛𝑑 nM Concentration of unbound mAb in endosomal space  
𝐶𝑖
𝐼𝑆 nM Concentration of mAb in interstitial space 
𝐶𝑖
𝐶𝑀𝐵𝑜𝑢𝑛𝑑 nmol / L 
interstitial 
Concentration of mAb bound to HER2 on the cell membrane  
𝑉𝑃𝑙𝑎𝑠𝑚𝑎 L Volume of plasma space 
𝑉𝐿𝑦𝑝𝑚ℎ𝑁𝑜𝑑𝑒 L Volume of lymphatic system components 
𝑉𝑖
𝑃 L Volume of organ plasma space  
𝑉𝑖
𝐸 L Volume of endosomal space  
𝑉𝑖
𝐼𝑆 L Volume of interstitial space  
𝐶𝑃𝑙𝑎𝑠𝑚𝑎
𝐸𝐶𝐷  nM Concentration of mAb-ECD complexes in plasma space 
𝐶𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒
𝐸𝐶𝐷  nM Concentration of mAb-ECD complexes in lymphatic system 
𝐶𝑖








Blood Compartment: Plasma  
Equation A6: 
𝑉𝑃𝑙𝑎𝑠𝑚𝑎 ×  
𝑑𝐶𝑃𝑙𝑎𝑠𝑚𝑎
𝑑𝑡
= (𝑃𝐿𝑄𝐻𝑒𝑎𝑟𝑡 − 𝐿𝐻𝑒𝑎𝑟𝑡) × 𝐶𝐻𝑒𝑎𝑟𝑡
𝑃 + (𝑃𝐿𝑄𝐾𝑖𝑑𝑛𝑒𝑦 − 𝐿𝐾𝑖𝑑𝑛𝑒𝑦) × 𝐶𝐾𝑖𝑑𝑛𝑒𝑦
𝑃
+ (𝑃𝐿𝑄𝑀𝑢𝑠𝑐𝑙𝑒 − 𝐿𝑀𝑢𝑠𝑐𝑙𝑒) × 𝐶𝑀𝑢𝑠𝑐𝑙𝑒
𝑃 + (𝑃𝐿𝑄𝑆𝑘𝑖𝑛 − 𝐿𝑆𝑘𝑖𝑛) × 𝐶𝑆𝑘𝑖𝑛
𝑃
+ (𝑃𝐿𝑄𝐵𝑟𝑎𝑖𝑛 − 𝐿𝐵𝑟𝑎𝑖𝑛) × 𝐶𝐵𝑟𝑎𝑖𝑛
𝑃 + (𝑃𝐿𝑄𝐴𝑑𝑖𝑝𝑜𝑠𝑒 − 𝐿𝐴𝑑𝑖𝑝𝑜𝑠𝑒) × 𝐶𝐴𝑑𝑖𝑝𝑜𝑠𝑒
𝑃
+ (𝑃𝐿𝑄𝑇ℎ𝑦𝑚𝑢𝑠 − 𝐿𝑇ℎ𝑦𝑚𝑢𝑠) × 𝐶𝑇ℎ𝑦𝑚𝑢𝑠
𝑃
+ (𝑃𝐿𝑄𝐿𝑖𝑣𝑒𝑟 − 𝐿𝐿𝑖𝑣𝑒𝑟 + 𝑃𝐿𝑄𝑆𝑡𝑜𝑚𝑎𝑐ℎ − 𝐿𝑆𝑡𝑜𝑚𝑎𝑐ℎ + 𝑃𝐿𝑄𝑆𝑝𝑙𝑒𝑒𝑛 − 𝐿𝑆𝑝𝑙𝑒𝑒𝑛
+ 𝑃𝐿𝑄𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 − 𝐿𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 + 𝑃𝐿𝑄𝑆𝐼𝑛𝑡 − 𝐿𝑆𝐼𝑛𝑡 + 𝑃𝐿𝑄𝐿𝐼𝑛𝑡 − 𝐿𝐿𝐼𝑛𝑡) × 𝐶𝐿𝑖𝑣𝑒𝑟
𝑃
+ (𝑃𝐿𝑄𝐵𝑜𝑛𝑒 − 𝐿𝐵𝑜𝑛𝑒) × 𝐶𝐵𝑜𝑛𝑒
𝑃 + (𝑃𝐿𝑄𝑂𝑡ℎ𝑒𝑟 − 𝐿𝑂𝑡ℎ𝑒𝑟) × 𝐶𝑂𝑡ℎ𝑒𝑟
𝑃
+ 𝐿𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒 × 𝐶𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒 −  𝑃𝐿𝑄𝐿𝑢𝑛𝑔 × 𝐶𝑃𝑙𝑎𝑠𝑚𝑎
− 𝐾𝑜𝑛
𝐸𝐶𝐷 × (𝐸𝐶𝐷 − 𝐶𝑃𝑙𝑎𝑠𝑚𝑎
𝐸𝐶𝐷 ) × 𝐶𝑃𝑙𝑎𝑠𝑚𝑎 × 𝑉𝑃𝑙𝑎𝑠𝑚𝑎
+ 𝐾𝑜𝑓𝑓
𝐸𝐶𝐷 × 𝐶𝑃𝑙𝑎𝑠𝑚𝑎











= (𝑃𝐿𝑄𝐻𝑒𝑎𝑟𝑡 − 𝐿𝐻𝑒𝑎𝑟𝑡) × 𝐶𝐻𝑒𝑎𝑟𝑡
𝑃,𝐸𝐶𝐷 + (𝑃𝐿𝑄𝐾𝑖𝑑𝑛𝑒𝑦 − 𝐿𝐾𝑖𝑑𝑛𝑒𝑦) × 𝐶𝐾𝑖𝑑𝑛𝑒𝑦
𝑃,𝐸𝐶𝐷
+ (𝑃𝐿𝑄𝑀𝑢𝑠𝑐𝑙𝑒 − 𝐿𝑀𝑢𝑠𝑐𝑙𝑒) × 𝐶𝑀𝑢𝑠𝑐𝑙𝑒
𝑃,𝐸𝐶𝐷 + (𝑃𝐿𝑄𝑆𝑘𝑖𝑛 − 𝐿𝑆𝑘𝑖𝑛) × 𝐶𝑆𝑘𝑖𝑛
𝑃,𝐸𝐶𝐷
+ (𝑃𝐿𝑄𝐵𝑟𝑎𝑖𝑛 − 𝐿𝐵𝑟𝑎𝑖𝑛) × 𝐶𝐵𝑟𝑎𝑖𝑛
𝑃,𝐸𝐶𝐷 + (𝑃𝐿𝑄𝐴𝑑𝑖𝑝𝑜𝑠𝑒 − 𝐿𝐴𝑑𝑖𝑝𝑜𝑠𝑒) × 𝐶𝐴𝑑𝑖𝑝𝑜𝑠𝑒
𝑃,𝐸𝐶𝐷
+ (𝑃𝐿𝑄𝑇ℎ𝑦𝑚𝑢𝑠 − 𝐿𝑇ℎ𝑦𝑚𝑢𝑠) × 𝐶𝑇ℎ𝑦𝑚𝑢𝑠
𝑃,𝐸𝐶𝐷
+ (𝑃𝐿𝑄𝐿𝑖𝑣𝑒𝑟 − 𝐿𝐿𝑖𝑣𝑒𝑟 + 𝑃𝐿𝑄𝑆𝑡𝑜𝑚𝑎𝑐ℎ − 𝐿𝑆𝑡𝑜𝑚𝑎𝑐ℎ + 𝑃𝐿𝑄𝑆𝑝𝑙𝑒𝑒𝑛 − 𝐿𝑆𝑝𝑙𝑒𝑒𝑛
+ 𝑃𝐿𝑄𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 − 𝐿𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 + 𝑃𝐿𝑄𝑆𝐼𝑛𝑡 − 𝐿𝑆𝐼𝑛𝑡 + 𝑃𝐿𝑄𝐿𝐼𝑛𝑡 − 𝐿𝐿𝐼𝑛𝑡) × 𝐶𝐿𝑖𝑣𝑒𝑟
𝑃,𝐸𝐶𝐷
+ (𝑃𝐿𝑄𝐵𝑜𝑛𝑒 − 𝐿𝐵𝑜𝑛𝑒) × 𝐶𝐵𝑜𝑛𝑒
𝑃,𝐸𝐶𝐷 + (𝑃𝐿𝑄𝑂𝑡ℎ𝑒𝑟 − 𝐿𝑂𝑡ℎ𝑒𝑟) × 𝐶𝑂𝑡ℎ𝑒𝑟
𝑃,𝐸𝐶𝐷
+ 𝐿𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒 × 𝐶𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒
𝐸𝐶𝐷 −  𝑃𝐿𝑄𝐿𝑢𝑛𝑔 × 𝐶𝑃𝑙𝑎𝑠𝑚𝑎
𝐸𝐶𝐷
+ 𝐾𝑜𝑛
𝐸𝐶𝐷 × (𝐸𝐶𝐷 − 𝐶𝑃𝑙𝑎𝑠𝑚𝑎
𝐸𝐶𝐷 ) × 𝐶𝑃𝑙𝑎𝑠𝑚𝑎 × 𝑉𝑃𝑙𝑎𝑠𝑚𝑎
− 𝐾𝑜𝑓𝑓
𝐸𝐶𝐷 × 𝐶𝑃𝑙𝑎𝑠𝑚𝑎
𝐸𝐶𝐷 × 𝑉𝑃𝑙𝑎𝑠𝑚𝑎 − 𝐾𝑑𝑒𝑔
𝐸𝐶𝐷 × 𝐶𝑃𝑙𝑎𝑠𝑚𝑎
















= (1 − 𝜎𝐻𝑒𝑎𝑟𝑡
𝐼𝑆 ) × 𝐿𝐻𝑒𝑎𝑟𝑡 × 𝐶𝐻𝑒𝑎𝑟𝑡
𝐼𝑆 + (1 −  𝜎𝐾𝑖𝑑𝑛𝑒𝑦
𝐼𝑆 ) × 𝐿𝐾𝑖𝑑𝑛𝑒𝑦 × 𝐶𝐾𝑖𝑑𝑛𝑒𝑦
𝐼𝑆
+ (1 −  𝜎𝑀𝑢𝑠𝑐𝑙𝑒
𝐼𝑆 ) × 𝐿𝑀𝑢𝑠𝑐𝑙𝑒 × 𝐶𝑀𝑢𝑠𝑐𝑙𝑒
𝐼𝑆 + (1 −  𝜎𝑆𝑘𝑖𝑛
𝐼𝑆 ) × 𝐿𝑆𝑘𝑖𝑛 × 𝐶𝑆𝑘𝑖𝑛
𝐼𝑆
+ (1 −  𝜎𝐵𝑟𝑎𝑖𝑛
𝐼𝑆 ) × 𝐿𝐵𝑟𝑎𝑖𝑛 × 𝐶𝐵𝑟𝑎𝑖𝑛
𝐼𝑆 + (1 −  𝜎𝐴𝑑𝑖𝑝𝑜𝑠𝑒
𝐼𝑆 ) × 𝐿𝐴𝑑𝑖𝑝𝑜𝑠𝑒 × 𝐶𝐴𝑑𝑖𝑝𝑜𝑠𝑒
𝐼𝑆
+ (1 −  𝜎𝑇ℎ𝑦𝑚𝑢𝑠
𝐼𝑆 ) × 𝐿𝑇ℎ𝑦𝑚𝑢𝑠 × 𝐶𝑇ℎ𝑦𝑚𝑢𝑠
𝐼𝑆 + (1 −  𝜎𝐿𝑖𝑣𝑒𝑟
𝐼𝑆 ) × 𝐿𝐿𝑖𝑣𝑒𝑟 × 𝐶𝐿𝑖𝑣𝑒𝑟
𝐼𝑆
+ (1 −  𝜎𝑆𝑡𝑜𝑚𝑎𝑐ℎ
𝐼𝑆 ) × 𝐿𝑆𝑡𝑜𝑚𝑎𝑐ℎ × 𝐶𝑆𝑡𝑜𝑚𝑎𝑐ℎ
𝐼𝑆
+ (1 −  𝜎𝑆𝑝𝑙𝑒𝑒𝑛
𝐼𝑆 ) × 𝐿𝑆𝑝𝑙𝑒𝑒𝑛 × 𝐶𝑆𝑝𝑙𝑒𝑒𝑛
𝐼𝑆
+ (1 −  𝜎𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠
𝐼𝑆 ) × 𝐿𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 × 𝐶𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠
𝐼𝑆 + (1 − 𝜎𝑆𝐼𝑛𝑡
𝐼𝑆 ) × 𝐿𝑆𝐼𝑛𝑡 × 𝐶𝑆𝐼𝑛𝑡
𝐼𝑆
+ (1 −  𝜎𝐿𝐼𝑛𝑡
𝐼𝑆 ) × 𝐿𝐿𝐼𝑛𝑡 × 𝐶𝐿𝐼𝑛𝑡
𝐼𝑆 + (1 −  𝜎𝐵𝑜𝑛𝑒
𝐼𝑆 ) × 𝐿𝐵𝑜𝑛𝑒 × 𝐶𝐵𝑜𝑛𝑒
𝐼𝑆
+ (1 −  𝜎𝑂𝑡ℎ𝑒𝑟
𝐼𝑆 ) × 𝐿𝑂𝑡ℎ𝑒𝑟 × 𝐶𝑂𝑡ℎ𝑒𝑟
𝐼𝑆 + (1 −  𝜎𝐿𝑢𝑛𝑔
𝐼𝑆 ) × 𝐿𝐿𝑢𝑛𝑔 × 𝐶𝐿𝑢𝑛𝑔
𝐼𝑆
− 𝐿𝐿𝑦𝑝𝑚ℎ𝑁𝑜𝑑𝑒 × 𝐶𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒
− 𝐾𝑜𝑛
𝐸𝐶𝐷 × (𝐸𝐶𝐷 − 𝐶𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒
𝐸𝐶𝐷 ) × 𝐶𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒 × 𝑉𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒
+ 𝐾𝑜𝑓𝑓
𝐸𝐶𝐷 × 𝐶𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒













= (1 − 𝜎𝐻𝑒𝑎𝑟𝑡
𝐼𝑆 ) × 𝐿𝐻𝑒𝑎𝑟𝑡 × 𝐶𝐻𝑒𝑎𝑟𝑡
𝐼𝑆,𝐸𝐶𝐷 + (1 − 𝜎𝐾𝑖𝑑𝑛𝑒𝑦
𝐼𝑆 ) × 𝐿𝐾𝑖𝑑𝑛𝑒𝑦 × 𝐶𝐾𝑖𝑑𝑛𝑒𝑦
𝐼𝑆,𝐸𝐶𝐷
+ (1 −  𝜎𝑀𝑢𝑠𝑐𝑙𝑒
𝐼𝑆 ) × 𝐿𝑀𝑢𝑠𝑐𝑙𝑒 × 𝐶𝑀𝑢𝑠𝑐𝑙𝑒
𝐼𝑆,𝐸𝐶𝐷 + (1 −  𝜎𝑆𝑘𝑖𝑛
𝐼𝑆 ) × 𝐿𝑆𝑘𝑖𝑛 × 𝐶𝑆𝑘𝑖𝑛
𝐼𝑆,𝐸𝐶𝐷
+ (1 −  𝜎𝐵𝑟𝑎𝑖𝑛
𝐼𝑆 ) × 𝐿𝐵𝑟𝑎𝑖𝑛 × 𝐶𝐵𝑟𝑎𝑖𝑛
𝐼𝑆,𝐸𝐶𝐷 + (1 − 𝜎𝐴𝑑𝑖𝑝𝑜𝑠𝑒
𝐼𝑆 ) × 𝐿𝐴𝑑𝑖𝑝𝑜𝑠𝑒 × 𝐶𝐴𝑑𝑖𝑝𝑜𝑠𝑒
𝐼𝑆,𝐸𝐶𝐷
+ (1 −  𝜎𝑇ℎ𝑦𝑚𝑢𝑠
𝐼𝑆 ) × 𝐿𝑇ℎ𝑦𝑚𝑢𝑠 × 𝐶𝑇ℎ𝑦𝑚𝑢𝑠
𝐼𝑆,𝐸𝐶𝐷 + (1 −  𝜎𝐿𝑖𝑣𝑒𝑟
𝐼𝑆 ) × 𝐿𝐿𝑖𝑣𝑒𝑟 × 𝐶𝐿𝑖𝑣𝑒𝑟
𝐼𝑆,𝐸𝐶𝐷
+ (1 −  𝜎𝑆𝑡𝑜𝑚𝑎𝑐ℎ
𝐼𝑆 ) × 𝐿𝑆𝑡𝑜𝑚𝑎𝑐ℎ × 𝐶𝑆𝑡𝑜𝑚𝑎𝑐ℎ
𝐼𝑆,𝐸𝐶𝐷
+ (1 −  𝜎𝑆𝑝𝑙𝑒𝑒𝑛
𝐼𝑆 ) × 𝐿𝑆𝑝𝑙𝑒𝑒𝑛 × 𝐶𝑆𝑝𝑙𝑒𝑒𝑛
𝐼𝑆,𝐸𝐶𝐷
+ (1 −  𝜎𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠
𝐼𝑆 ) × 𝐿𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 × 𝐶𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠
𝐼𝑆,𝐸𝐶𝐷 + (1 − 𝜎𝑆𝐼𝑛𝑡
𝐼𝑆 ) × 𝐿𝑆𝐼𝑛𝑡 × 𝐶𝑆𝐼𝑛𝑡
𝐼𝑆,𝐸𝐶𝐷
+ (1 −  𝜎𝐿𝐼𝑛𝑡
𝐼𝑆 ) × 𝐿𝐿𝐼𝑛𝑡 × 𝐶𝐿𝐼𝑛𝑡
𝐼𝑆,𝐸𝐶𝐷 + (1 −  𝜎𝐵𝑜𝑛𝑒
𝐼𝑆 ) × 𝐿𝐵𝑜𝑛𝑒 × 𝐶𝐵𝑜𝑛𝑒
𝐼𝑆,𝐸𝐶𝐷
+ (1 −  𝜎𝑂𝑡ℎ𝑒𝑟
𝐼𝑆 ) × 𝐿𝑂𝑡ℎ𝑒𝑟 × 𝐶𝑂𝑡ℎ𝑒𝑟
𝐼𝑆,𝐸𝐶𝐷 + (1 −  𝜎𝐿𝑢𝑛𝑔
𝐼𝑆 ) × 𝐿𝐿𝑢𝑛𝑔 × 𝐶𝐿𝑢𝑛𝑔
𝐼𝑆,𝐸𝐶𝐷
− 𝐿𝐿𝑦𝑝𝑚ℎ𝑁𝑜𝑑𝑒 × 𝐶𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒
𝐸𝐶𝐷
+ 𝐾𝑜𝑛
𝐸𝐶𝐷 × (𝐸𝐶𝐷 − 𝐶𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒
𝐸𝐶𝐷 ) × 𝐶𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒 × 𝑉𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒
− 𝐾𝑜𝑓𝑓
𝐸𝐶𝐷 × 𝐶𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒
𝐸𝐶𝐷 × 𝑉𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒 −  𝐾𝑑𝑒𝑔
𝐸𝐶𝐷 × 𝐶𝐿𝑦𝑚𝑝ℎ𝑁𝑜𝑑𝑒
















= 𝑃𝐿𝑄𝑖 × 𝐶𝑗
𝑃 − (𝑃𝐿𝑄𝑖 − 𝐿𝑖) × 𝐶𝑖
𝑃 − 𝐹2 × (1 − 𝜎𝑖
𝑉) × 𝐿𝑖 × 𝐶𝑖
𝑃 − 𝐶𝐿𝑢𝑝𝑖 × 𝐶𝑖
𝑃
+ 𝐶𝐿𝑢𝑝𝑖 × 𝐹𝑅 × 𝐶𝑖
𝐸𝐵𝑜𝑢𝑛𝑑 − 𝐾𝑜𝑛














= 𝑃𝐿𝑄𝑖 × 𝐶𝑗
𝑃,𝐸𝐶𝐷 − (𝑃𝐿𝑄𝑖 − 𝐿𝑖) × 𝐶𝑖
𝑃,𝐸𝐶𝐷 − 𝐹2 × (1 − 𝜎𝑖
𝑉) × 𝐿𝑖 × 𝐶𝑖
𝑃,𝐸𝐶𝐷
+ 𝐾𝑜𝑛













= 𝑃𝐿𝑄𝐿𝑖𝑣𝑒𝑟 × 𝐶𝐿𝑢𝑛𝑔
𝑃 + (𝑃𝐿𝑄𝑆𝑡𝑜𝑚𝑎𝑐ℎ − 𝐿𝑆𝑡𝑜𝑚𝑎𝑐ℎ) × 𝐶𝑆𝑡𝑜𝑚𝑎𝑐ℎ
𝑃
+ (𝑃𝐿𝑄𝑆𝑝𝑙𝑒𝑒𝑛 − 𝐿𝑆𝑝𝑙𝑒𝑒𝑛) × 𝐶𝑆𝑝𝑙𝑒𝑒𝑛
𝑃 + (𝑃𝐿𝑄𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 − 𝐿𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠) × 𝐶𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠
𝑃
+ (𝑃𝐿𝑄𝑆𝐼𝑛𝑡 − 𝐿𝑆𝐼𝑛𝑡) × 𝐶𝑆𝐼𝑛𝑡
𝑃 + (𝑃𝐿𝑄𝐿𝐼𝑛𝑡 − 𝐿𝐿𝑖𝑛𝑡) × 𝐶𝐿𝐼𝑛𝑡
𝑃
−  (𝑃𝐿𝑄𝐿𝑖𝑣𝑒𝑟 − 𝐿𝐿𝑖𝑣𝑒𝑟 + 𝑃𝐿𝑄𝑆𝑡𝑜𝑚𝑎𝑐ℎ − 𝐿𝑆𝑡𝑜𝑚𝑎𝑐ℎ + 𝑃𝐿𝑄𝑆𝑝𝑙𝑒𝑒𝑛 − 𝐿𝑆𝑝𝑙𝑒𝑒𝑛
+ 𝑃𝐿𝑄𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 − 𝐿𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 + 𝑃𝐿𝑄𝑆𝐼𝑛𝑡 − 𝐿𝑆𝐼𝑛𝑡 + 𝑃𝐿𝑄𝐿𝐼𝑛𝑡 − 𝐿𝐿𝐼𝑛𝑡) × 𝐶𝐿𝑖𝑣𝑒𝑟
𝑃
− 𝐹2 × (1 − 𝜎𝐿𝑖𝑣𝑒𝑟
𝑉 ) × 𝐿𝐿𝑖𝑣𝑒𝑟 × 𝐶𝐿𝑖𝑣𝑒𝑟
𝑃 − 𝐶𝐿𝑢𝑝𝐿𝑖𝑣𝑒𝑟 × 𝐶𝐿𝑖𝑣𝑒𝑟
𝑃
+ 𝐶𝐿𝑢𝑝𝐿𝑖𝑣𝑒𝑟 × 𝐹𝑅 × 𝐶𝐿𝑖𝑣𝑒𝑟
𝐸𝐵𝑜𝑢𝑛𝑑 − 𝐾𝑜𝑛

















= 𝑃𝐿𝑄𝐿𝑖𝑣𝑒𝑟 × 𝐶𝐿𝑢𝑛𝑔
𝑃,𝐸𝐶𝐷 + (𝑃𝐿𝑄𝑆𝑡𝑜𝑚𝑎𝑐ℎ − 𝐿𝑆𝑡𝑜𝑚𝑎𝑐ℎ) × 𝐶𝑆𝑡𝑜𝑚𝑎𝑐ℎ
𝑃,𝐸𝐶𝐷
+ (𝑃𝐿𝑄𝑆𝑝𝑙𝑒𝑒𝑛 − 𝐿𝑆𝑝𝑙𝑒𝑒𝑛) × 𝐶𝑆𝑝𝑙𝑒𝑒𝑛
𝑃,𝐸𝐶𝐷 + (𝑃𝐿𝑄𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 − 𝐿𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠) × 𝐶𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠
𝑃,𝐸𝐶𝐷
+ (𝑃𝐿𝑄𝑆𝐼𝑛𝑡 − 𝐿𝑆𝐼𝑛𝑡) × 𝐶𝑆𝐼𝑛𝑡
𝑃,𝐸𝐶𝐷 + (𝑃𝐿𝑄𝐿𝐼𝑛𝑡 − 𝐿𝐿𝑖𝑛𝑡) × 𝐶𝐿𝐼𝑛𝑡
𝑃,𝐸𝐶𝐷
−  (𝑃𝐿𝑄𝐿𝑖𝑣𝑒𝑟 − 𝐿𝐿𝑖𝑣𝑒𝑟 + 𝑃𝐿𝑄𝑆𝑡𝑜𝑚𝑎𝑐ℎ − 𝐿𝑆𝑡𝑜𝑚𝑎𝑐ℎ + 𝑃𝐿𝑄𝑆𝑝𝑙𝑒𝑒𝑛 − 𝐿𝑆𝑝𝑙𝑒𝑒𝑛
+ 𝑃𝐿𝑄𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 − 𝐿𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 + 𝑃𝐿𝑄𝑆𝐼𝑛𝑡 − 𝐿𝑆𝐼𝑛𝑡 + 𝑃𝐿𝑄𝐿𝐼𝑛𝑡 − 𝐿𝐿𝐼𝑛𝑡) × 𝐶𝐿𝑖𝑣𝑒𝑟
𝑃,𝐸𝐶𝐷
− 𝐹2 × (1 − 𝜎𝐿𝑖𝑣𝑒𝑟
𝑉 ) × 𝐿𝐿𝑖𝑣𝑒𝑟 × 𝐶𝐿𝑖𝑣𝑒𝑟
𝑃,𝐸𝐶𝐷
+ 𝐾𝑜𝑛



























𝐹𝑐𝑅𝑛  × 𝐶𝑖


































= 𝐹2 × (1 − 𝜎𝑖
𝑉) × 𝐿𝑖 × 𝐶𝑖
𝑃 − (1 −  𝜎𝑖
𝐼𝑆) × 𝐿𝑖 × 𝐶𝑖
𝐼𝑆 − 𝐶𝐿𝑢𝑝𝑖 × 𝐶𝑖
𝐼𝑆


























= 𝐹2 × (1 − 𝜎𝑖
𝑉) × 𝐿𝑖 × 𝐶𝑖
𝑃,𝐸𝐶𝐷 − (1 −  𝜎𝑖
𝐼𝑆) × 𝐿𝑖 × 𝐶𝑖
𝐼𝑆,𝐸𝐶𝐷
+ 𝐾𝑜𝑛




























































Global Sensitivity Analysis Method 
We can describe the PBPK model by an ordinary differential equation parameterized by a vector 𝑝 =
[𝑝1 ⋯ 𝑝𝑛]: 
𝑑𝑥
𝑑𝑡
(𝑡) =  𝑓(𝑥(𝑡), 𝑝, 𝑡) 
𝑦(𝑡, 𝑝1, ⋯ , 𝑝𝑛) = 𝑔(𝑥(𝑡)) 
where 𝑥 is a vector of concentrations of mAb in all compartments, with 𝑦 being the measured output 
– the concentration of mAb in plasma. Starting from zero initial conditions (representing the absence 
of mAb prior to administration), the concentration of mAb in the different compartments over time is 
given by the solution to this ODE. For the global sensitivity analysis, we seek to quantify the variance 
of the area under the curve, 𝐴(𝑝1, ⋯ , 𝑝𝑛) = ∫ 𝑦 𝑑𝑡
𝑇
0
, when the parameters 𝑝1, ⋯ , 𝑝𝑛 are sampled from 
a given distribution. To calculate this variance, we adopt the approaches of Sobol and Saltelli.297 
Without loss of generality, each of the parameters 𝑝1, ⋯ , 𝑝𝑛 is assumed to vary independently and 
have a uniform distribution over the interval [0,1]. Under these assumptions, the expected value 𝐴0 of 
𝐴 is given by  








while the variance 𝐷 of 𝐴 is  










It is possible to also formulate an expression for the deviation between 𝐴, averaged over all 
parameters except 𝑝𝑗, and the expected value 𝐴0: 









for which 𝐸[𝐴𝑗] = 0. For a given value of 𝑝𝑗, this function quantifies the deviation of 𝐴 from the 
expected value 𝐴0. The variance 𝐷𝑗 of 𝐴𝑗(𝑝𝑗) over the distribution of 𝑝𝑗 gives an absolute measure of 
the sensitivity of 𝐴 with respect to variations solely in 𝑝𝑗. This variance is given by  
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To compare sensitivity with respect to the different parameters, one can define the relative sensitivity 





Beyond the sensitivity of 𝐴 with respect to variation solely in 𝑝𝑗, it is instructive to quantify the 
relative sensitivity of 𝐴 with respect to 𝑝𝑗 varying together with the other parameters. A derivation 
similar to that above, given in Homma & Saltelli,298 defines this relative total sensitivity with respect 
to 𝑝𝑗, denoted  𝑆𝑇𝑗, as 




where ?̅?𝑗 quantifies the variance of 𝐴 due to variations in all parameters save 𝑝𝑗.  
Since there is no analytical expression for 𝐴 due to the nonlinearity of the PBPK model, the integrals 
used to evaluate 𝑆𝑗 and 𝑆𝑇𝑗 were calculated using quasi-Monte Carlo integrals. To ensure that these 
integrals were evaluated over a suitably large range of points that covers the parameter space, a Sobol 
sequence was constructed to generate test points as described in Saltelli.297   
The parameters were sampled from uniform distributions centered on mean values with domains 
spanning plus and minus one standard deviation. The means of these distributions, along with the 
coefficients of variation used to calculate the domains of the distributions are given in Table 7 in the 
main body of the work along with the result of the global sensitivity analysis. 
Definitions: 
The first order global sensitivity of an output with respect to a parameter assesses the normalized 
variance of the output when marginalized over all parameters except the parameter of interest. 
The total global sensitivity of an output with respect to a parameter assesses the difference between 
the normalized variance of the output and its normalized variance when marginalized over the 





Table A2. Basic reference parameters for a Caucasian adult male 
Parameter Value 
Height 1.77 m 
Body Mass 73.00 kg 
Body Surface Area  1.90 m2 
Cardiac Output 360.50 L/h 
Total Plasma Flow 198.28 L/h 
Total Blood Volume 5.67 L 
Total Plasma Volume 3.12 L 
Hematocrit 0.45 
 
Table A3. Organ sizes and fluid flow rates for the reference male 








Blooda 2.85 1.06 198.28  
Lymph 0.2621 1 
 
0.4084 
Heart 0.386 1.03 8.58 0.01716 
Kidney 0.422 1.05 40.75 0.0815 
Muscle 29.784 1.04 36.46 0.07292 
Skin 3.468 1.1 10.72 0.02144 
Brain 1.5172 1.03 25.74 0.05148 
Adipose 17.26 0.916 10.71 0.02142 
Thymus 0.0064 1 0.079 0.000158 
Liver 2.36 1.05 13.94 0.02788 
Stomach 0.206 1.05 2.14 0.00428 
Spleen 0.2284 1.05 6.44 0.01288 
Pancreas 0.1736 1.04 2.14 0.00428 
S. Intestine 0.8628 1.04 21.45 0.0429 
L. Intestine 0.4932 1.04 8.58 0.01716 
Bone 7.018 1.3 4.28 0.00856 
Other 5.09029 1 6.23 0.01246 
Lung 0.612 1.05 198.28 0.0119 
a Total blood mass includes the mass in circulation within organs 
b Initial guess for total lymph flow was 0.2% of plasma flow  
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Table A4. Organ sub-compartment volumes for the reference male 











    
Lymph 2.62E-01 
    
Heart 3.75E-01 1.44E-02 1.88E-03 5.36E-02 2.93E-01 
Kidney 4.02E-01 2.20E-02 2.01E-03 6.03E-02 2.99E-01 
Muscle 2.86E+01 6.30E-01 1.43E-01 3.72E+00 2.36E+01 
Skin 3.15E+00 1.17E-01 1.57E-02 1.04E+00 1.88E+00 
Brain 1.47E+00 3.24E-02 7.37E-03 2.65E-01 1.14E+00 
Adipose 1.88E+01 2.07E-01 9.42E-02 3.20E+00 1.52E+01 
Thymus 6.41E-03 3.53E-04 3.21E-05 1.09E-03 4.65E-03 
Liver 2.25E+00 1.92E-01 1.12E-02 4.50E-01 1.44E+00 
Stomach 1.96E-01 4.90E-03 9.81E-04 1.96E-02 1.67E-01 
Spleen 2.18E-01 2.64E-02 1.09E-03 4.36E-02 1.25E-01 
Pancreas 1.67E-01 9.15E-03 8.31E-04 2.89E-02 1.20E-01 
S. Intestine 8.30E-01 1.33E-02 4.16E-03 1.45E-01 6.57E-01 
L. Intestine 4.74E-01 7.56E-03 2.37E-03 8.25E-02 3.76E-01 
Bone 5.40E+00 1.19E-01 2.70E-02 1.00E+00 4.15E+00 
Other 5.09E+00 2.14E-01 2.55E-02 8.72E-01 3.80E+00 
Lung 5.83E-01 3.21E-02 2.91E-03 1.75E-01 3.47E-01 
a Total blood volume includes the volume in circulation within organs 
 
Table A5. Basic reference parameters for a Caucasian adult female 
Parameter Value 
Height 1.637 m 
Body Mass 60 kg 
Body Surface Area 1.66 m2 





Table A6. Organ sizes and fluid flow rates for the reference female 








Blooda 1.7835 1.06 197.15  
Lymph 0.2154 1  0.406 
Heart 0.291 1.03 10.58 0.0212 
Kidney 0.357 1.05 36.41 0.0728 
Muscle 17.93 1.04 25.5 0.0510 
Skin 2.423 1.1 10.6 0.0212 
Brain 1.35 1.03 25.5 0.0510 
Adipose 21.15 0.916 18.045 0.0361 
Thymus 0.0053 1 0.094 0.0002 
Liver 1.81 1.05 13.814 0.0276 
Stomach 0.181 1.05 2.11 0.0042 
Spleen 0.1874 1.05 6.46 0.0129 
Pancreas 0.1446 1.04 2.056 0.0041 
S. Intestine 0.7558 1.04 23.5 0.0470 
L. Intestine 0.4502 1.04 10.616 0.0212 
Bone 5.223 1.3 4.247 0.0085 
Other 5.241 1 7.35 0.0147 
Lung 0.502 1.05 197.15 0.0118 
a Total blood mass includes the mass in circulation within organs 
b Initial guess for total lymph flow was 0.2% of plasma flow  
 
The volumes of the organ sub-compartments (plasma space, endosomal space, interstitial space and 
cellular space) were calculated for each organ based on the same fractions used for healthy males. 
Tumour volume was 20 mL. Estimates for the vascular, interstitial and cellular volume fractions, the 
reflection coefficients, plasma flow and lymph flow of the tumour were the same as in the model by 
Glassman and Balthasar.109 The endosomal volume fraction was 0.5% of tumour volume, consistent 
with the platform model.135 Concentration of HER2 in the tumour was set to be 25-fold higher than in 






Table A7. Tumour Parameters 
Parameter Value Parameter Value 
Plasma Volume (L) 1.40E-03 Plasma Flow (L/h) 3.38E-02 
Endosomal Volume (L) 1.66E-04 Lymph Flow (L/h) 6.78E-05 
Interstitial Volume (L) 1.09E-02 Vascular Reflection [𝜎𝑉] 0.842 





Table A8. Reflection Coefficients 
Organ 𝜎𝑉 Estimate 𝜎𝑉 Effective 𝜎𝐼𝑆 Estimate 
Heart 0.95 0.83 0.2 
Kidney 0.9 0.67 0.2 
Muscle 0.95 0.83 0.2 
Skin 0.95 0.83 0.2 
Brain 0.99 0.97 0.2 
Adipose 0.95 0.83 0.2 
Thymus 0.9 0.67 0.2 
Liver 0.85 0.50 0.2 
Stomach 0.95 0.83 0.2 
Spleen 0.85 0.50 0.2 
Pancreas 0.9 0.67 0.2 
S. Intestine 0.9 0.67 0.2 
L. Intestine 0.95 0.83 0.2 
Bone 0.85 0.50 0.2 
Other 0.95 0.83 0.2 
Lung 0.95 0.83 0.2 
 
The initial values for the reflection coefficient, as well as the effective vascular reflection coefficients 
(σv) are given in Table A8. The fitted value for 𝐹2 was 3.35. Effective vascular reflection coefficients 
for each tissue were calculated as:109   
𝜎𝐸𝑓𝑓





Appendix B: Supplementary Material for Chapter 6 
Table B1 Data collected for derivation of the ontogeny profile for capillary density 
Age Medium Median Capillary Density 
(1/mm2) 
Median Capillary Density 
(1/mm) 
Dolezalova et al., 2002528 
2 years Nail Fold  6.75 
3 years Nail Fold 
 
6.80 
4 years Nail Fold 
 
6.85 
5 years Nail Fold 
 
6.90 
6 years Nail Fold 
 
6.96 
7 years Nail Fold 
 
7.01 
8 years Nail Fold 
 
7.06 
9 years Nail Fold 
 
7.11 
10 years Nail Fold 
 
7.16 
11 years Nail Fold 
 
7.21 
12 years Nail Fold 
 
7.27 
13 years Nail Fold 
 
7.32 
14 years Nail Fold 
 
7.37 
18 years Nail Fold 
 
7.58 
25 years Nail Fold 
 
7.94 
30 years Nail Fold 
 
8.20 
Top et al., 2011467 
















D’Souza et al., 2011468 
 
207 
Preterm Neonate Skin (toe) 36 
 
Term Neonate Skin (toe) 29 
 
Schaefer et al., 2016464 
[0-1] years Peritoneum 223 
 
[1-2] years Peritoneum 89 
 
[2-7] years Peritoneum 76 
 
[7-12] years Peritoneum 35 
 
[12-18] years Peritoneum 89 
 
[18-40] years Peritoneum 106 
 
 
Method for Ontogeny Profile Generation: 
The U-curve shape was obtained from Schaefer et al., 2016,464 Figure 3 and the review by Ingegnoli 
et al.,527 2013, section “Capillaroscopy in Healthy Children” with acknowledgement of the animal 
studies mentioned in the main body of the manuscript.533-535 
For this analysis, the mean adult is defined as a healthy male with an age of 30 years. 
All ontogeny factors were calculated relatively to the adult or other previously established 
measurements in the workflow. 
Ontogeny factors are rounded to the nearest tenth of a decimal to acknowledge the uncertainty around 
the measurements. 
The latter part of the capillary density profile (2 years – 30 years) can be constructed using the linear 
regression from Dolezalova et al., 2002,528 Figure 3.  
Age Capillary Density  
(Fraction of Adult) 
2 – 6 years 0.8 
6 – 12 years 0.9 
12 – 18 years 1.0 
Adult 1.0 
 
The relative difference in capillary density between an infant at birth and a child at 2 years of age was 




Age Capillary Density  
(Fraction of Adult) 
Birth 1.3 
2 – 6 years 0.8 
 
A linear interpolation over time according to age was then applied between birth and age 2. 
Age Capillary Density  
(Fraction of Adult) 
Birth 1.3 
1 – 3 months 1.1 
3 – 6 months 1.0 
6 – 12 months 0.9 
1 – 2 years 0.8 
2 – 6 years 0.8 
 
 Finally, the relative capillary density in a preterm infant was calculated with reference to the 
capillary density at birth using the data reported by D’Souza et al., 2011,468 Figure 1. 
Age Capillary Density  
(Fraction of Adult) 
Preterm 1.6 
Birth 1.3 
 
